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Abstract
Molecular Classification and Prediction of Metastatic Potential in 
Early Malignant Melanoma:
Improvement of Prognostic Accuracy by 
Quantitative in situ Proteomic Analysis
Aaron J. Berger 
2006
The incidence of cutaneous malignant melanoma continues to increase every year, 
and remains the leading cause of skin cancer death in industrialized countries. In spite of 
the aggressive nature of advanced melanoma, there are no standard biological assays in 
clinical usage that can predict metastasis. This may be due, in part, to the inadequacy of 
reproducible assessment of protein expression using traditional immunohistochemistry. 
This dissertation will discuss the use of tissue microarrays combined with quantitative in 
situ molecular analysis of protein expression to allow prediction of melanoma metastasis. 
Through the identification and validation of novel prognostic biomarkers, we seek to 
identify subsets of patients that are at high or low risk for melanoma recurrence or 
melanoma-related death. Some of these biomarkers may also serve as potential targets 
for future biologic therapy in melanoma, a disease for which no effective medical 
treatment is currently available. We demonstrate that quantitative assessment of a small 
number of markers is predictive of metastasis and outcome, augmenting the current 
system of prognosis.
The dissertation begins with a brief introduction on the current state of melanoma 
diagnosis, staging, and treatment, as well as a review of current efforts to understand the 
biology of melanoma progression and metastasis. The fundamentals of tissue microarray 
technology are then described. Critical aspects of quantitative immunohistochemistry,
i
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including a description of the Automated Quantitative Analysis (AQUA) system 
developed in our laboratory, are also addressed. The second chapter demonstrates the use 
of tissue microarray technology to examine melanoma specimens by the current field 
standard, with a study of activating transcription factor 2 (ATF2); an example of semi- 
quantitative immunohistochemical analysis of protein expression. The third chapter 
provides validation of the AQUA technology on melanoma tissue by evaluation of the 
human homologue of murine double minute 2 protein (HDM2). Chapter four 
demonstrates an example of the critical—and beneficial—aspect of subcellular 
compartmentalization that the AQUA system provides, demonstrating that the ratio of 
cytoplasmic-to-nuclear expression of activator protein 2 (AP-2) predicts outcome in 
melanoma patients. The last chapter draws these concepts together and presents results 
from the analysis of 50 protein biomarkers in melanoma. It also introduces the use of a 
number of statistical methods (traditional and novel) employed to develop an optimal 
biomarker set for future analyses.
n
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This dissertation is dedicated to the memory of my friend Marco Palma. If he were alive, 
I think he’d be doing this type of work. I miss him with each day that passes.
v
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Acknowledgements
First and foremost, I would like to thank my mentor, David Rimm, M.D., Ph.D. I 
was drawn to him and his lab based on his deep interest in translational research, as well 
as his remarkable ability to describe extremely complicated concepts scientists, 
clinicians, and laypeople. I initially ‘discovered’ David as he was a guest lecturer in a 
seminar course, and then again as a section leader for the medical school Pathology 
course. After almost committing myself to another laboratory, I cam back from six 
months of medical school clerkships with a strong desire to work in David’s lab on 
clinically relevant problems in cancer research. The type of work we do in his lab will 
hopefully change the face of oncology care in our society. The tools developed and 
refined in our lab are unique and exciting. David is an outstanding mentor; he always 
puts his students first. His creativity, intellectual curiosity, and courage to pursue the 
answers to complex, almost ‘unanswerable’ questions are admirable traits that I hope I 
have acquired. In addition, his enthusiasm is infectious.
The second person I would like to thank is Robert (Bob) Camp, M.D., Ph.D. Bob 
is probably one of the smartest people I know, and among the best dressed. Without 
Bob’s mind, ‘vision’ and programming skills, none of this work would be possible. He is 
an asset to this lab, the department, the world in general; a true genius.
All members of the Rimm lab deserve recognition in terms of the assistance they 
have provided me on this journey. In particular, I would like to thank the graduate 
students (past and present) who have provided guidance and support (intellectual and 
emotional) throughout this process: Elayne Provost, Ph.D., Derek Pappas, Ph.D., Marisa 
Dolled-Filhart, Ph.D., Jena Giltnane, and Sharon Pozner. THANK YOU! Other
vi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
individuals who have provided tremendous assistance include Kyle DiVito and Melissa 
Cregger, who took many of my projects into their own hands. Additionally, Sophya 
Rodov and Harriet Kluger, M.D. were quite helpful. Jay Cowan, Maciej Zerkowski, Tom 
D ’Aquila, Mark Gustavson, Ph.D., Summar Siddiqui, Malini Harigopal, M.D., Gina 
Chung, M.D., Amanda Psyrri, M.D., and Carola Zalles, M.D. all became my friends and 
made graduate student life more palatable. The Tissue Microarray Facility, run by Lori 
Charette and Joanna Graham, deserves special mention. Without your hardwork and 
help, the puzzle ends up missing pieces.
Critical collaborators on my projects include Dr. Stephan Ariyan, M.D. and his 
assistant Carolyn Truini, Michael Krauthammer, M.D., Ph.D. (Bioinformatics) and 
Antonio Subtil, M.D. (Dermatopathology).
People who have made the Department of Pathology a truly hospitable and fun 
place to be include JoAnn Falato, Dagmar Moore, the business office crew (Janice, 
Rachel, and Beth), and JoAnn D ’Agostino.
In terms of my personal life, I am grateful to all of my friends, but especially Lee 
Sylvestre for keeping everything in perspective.
I would like to express thanks to my Dissertation Committee (Michael 
Kashgarian, M.D., Ruth Halaban, Ph.D., and Jeffrey Sklar, M.D., Ph.D.) for their 
feedback and suggestions, as well as their acceptance of this project as a meaningful 
endeavor.
I also owe a debt of gratitude to the MD/PhD Program (Jim Jamieson, M.D.,
Ph.D. and Sue Sansone) for the support that they have provided (and continue to provide) 
in my attempt to become a physician-scientist.
vii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table of Contents
A bstract......................................................................................................................................i
Dedication.................................................................................................................................v
Acknowledgements............................................................................................................... vi
Table of Contents............................................................................................................... viii
Chapter 1: Introduction.........................................................................................................1
Current Understanding and Treatment of Melanoma........................................................ 1
Prognostic Indicators in Melanoma.....................................................................................5
Molecular Classification of Melanoma..............................................................................13
Differential expression of genes discovered by cDNA microarray analysis................. 16
Tissue Microarray Technology..........................................................................................32
Quantitative Immunohistochemistry..................................................................................36
Oxidation and Storage.................................................................................................... 36
Fixation and Antigen Retrieval......................................................................................37
Standardization of Immunohistochemistry...................................................................40
Quantitative Immunohistochemistry........................................................................... 43
Fluorescence-based Platforms for Quantitative Analysis......................................... 46
Statistical Approaches to Tissue Microarray Data......................................................... 53
Survival analysis: Kaplan-Meier..................................................................................53
Survival analysis: Cox Proportional Hazard Analysis...............................................54
Hierarchical Cluster Analysis......................................................................................56
Genetic Algorithms.......................................................................................................59
X-tile Analysis.............................................................................................................. 60
Model Selection and Model Assessment.................................................................... 61
Chapter 2: Subcellular Localization of Activating Transcription Factor 2 in
Melanoma Specimens Predicts Patient Survival............................................................64
Abstract.............................................................................................................................. 64
Introduction........................................................................................................................ 65
Materials and Methods...................................................................................................... 66
Tissue Microarray Construction.................................................................................. 66
Immunohistochemistry................................................................................................. 66
Evaluation of the Immunohistochemical Staining......................................................67
Statistical Analysis.........................................................................................................68
Results.................................................................................................................................69
Immunohistochemical Staining of Melanoma Tissue Microarrays.......................... 69
Survival Analysis...........................................................................................................70
Clinicopathological Correlations and Multivariate Analyses....................................75
Discussion........................................................................................................................... 76
Chapter 3: Automated Quantitative Analysis (AQUA) of HDM2 Expression in 
Malignant Melanoma Shows Association with Early Stage Disease and Improved
Outcome..................................................................................................................................79
Abstract................................................................................................................................79
Introduction......................................................................................................................... 80
Materials and Methods....................................................................................................... 83
Tissue Microarray Construction................................................................................... 83
viii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Immunohistochemistry.................................................................................................. 83
Automated Image Acquisition and Analysis............................................................... 84
Data Analysis..................................................................................................................87
Results and Discussion...................................................................................................... 87
Validation of Microarray Cohort.................................................................................. 87
Automated Analysis of HDM2 Expression in Melanoma.......................................... 90
Survival Analysis............................................................................................................91
Clinicopathologic Correlations..................................................................................... 92
Discussion........................................................................................................................... 96
Chapter 4: Automated Quantitative Analysis of AP-2 subcellular expression in
Melanoma Tissue M icroarrays Correlates with Survival Prediction......................... 99
Abstract................................................................................................................................99
Introduction........................................................................................................................101
Materials and Methods......................................................................................................104
Patients and Case Selection......................................................................................... 104
Tissue Microarray Construction..................................................................................104
Immunofluorescent Detection of MART-1 and AP-2 for Laser Scanning Cytometry
Analysis..........................................................................................................................105
Laser Scanning Cytometry Analysis............................................................................106
Immuno fluorescent Detection of SI 00 and AP-2 for AQUA Analysis....................107
Automated Image Acquisition and Analysis..............................................................108
Statistical Analysis........................................................................................................ 109
Results................................................................................................................................ 110
Immuno fluorescent staining of Melanoma Tissue Microarrays............................... 110
Automated Analysis of AP-2 Expression in Melanoma............................................112
Survival Analysis and Clinicopathological Correlations...........................................117
Discussion.......................................................................................................................... 121
Chapter 5: Improvement of Outcome Prediction in Prim ary Cutaneous Melanoma
by Quantitative (AQUA™) Analysis of Tissue B iom arkers........................................125
Abstract...............................................................................................................................125
Introduction........................................................................................................................ 127
Materials and Methods...................................................................................................... 133
Tissue Microarray Construction and Cohort Descriptions.........................................133
Biomarker Selection...................................................................................................... 134
Immunohistochemistry..................................................................................................136
Automated image acquisition and analysis..................................................................139
Data analysis...................................................................................................................140
Hierarchical Clustering..................................................................................................140
Univariate logistic regression followed by Classification Error / ROC fitting for
multivariate logistic regression m odels.......................................................................140
Aiken Information Coefficient (AIC)...........................................................................141
Genetic Algorithm..........................................................................................................142
Survival analysis.............................................................................................................143
Results.................................................................................................................................144
Protein Expression Profiling of Melanoma..................................................................144
Clustering Analysis........................................................................................................ 146
ix
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Univariate logistic regression followed by Classification Error / ROC fitting for
multivariate logistic regression models.......................................................................149
Cox Proportional Hazard and AIC...............................................................................152
Genetic Algorithm.........................................................................................................155
Discussion..........................................................................................................................162
References:................................................................................................................................ 171
x
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table of Figures
Figure 1. Cross-section of skin demonstrating the methods for measurement of Breslow
depth and Clark level......................................................................................... ............ 5
Figure 2. Fifteen-year survival curves for melanoma by stage............................... .......... 11
Figure 3. Hierarchical clustering from Hoek et al.................................................... .......... 18
Figure 4. Hierarchical clustering dendrogram from Bittner et al............................ .......... 19
Figure 5. Clustergram demonstrating the top 22 genes from Bittner et al........................ 20
Figure 6. Molecular model for melanoma invasion and metastasis........................ ......... 26
Figure 7. Categorization of differentially expressed genes...................................... ......... 28
Figure 8. Tissue microarray construction.................................................................. ......... 33
Figure 9. Effects of oxidation on tissue antigenicity............................................... ......... 37
Figure 10. AQUA software........................................................................................ ......... 48
Figure 11. Schematic of AQUA processing............................................................. ......... 52
Figure 12. Immunohistochemical staining of ATF2 in melanoma......................... ......... 70
Figure 13. Kaplan-Meier survival curves for ATF2 in melanoma......................... ......... 71
Figure 14. Kaplan Meier survival curves for risk groups defined by ATF2.......... ......... 72
Figure 15. Schematic demonstration of AQUA protocol applied to melanoma.... ......... 86
Figure 16. Melanoma TMA characteristics............................................................... ......... 89
Figure 17. HDM2 protein expression in melanoma.................................................. ..........95
Figure 18. Automated detection of AP-2 in melanocytes........................................ ....... I l l
Figure 19. LSC-based quantitative analysis of subcellular AP-2 expression....... ....... 115
Figure 20. Box plots demonstrating compartment-specific AQUA scores for AP-2.... 116
Figure 21. AQUA analysis of subcellular AP-2 expression.................................... ....... 119
Figure 22.Unsupervised hierarchical clustering of protein expression................... ....... 147
Figure 23. Semi-supervised hierarchical clustering.................................................. ....... 148
Figure 24. Missclassification error and 95% Cl for Models including Molecular Markers
+ Breslow Depth................................................................................................. ....... 150
Figure 25. Missclassification error and 95% Cl for Models including Clinicopathologic
Variables...................................................................................................................... 151
Figure 26. Plot of Akaike Information Coefficient (AIC) score by number of variables
included in Cox multivariate models.................................................................. ....... 152
Figure 27. Genetic algorithm. Plot of risk ratio by generation number.......................... 156
Figure 28. Kaplan-Meier plot of genetic algorithm applied to primary melanoma........ 157
Figure 29. Kaplan-Meier plot demonstrating stratification of patients by Breslow depth
and genetic algorithm risk score.......................................................................... ...... 158
Figure 30. Receiver-operator characteristic curve for prediction of SLN status by Breslow
depth in SLN (YTMA 76) Validation cohort.................................................... ...... 159
Figure 31. Prediction of metastasis by Breslow depth in Validation cohort.......... ...... 160
Figure 32. Prediction of metastasis by SLN status in Validation cohort................. ...... 160
Figure 33. Prediction of metastasis by GA risk test on Validation cohort.............. ...... 161
xi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Tables
Table 1. Melanoma TNM Classification.............................................................................. 10
Table 2. Stage Grouping for Cutaneous Melanoma..............................................................10
Table 3. Previous IHC Studies demonstrating markers with prognostic potential............ 15
Table 4. Comparison of genes between Valery et al. and Bittner et al. studies................. 21
Table 5. Differentially expressed genes in Seykora et al. study......................................... 23
Table 6. Enhanced gene expression in metastatic melanomas........................................... 25
Table 7. Commercially Available Automated Analysis Systems....................................... 45
Table 8. Univariate analysis of ATF2 expression by tumor site and subcellular
localization.......................................................................................................................74
Table 9. Multivariate Analysis of ATF2 Expression Pattern and Other Histopathological
Variables among Primary Lesions................................................................................ 75
Table 10. Tissue Microarray Characteristics........................................................................ 88
Table 11. HDM2 Protein Expression within Tumor Nuclei by AQUA Analysis.............91
Table 12. HDM2 Expression and Clinicopathologic Features of Primary Lesions...........93
Table 13. Characteristics of Tissue Cores Analyzed using LSC....................................... 115
Table 14. Subcellular Expression of AP-2 by Tissue Type............................................... 117
Table 15. Cox Univariate Survival Analysis of Continuous Variables.............................119
Table 16. Multivariate Suvival Analysis of AP2 Expression Pattern and Standard
Elistopathological Variables Among Primary Lesions.............................................. 121
Table 17. INITIAL LIST OF MELANOMA BIOMARKERS.........................................135
Table 18. Antibodies Examined in the Study, indicating Source, Clone, and Dilution.. 138 
Table 19. Comparison of Protein Expression Levels in Primary versus Metatstatic
Specimens......................................................................................................................145
Table 20. Top scoring variables in univariate regression.................................................. 149
Table 21. Univariate Prediction of Melanoma-Specific Death at 20 year follow-up 153
Table 22. Univariate Prediction of Melanoma-Specific Death at 20 year follow-up (Only 
Primary Specimens)...................................................................................................... 154
Xll
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 1: Introduction
Current Understanding and Treatment of Melanoma
Malignant melanoma is currently the most rapidly increasing malignancy in the 
United States.1 It is currently the sixth most common cancer in the US; for 2005, 59,580 
new cases will be diagnosed and the disease will be responsible for approximately 7,770
2 3deaths. Melanoma is also the most common fatal malignancy among young adults. 
Among cancers, its mortality rate is surpassed only by lung cancer.4 Current estimates 
predict that 1 in 71 individuals will develop melanoma during their lifetime, up from an 
initial estimate of 1 in 600 in 1960 and 1 in 150 in 1985.1 There is no clear explanation 
for this increase in incidence, though a combination of increased recreational sun 
exposure and global ozone depletion have been held partly responsible.5 However, the 
relationship between sun exposure and melanoma remains complex.
The cell of origin is the melanocyte, and melanoma can arise in normal-appearing 
skin, solar lentigo, or atypical, benign melanocytic lesions.4 Studies on familial, as well 
as sporadic, melanoma have demonstrated that there are clear genetic underpinnings to
the evolution of this disease.6'14 It appears that the genetic pathways of melanoma
12involve many genes with probable links to ultraviolet light exposure. The definitive 
diagnosis of melanoma is often quite complicated and uncertain even in the hands of the 
most skilled dermatopathologists. In addition, while a number of clinical and pathologic 
factors have been described and established as markers of prognosis, there is room for 
significant improvement in terms of accuracy. There are currently no accepted 
histopathological, molecular, or immunohistochemical markers to define subsets of this 
neoplasm.15
1
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Regarding prognosis, early detection and treatment are critical and result in 
improved patient survival rates. Surgical excision remains the mainstay of treatment but 
many new promising therapies are being investigated.16 However, non-surgical treatment
• 1 7 *of advanced disease has been largely unsuccessful. The literature regarding effective 
adjuvant therapy for melanoma is questionable at best, and experts tend to recommend 
that patients with advanced disease enroll in a clinical trial.18
The prognosis of isolated, primary cutaneous melanoma remains favorable, with a 
5-year overall survival rate above 90%. However, the discovery of metastatic disease 
dramatically affects outcome. The presence of regional lymph node metastases reduces 
5-year overall survival rates to 10-46%.19 Although the use of sentinel lymph node 
biopsy has improved the staging of melanoma, there is a critical need to determine the 
metastatic potential of melanoma early in disease progression. It is not uncommon to 
have widely disseminated disease at the time of initial diagnosis. The fact that patients 
with local or nodal recurrences fare as poorly as those with overt distant metastases 
implies that the former events are predictors of subclinical systemic disease.20 A more 
precise staging system is needed; one which will take into account the aggressive nature 
of the disease.
The histopathologic progression of melanoma is thought to progress through a 
series of defined stages, yet melanoma has been shown to arise spontaneously in the 
context of normal-appearing skin. Normal skin typically has an even distribution of 
melanocytes at the basal layer of the epidermis, with one melanocyte found for every 4 or 
5 basal cells.21 The compound nevus, a benign proliferation of melanocytes, is defined 
by uniform nests of melanocytes. The dysplastic nevus demonstrates irregular and
2
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bridging nests of atypical melanocytes. In situ melanoma remains confined to the 
epidermis. Early melanoma development is characterized by the radial growth pattern. A 
vertical growth phase can follow, which is thought to indicate the transition to a more 
aggressive and lethal condition, characterized by tumor invasion into the underlying 
dermis and subcutis, and often presages metastasis to distant sites. While melanoma 
tends to spread to nonvisceral sites such as skin or lymph nodes, it is notorious for its
ability to metastasize to practically any organ, including lung, liver, brain, bone, and
22small intestine.
Initial management of the primary lesion is by surgery. A wide local excision 
removes the tumor along with a margin of normal appearing skin. Current clinical 
guidelines dictate that the margin of excision be proportional to the depth of tumor 
invasion into the skin. If the tumor depth is < 1 mm, a 1 cm margin is recommended, 
while a depth of 1 -2 mm suggests a 1 -2 cm margin. When the tumor depth exceeds 2
23 24mm, guidelines recommend a 2 cm margin of normal skin. ’ The surgical treatment of 
melanoma, in particular, can range from a marginal biopsy to wide local excision with 
regional lymphadenectomy, and advance in some cases to include extraction of distant 
metastases.
Adjuvant therapy for melanoma is limited at best. Over the past 20 years, 
numerous agents have been evaluated in a series of both nonrandomized and randomized 
adjuvant therapy trials in melanoma patients. While many of these clinical trials suffered 
from serious methodological problems such as inadequate statistical power, use of 
inappropriate controls, and/or lack of stratification for known prognostic factors, the 
major obstacle to the success of adjuvant therapy of melanoma has been the lack of active
3
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agents. Popular agents that have demonstrated little or no benefit include: BCG, 
levamisole, interferon gamma, interleukin-2, retinoids, dacarbazine, and megestrol 
acetate.25
High-dose interferon (IFN) alpha-2b is the only FDA-approved agent for the 
adjuvant treatment of melanoma in the US. This treatment is used predominantly for 
high-risk, stage III (i.e., lymph node disease) patients with cutaneous primaries; these 
patients have a 50-85% risk of further metastasis.19 However, the benefit of this 
treatment is controversial. The initial multicenter study, in 1995, reported improved 
long-term and disease-free survival in melanoma patients.26 However, more recent 
clinical trials have demonstrated that while there is an approximate 10% reduction in risk 
of recurrence, there is no effect on overall survival. In addition, despite 20 years of 
study, the mechanisms of IFN’s antitumor activities remain unknown. Studies speculate 
that its efficacy may lie in its immunomodulatory functions, its antiangiogenic activities, 
or it may have direct antiproliferative effects on melanoma.27 Without understanding its 
mechanism of action, surrogate markers of response/remission cannot be used to guide 
dose selection and duration of therapy.
The absence of effective medical treatment for melanoma leads many patients 
with advanced disease to enroll in clinical trials. Current experimental treatments for 
melanoma are based on immunotherapy, through immune-boosting cytokines (e.g., IL-2 
or GM-CSF) and/or vaccines against melanoma-specific antigens, or molecularly- 
targeted therapy with specific inhibitors.
4
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Prognostic Indicators in Melanoma
Prognosis in melanoma is currently determined by a number of factors unique to 
the primary lesion, as well as the presence of loco-regional (lymph node and in-transit 
metastases) and distant metastatic disease. Over the past 30 years, a number of models 
have been developed to predict patient outcome for cutaneous melanoma based on 
characteristics unique to the primary lesion. The information gleaned from these studies, 
through both univariate and multivariate analyses, has been incorporated into the most 
recent Melanoma Staging System of the American Joint Committee on Cancer (AJCC). 
The first published reports of variables to predict survival in primary melanoma
78 70 70came with publications from A Breslow ’ and WH Clark in the 1970s. The models 
they described have changed little and remain the most powerful and reliable predictors 
of survival based on characteristics of the primary cutaneous lesion. The figure below
77demonstrates how each of these criteria are measured:
Breslow
Thickness
Clark’s
Level Boundary
Granular cell layer I
Epidermis I I
Papillary dermis I I I
'Reticular dermis IV
Subcutaneous fat V
Intra-epidermal
Breaching of the epidermal-dermal 
basement membrane and involves 
the papillary dermis
Tumor fills the papillary dermis 
forming a cohesive nodule or plaques
Invasion into reticular dermis
Invasions into subcutaneous fat
Figure 1 (adapted from Chin et al. ). Cross-section of skin demonstrating the methods for 
measurement o f Breslow depth and Clark level.
Wallace Clark first described the phenomenon of the ‘early radial’ and Tate 
vertical’ growth phases in primary cutaneous melanoma. He also demonstrated that the
5
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radial growth phase is only rarely associated with the development of metastases, while 
the vertical growth phase is more commonly associated with subsequent metastatic 
disease. From these observations, he developed a classification system for staging 
primary cutaneous melanomas, in which the depth of tumor invasion is measured relative 
to the anatomical layers of the skin. Alexander Breslow’s classification suggests that 
incidence of metastasis in primary cutaneous melanoma is proportional to maximal tumor 
thickness; it is based on the direct measurement (depth in millimeters) of invasion from 
the lowest level of the epidermis to the deepest level of invasion.
Clark’s measurement is an indirect measure of tumor thickness and is not as 
accurate as Breslow’s in predicting metastases because of the marked variation in 
thickness within each level30, which can also vary depending on anatomical location.
The marked variability in skin layers and the difficulty in discriminating those layers 
from each other leads to a great deal of interobserver variability amongst pathologists.
For these reasons, the Breslow depth remains a stronger and more reliable predictor of 
metastatic potential.
The current AJCC Staging Sytem for local disease is based on the following 
criteria: tumor thickness (Breslow thickness), ulceration, and—in the case of very thin 
lesions—level of invasion (Clark level).19 However, there are a number of other factors
31that have shown significant prognostic value in melanoma. Among the clinical
TO 'X f* 7 ^  7 7prognostic factors are: age ' (older age is unfavorable); gender ' (females have
i f  i o  n n
improved survival over men); and anatomical location ’ (head, neck and axial 
melanomas fare worse than melanoma on the extremities).
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In addition to Breslow measurement and Clark level, a number of other 
histopathological characteristics in melanoma have been observed to correlate with 
disease outcome. Other strong histological predictors of outcome include: lesion 
ulceration35’41"46, mitotic rate47, and microscopic satellitosis (discrete nests of tumor cells 
separated from the main body of the tumor by normal subcutaneous tissue). Less 
powerful histopathological factors include: histologic subtype (i.e., superficial spreading, 
nodular, lentigo maligna, acral lentiginous, desmoplastic; acral and nodular melanomas 
may be more aggressive than other types4), angiogenesis48, vascular invasion, regression, 
and tumor infiltrating lymphocytes. Of all clinical and pathological criteria, the majority 
of studies demonstrate that tumor thickness (Breslow) is the most reliable independent 
prognostic factor in cutaneous melanoma.28,35,39,40,42,43,49"54
Current methods of prognosis in cutaneous melanoma are far from precise, and, 
aside from minor adjustments, have not changed much over the past 30 years. It should 
be noted that the mortality rate from melanoma is decreasing but this has been associated 
with earlier clinical recognition (on the part of patients and their physicians) and 
expedited surgical treatment. It is important to note that the histopathologic 
characteristics of the primary tumor may not necessarily be indicative of tumor 
aggressiveness. There are a surprisingly large number of cases of melanoma in which 
tumor thickness does not predict outcome; cases in which thin melanoma turns out to be 
aggressive36,38,44,54-76 or thick melanoma indolent77-80.
Regarding loco-regional or metastatic disease, the “up”-staging of melanoma has 
become dependent upon sentinel lymph node (SLN) biopsy. It is imperative to determine 
if a patient has metastatic disease—regional or distant—at the time of initial diagnosis for
7
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proper staging. Originally developed to aid in the prognosis and treatment of penile
carcinoma, it has become common practice in the diagnostic evaluation of a number of
81 *cancers, particularly melanoma. The procedure for SLN biopsy involves the injection
of a colored dye, as well as a radiotracer, to determine the lymphatic drainage of a
primary tumor and identify the first lymph nodes in a regional group. The SLN serves as
a guide to the status of the rest of the nodes in the respective lymph node basin. If the
SLN is negative for disease, it can be assumed that rest of the regional nodes are also
negative. If this is the result, the patient will be spared an “unnecessary”, invasive and
debilitating procedure.
Techniques in surgery and nuclear medicine have advanced so rapidly that SLN
biopsy is now a well-established standard procedure in many countries.82 It is a relatively
accurate mechanism for predicting the pathologic status of regional lymph nodes, and, in
O'}
turn, aiding in the prediction of patient outcome. Shown to be the most important 
prognostic factor in determining survival in melanoma , it has become an essential 
component of the AJCC TNM classification of melanoma.19
The decision to perform a sentinel lymph node biopsy (in the absence of clinically 
apparent LN disease) is typically based upon the Breslow depth of the primary lesion.
The criteria necessary to go forth with this procedure varies from surgeon to surgeon. It 
is often based on the surgeon’s discretion. Generally, the threshold for performing a 
sentinel lymph node biopsy in the absence of clinical lymph node involvement is a
o c  .
primary lesion around 1 mm thick , and the procedure is quickly becoming the standard 
of care for patients with primary melanoma greater than 1 mm in thickness.86 The true
8
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benefit of this procedure lies in its ability to aid in the accurate staging of patients for 
prognostic purposes.
The degree of sentinel lymph node disease, in which the lymph node disease 
ranges from only detectable at the molecular level (i.e., through RT-PCR analysis for 
melanoma-specific markers) to grossly apparent (i.e., large pigmented deposits in lymph 
nodes), and its relevance to prognosis is under investigation by a number of groups. 
Because of the precision afforded by SLNB, the AJCC revised its staging system for 
melanoma.19 Nodal involvement is distinguished first on the basis of the number of 
nodes with disease, and then on micro- versus macro-scopic involvement. It should be 
noted that IHC increases detection rate in SLN by at least 10% over H&E alone.87 The 
staging system is demonstrated by the tables below:
9
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Table 1. Melanoma TNM Classification (adapted from Balch et al.)19
T classification Thickness Ulceration Status
T1 <1.0 mm a: without ulceration
b: with ulceration or Clark level > III
T2 1.01-2.0 mm a: without ulceration 
b: with ulceration
T3 2.01-4.0 mm a: without ulceration 
b: with ulceration
T4 >4.0 mm a: without ulceration 
b: with ulceration
N classification No. of Nodes Nodal Metastatic Mass
N1 1 node a: only detected by pathology 
b: clinically detectable
N2 2-3 nodes a: only detected by pathology
b: clinically detectable
c: in transit mets without nodal disease
N3 > 4 nodes
M classification Site Serum LDH
M ia Distant skin, subcutaneous, or nodal 
mets Normal
M lb Lung metastases Normal
M lc All other visceral metastases Normal
Any distant metastases Elevated
Table 2. Stage Grouping for Cutaneous Melanoma (adapted from Balch et al)19
Stage T N M
0 Tis NO M0
IA Tla NO M0
IB Tib
T2a
NO M0
IIA T2b NO M0
T3a NO M0
IIB T3b NO M0
T4a NO M0
IIC T4b NO M0
III Any T N1 or N2 or N3 M0
IV Any T Any N Any M l
10
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The following graph demonstrates Kaplan-Meier survival curves for 17,600 
melanoma patients, grouped by the new staging system. The AJCC staging system for 
melanoma appears to be quite reliable for predicting survival based on primary tumor 
characteristics and nodal/metastatic status.19
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Figure 2 (adapted from Balch et al.19). Fifteen-year survival curves comparing localized 
melanoma (stages II and I), regional metastases (stage III), and distant metastases (stage IV). The 
numbers in parentheses are patients from the AJCC melanoma staging database used to calculate 
the survival rates. The differences between the curves are significant (P < .0001).
To date, there have not been any widely accepted immunohistochemical—or 
other molecular—markers to predict patient outcome or guide therapy in melanoma. 
There is a need for a more precise diagnosis of melanoma through molecular staging, 
similar to the use of HER2 in breast cancer. One of the major impediments to the 
development of useful molecular assays for melanoma is the absence of any molecularly- 
targeted therapy for the disease. In fact, there are no effective biological, 
chemotherapeutic, or biochemotherapeutic treatments for melanoma. There have been
11
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some attempts to develop molecularly targeted therapies for melanoma but success, at 
even the level of cell culture, is rare; translation to the clinical setting is rarer still.
There have been a number of studies that have evaluated markers on an individual 
basis and on a relatively small number of patients.88,89 In addition, none of these studies 
have made use of automated quantitative analysis. Differences in expression levels in the 
tissues have been based on those that are perceptible only by the human eye. Those 
molecular markers that have not shown statistical significance may not have been 
evaluated on a large enough patient cohort.
The advent of high-throughput genomic technologies has made it possible to 
survey the expression of a large number of genes simultaneously in cancer tissue. 
Additionally, the availability of quantitative analysis introduces the ability to more 
accurately discriminate expression levels within tumors and relate those to recurrence, 
survival, and response to therapy.
While a number of clinical and pathologic factors have been established as 
markers of prognosis, no marker, molecular or morphologic, can exceed the predictive 
strength of assessment of metastasis to lymph nodes. The presence of metastasis to 
lymph node metastases reduces 5-year overall survival rates by between 10 and 30%, for 
any given stage of the disease.90
The use of sentinel lymph node biopsy has significantly improved the staging of 
melanoma, but this procedure is both morbid and imperfect. In a recent series by our 
collaborator, Dr. Stephan Ariyan, only 11% of 263 patients showed metastasis in the 
sentinel node. Although this rate is somewhat lower than other larger series91, highest 
numbers from other studies are near 25% and related to the depth of the primary tumor.
12
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Overall, between 75% and 90% of the procedures are done unnecessarily. Furthermore, 
of the 10% of the patients in the Yale study that developed local recurrence or distant 
metastasis, only about half were predicted by positive sentinel nodes. In other studies as
92many as 25% of negative nodes will ultimately develop recurrent disease. Thus, there 
is a critical need to predict which patients will have nodal disease, or more importantly, 
which patients have a disease subclass that will progress compared to those that will not.
This clinical problem is compounded by the fact that the amount of tissue 
available for making this determination is often very small. It has, historically, been 
difficult to look at low stage melanomas since the material is nearly completely 
exhausted at diagnosis. A number of new developments that have been advanced in the 
last few years can now be combined to address this issue.
Molecular Classification of Melanoma
While the morphological biology of melanoma progression is well described, the 
genetic changes that take place as lesions invade deeper and ultimately become metastatic 
are not well understood. Work is under way in a number of laboratories to describe these 
changes and use them for their prognostic potential (to help predict aggressive potential) 
and ultimately develop therapies that target these changes. No single marker has 
distinguished itself in a manner that it has been broadly accepted, but many markers have 
shown promise in small, single institution studies or in basic cell biological studies.
These efforts provide a good starting place for our goal of predicting metastatic potential. 
We aim to take advantage of these efforts to select markers whose expression is likely to 
be correlated with metastasis, based on the historic, basic and translational work related 
to each marker. Data from cDNA array studies suggest numerous markers will be
13
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required for disease classification or prediction of metastasis. We believe this will also 
be true of protein markers, although we believe substantially fewer markers are required.
A number of studies have been performed identifying gene expression profiles 
unique to melanoma relative to normal melanocytes or nevi. In addition, a number of 
relatively small-scale immunohistochemical and in situ mRNA-DNA hybridization 
studies have been published over the past few years. Additionally, it has been 
demonstrated that previously unrecognized gradations of melanoma can be distinguished
15by gene expression profiling.
We seek to discover a set of molecular markers that can be used as an 
independent predictor of survival, to be used on a regular basis to aid in patient 
prognosis. Assessing a small battery of markers at the time of initial diagnosis will aid 
clinicians in the prognosis of their patient’s disease, and may, in some cases, provide 
therapeutic guidance. Though the current aim of this project is to define aggressive 
melanoma from ‘benign—less aggressive’ melanoma, a number of molecular targets will 
be defined that may have therapeutic potential.
14
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Table 3. Previous IHC Studies demonstrating markers with prognostic potential:
Author/Date Markers Patient/Sample Number Correlation with Survival
Eliopoulos, P. M R  2002” •  HER-2 51 lesions > 10 mm /  1 lesions < 1 mm • HER-2 overexpressed in 29.4%  o f  thick lesions; 
none in thin.
•  N o prognostic significance in this study.
Ferrier, CM. B JC  200094 •  tPA
•  uPA
• PAI-1
•  PAI-2
•  uPAR
214 primary melanomas (only local disease at 
time o f  acquisition)
•  High tPA expression correlates with good  
outcome.
Florenes, VA J P a th  200395 •  Cyclin A
• Ki-67
172 primary (110 sup + 62 nod) /  73 mets /  10 
nevi
•  Cyclin A  independent predictor o f  survival 
(p=0.0003) in SSM .
•  Cyclin A  & Ki67 correlate with depth in SSM.
Florenes, VA. CCR  2000” •  Cyclin D1
• Cyclin D3
172 primary (110 sup + 62 nod) /  73 mets /1 0  
nevi
•  Cyclin DI expression correlates with SSM  
relapse (p<0.001) and early death (p=0.009)
Florenes, VA. A JP  1998'" •  p27 113 primary /  45 metastases (36 distant) / 4 nevi •  Inverse correlation with DFS (stronger in nodular 
than SSM ).
G radilone”  A. JC O  2003 •  Survivin
•  bcl-2
•  bax
• bcl-X
36 SL N ’s evaluated by RT-PCR (and IHC in 
som e cases)
•  Survivin expression correlates with survival, but 
not bcl-2, bax, or bcl-X.
Flieken, TJ. Cancer 1999” •  p53
•  p i  integrin
• 33 integrin
111 intermediate-thickness primary melanomas •  p53: no association with survival.
•  pi integrin: correlates with survival (p=0.0004)
•  p3 integrin: correlates with survival (p=0.0001)
Kageshita, T. B JD  2001 ™ •  P-catenin 91 primary /  50 mets /  50 nevi •  Loss o f  P-cat expression associated with disease 
progression. Thickness inversely correlates with 
B-cat.
Karjalainen, JM. A JP  2000191 •  CD44
•  Hyaluronan
292 stage I melanomas •  Reduced cell surface CD44 and HA levels 
associate with poor prognosis.
Kunz, M. A D V 2002192 •  Thombospondin2
• Desm oglein 2
Tbsp2: 5 primary and 5 mets 
Dsmg2: 20 primary and 20 mets
•  Neither antibody stained well in primaries, but 
all mets show ed expression o f  Thrombospondin 2 
and Desm oglein 2.
Massi, D. Hum Path  1999™ •  Osteonectin 188 thin primaries •  Osteonectin overexpression correlates with 
progression and betastasis.
Miranda, E. JS O  2003"“ •  Apo D 32 invasive /  8 in situ  / 1 0  benign lesions •  Apo D  expression higher in nodular (p = 0.011).
•  Signifcant corr with Clark (p=0.046)
Morgan, MB. A JD P  1999"° •  p27 (kipl) 21 melanomas /  21 Spitz nevi /  21 compound 
nevi
•  N o difference in staining between groups.
•  N ot useful in distinguishing between lesions.
Niezabitowski, A. JSO  1999106 •  Ki-67
•  PCNA
•  p53
• Vimentin
•  S100
•  HMB45 
(gplOO)
•  Vimentin
93 patients •  Ki-67, PCNA, & HMB45 overexpression  
correlate with decreased survival.
Ostmeier, H. C ancer 1999lu/ •  VLA-2
•  HLA- 
ABC
•  HLA- 
DR
•  NKI- 
beteb
•  Mel 14
•  ICAM-1
•  K -l-2
•  G-7-E2
•  H-2-4-7
> 500 primary melanomas • N one o f  these markers improved the prognostic 
model that included Breslow, localization, or 
mitoses.
Ostmeier, H. BJD  2 0 0 I1"* •  Ki-67
•  HLA- 
DQ
•  HLA- 
DP
•  M uc 18
•  A -10-33
•  Transferrin 
receptor
•  H -2-8-10
Biopsies from 688 patients •  Ki-67 (n=399) and HLA-DQ (n=452) retain 
prognostic significance in multivariate analyses.
P o lskyD  JN C 1 2002™ •  HDM2
•  p53
•  Ki-67
134 patients •  HDM 2 overexpression correlates with survival.
Salti, GI. CR  200 0 1"1 •  MiTF 63 intermediate thickness (l-4m m ) melanomas •  Increased MiTF expression correlates with 
improved survival.
Sparrow, LE. A JD P  1998*11 •  MIB-1 11 thin that later metastasized / 11 thin control 
tumors (nonprogressors)
25 benign and 70 malignant melanomas
•  Strong correlation with Clark (r=0.71)and 
Breslow (r=0.77)
Straume, O. A JP  2002112 •  VEGF-C
•  FLT-4
• bFGF
•  FGFR-I
•  IL-8
•  Ephrin- 
A1
•  EphA2
202 VGP melanoma cases / 68 mets from 58 
p t’s
•  Ephrin-Al con-elated directly with Breslow  
(p=0.017), Clark (p=0.004), &  ulceration
(p=0.006)
Straume, O. CCR  2000* •  p i 6
•  Ki-67
•  p53
Same as above •  loss o f  nuclear p l6  = increased Ki-67 and poor 
prognosis
•  absence o f  p53 correlates with improved survival
Straume, O. A /P  2001 *1U •  VEGF
•  Flt-1, kdr
•  Tsp-1
Straume, O. / J C \9 9 1 Ui •  p l6
•  p53
102 nodular melanomas •  Loss o f  p l6  expression con-elates with reduced 
survival & recurrent disease (p=0.013)
•  p53 was not prognostically important.
Vaisanen, A. J  Path  1998“ * •  MMP-2 50 primary skin melanomas •  High M M P-2 expression indicates an 
unfavorable prognosis.
Although some of the studies listed above have demonstrated that the levels of 
melanoma-associated proteins can serve as markers to predict disease outcome, there are
15
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a multitude of genes and gene products with prognostic potential in patients with 
localized melanoma. The expression of thousands of genes in melanoma tumors and cell 
lines can be surveyed using cDNA microarrays. It has been proposed for various cancers 
that a discrete and previously unrecognizable cancer taxonomy can be identified by 
assessing the systemized data acquired from gene expression experiments.15 Most gene 
expression studies reported thus far have been based on cell lines, which may not be 
entirely representative of in vivo tumor biology. The data acquired must be validated on 
in vivo models and patient samples.
Differential expression of genes discovered by cDNA microarrav analysis
Melanoma is an unpredictable cancer. It is not clear what genetic changes take 
place in melanoma progression. Through comparative gene expression studies, a number 
of investigators are intensively trying to understand the molecular pathogenesis of 
melanoma. As this cancer remains refractory to virtually every pharmacologic treatment, 
and has an incredible potential for aggressive growth, it is not surprising that many 
melanoma patients submit themselves to toxic and experimental therapies.116 The 
products from cDNA microarray analyses not only provide validation of previously 
identified biomarkers, but also offer new genes that might be useful in molecular 
diagnosis, pathogenesis studies, and possible molecular targets for therapeutic 
interventions.
In collaboration with Dr. Ruth Halaban, we have participated in a study which
117sought to profile genome-wide changes in melanoma. Using cDNA microarrays, 
global expression changes were assessed in melanomas compared to normal melanocytes 
(harvested from newborn foreskins). Affymetrix and spotted oligonucleotide microarrays
16
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were used to assess global differential gene expression comparing normal human 
melanocytes with six independent melanoma cell strains from advanced lesions. The 
data, validated at the protein level for selected genes, confirmed the overexpression in 
melanoma cells relative to normal melanocytes of several genes in the growth 
factor/receptor family that confer growth advantage and metastasis. In addition, novel 
pathways and patterns of associated expression in melanoma cells not reported before 
emerged, including the following: (a) activation of the NOTCH pathway; (b) increased 
Twist expression and altered expression of additional transcriptional regulators 
implicated in embryonic development and epidermal/mesenchymal transition; (c) 
coordinated activation of cancer/testis antigens; (d) coordinated down-regulation of 
several immune modulation genes, in particular in the IFN pathways; (e) down-regulation 
of several genes implicated in membrane trafficking events; and (j) down-regulation of 
growth suppressors, such as the Prader-Willi gene NECDIN, whose function was 
confirmed by overexpression of ectopic Flag-necdin. Validation of differential expression 
using melanoma tissue microarrays showed that reduced ubiquitin carboxy-terminal 
esterase LI in primary melanoma is associated with worse outcome and that increased 
expression of the basic helix-loop-helix protein Twist is associated with worse outcome. 
Some differentially expressed genes reside on chromosomal regions displaying common 
loss or gain in melanomas or are known to be regulated by CpG promoter methylation. 
These results provide a comprehensive view of changes in advanced melanoma relative 
to normal melanocytes and reveal new targets that can be used in assessing prognosis, 
staging, and therapy of melanoma patients.
17
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In summary, the data demonstrate that changes take place in previously 
recognized melanoma-activated pathways (e.g., upregulation of transcriptional proteins, 
activation of cancer/testis antigens, downreguation of immunomodulatory gene 
expression and growth suppressor expression), as well as some novel associations (e.g., 
upregulation of the NOTCH pathway). The figure below demonstrates unsupervised 
hierarchical clustering of gene expression profiles in these melanoma cell lines and 
normal melanocytes.
Figure 3 (adapted from Hoek et al.117). Hierarchical Clustering. Cluster map and 
phylogenetic tree resulting from a hierarchical cluster analysis of normalized intensity 
data across two control (melanocytes; NM) and six sample (melanoma, as indicated) data 
sets. Genes were selected for clustering according to a fold change and signal intensity 
cutoff protocol described in the text. Clustering was performed using GeneSpring 6.0 
(Silicon Genetics, Inc.).
Bittner et al.15 examined the expression profiles for 31 melanomas—biopsies and 
cell lines—relative to 7 control cell lines. Using a matrix of Pearson correlation 
coefficients from complete pair-wise comparison of all experiments, the authors 
developed a hierarchical clustering dendrogram as well as a three-dimensional
18
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multidimensional scaling (MDS) plot. The MDS plot displays the position of each tumor 
sample in relative Euclidean space; the distance between them represents their 
approximate degree of correlation.118 With this plot, the authors were able to distinguish 
a gene expression profile unique to 19 of the melanomas. The figures below display the 
dendrogram and MDS plot showing the major cluster of 19 samples (within the cylinder) 
and the relative expression of the top 22 genes used to discriminate this cluster. Their 
analysis is by no means complete, and they state that “the extent to which melanoma 
samples can be clinically subdivided by expression patterns remains to be elucidated.” 
The information their ‘weighted’ list of genes provides should allow for the dissection of 
other clinically relevant subsets for melanoma.
Dendrogram MDS Plot
J'i
34 :
3 5  :
■J 1
4  ■
<1 - 
- i ; .
- t . f i  . i
t:
Figure 4 (adapted from Bittner et al.15). [Left] Hierarchical clustering dendrogram demonstrating 
a unique cluster of 19 melanomas at the centre. [Right] MDS three-dimensional plot of all 31 
cutaneous melanoma samples showing major cluster of 19 samples (blue, within cylinder).
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Top 22 Genes
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Figure 5 (adapted from Bittner et al.15). After MDS analysis, ranking genes according to their 
impact on minimizing cluster volume and maximizing centre-to-centre inter-cluster distance, this 
clustergram demonstrates the top 22 genes obtained by these criteria listed in order of decreasing 
weight.
Based on the results of the above study, Weeraratna et al. investigated the role of 
WNT5A in melanoma further. In transfected cell lines, they demonstrated that WNT5A 
expression correlates with increased cell motility and invasiveness. They were also able 
to show that WNT5A expression in human melanoma biopsies correlates directly with 
increasing tumor grade, and inversely with patient survival.119
Valery et al.120 identified the target genes of ultraviolet (UV) stress response by 
culturing normal human melanocytes in the presence of UV irradiation. Out of the -9000 
genes on their cDNA microarray, they noted that 198 were found to be modulated >1.9 
times over the non-irradiated cells. The majority of the genes they identified are involved 
in DNA or RNA binding/synthesis/modification or ribosomal proteins. Others included 
transcription factors, receptors, tumor suppressors and oncogenes. Although they did not 
perform any cluster analyses, they did compare their results with those of the Bittner15
20
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
study (Table 4). Although the identified genes are not necessarily melanoma-specific, 
they are potential markers of disease, capable of being used in the development of new 
molecular-based strategies for risk prediction in melanoma patients.
Table 4. Comparison of genes between Valery et al. and Bittner et al. studies.
Clones IValery e t  a l .  | Bittner e t  a l .
Concordant Up-Regulation
Actin-related protein 2/3 complex, subunit IB (41 kDa) 4- 4- |
Actin, gamma 1 4- 4- |
Adenine phosphoribosyltransferase 4- +  |
Adenylate cyclase 9 4- 4- J
Aquaporin 4 f + J
ATP synthase, H+ transporting, mitochondrial FO complex, subunit c (9) isoform 3 4- 4- j
ATP synthase, H+ transporting, mitochondrial FI complex, a-subunit, isoform  1, cardiac muscle 4- 4- |
Receptor (calcitonin) activity modifying protein 1 4- +  1
Guanylate kinase 1 4- +  J
Human clone 23815 mRNA sequence 4- +  |
Mannosidase, alpha, class 2B, member 1 4- 4- |
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7 (18 kDa, B18) 4- 4- ]
Phosphofructokinase, liver 4- +  |
Protein tyrosine phosphatase, receptor type, c polypeptide-associated protein 4- 4- |
Ribose 5-phosphate isomerase A (ribose 5-phosphate epimerase) 4- 4- |
Ribosomal protein LI 0 4- 4- |
Ribosomal protein LI 9 4- 4- |
Ribosomal protein S 14 4- 4- j
Syndecan 4 (amphiglycan, ryudocan) 4- 4-
Concordant Down-Regulation
Apoptosis inhibitor hiap-1 - -
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 - -
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase 68 kDa) - -
E74-like factor 1 (ets domain transcription factor) - -
Fibronectin 1 - -
Hypoxia-inducible factor 1, alpha subunit (basic helix~ Ioop—helix transcription factor) - -
Interferon regulatory factor 2 - -
Mitogen-activated protein kinase kinase kinase 7 - -
Multimerin - -
Protein tyrosine phosphatase, nonreceptor type 12 - -
Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 - -
Solute carrier family 12 (sodium/chloride transporters), member 3 - -
SON DNA binding protein - -
Translin-associated factor X -
Zinc finger protein 184 (Kruppel-like) -
Zinc finger protein 38 (KOX 25) -
Discordance
arsA (bacterial) arsenite transporter, ATP-binding, homolog 1 4- -
C3H-type zinc finger protein; similar to D, melanogaster muscleblind B protein - +  |
Chromodomain helicase DNA binding protein 1 - +  |
Coatomer protein complex, subunit beta - 4- |
Hypothetical protein PI p373c6 - 4- |
Interferon, gamma-inducible protein 16 +
Kinesin family mem ber 5B 4-
Laminin receptor 1 (67 kDa, ribosomal protein SA) 4-
Leucine-rich repeat (in FLII) interacting protein 1 +
Maior histocompatibility complex, class I, C 4- 1
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Clones Valery et al. [Bittner et al. |
Myosin, light polypeptide 1, alkali; skeletal, fast + -
Myosin, light polypeptide 6, alkali, smooth muscle and nonmuscle + -
Pre-B-cell colony-enhancing factor - + |
Proteasome (prosome, macropain) subunit, beta type, 6 + -
RAN binding protein 2 like 1 - + and - |
Ras-GTPase-activating protein SH3-domain-binding protein - + ]
Ribosomal protein L28 f -
Ribosomal protein S23 f -
Serum/glucocorticoid regulated kinase - + |
Solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 - -l- |
Suppression o f  tumorigenicity 16 (melanoma differentiation, ST16) + |
Transducin-like enhancer o f split 4, homolog o f Drosophila E (spl) + -
UDP-glucose ceramide glucosyltransferase - + J
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog +• |
Zinc finger protein 7 (KOX 4, clone HF.16) +- |
+ = overexpressed; - = underexpressed I
Seykora et al.121 demonstrated differences in gene expression between nevi and 
melanomas. Nevi mRNA was pooled from four benign melanocytic lesions, while 
melanoma mRNA was collected from two nodular primaries and two metastatic lesions. 
It is not clear how pooling samples from different locations (and possibly different 
patients) may have affected the results of their experiments, but they do provide a chart 
demonstrating genes that can be used to classify nevi and melanoma.
22
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Table 5. Differentially expressed genes in Seykora et al. study.
Ratio of Expression in 
Melanoma Relative to Nevi
Expressed GADPH 0.9
similarly in HLA Class I 1.3
melanoma Matrix metalloproteinase 14 precursor 0.9
and nevi Fibroblast growth factor 8 1.0
Glia-derive neurite-promoting factor 1.1
Expressed Cdc2-related protein kinase 3.5
preferentially Cyclin D 1 2.7
in melanoma PCNA 1.3
c-Jun N-terminal protein 3.3
c-Myc binding protein MM1 13.5
Notch 2 4.3
CD59 10.25
P4 integrin 3.7
Matrix metalloproteinase 17 3.3
Nucleoside diphosphate kinase B 3.5
Early growth response protein 1 5.2
Pleiotrophin 33
40S ribosomal protein 3.5
Expressed Growth factor receptor bound protein 2 0.8
preferentially Glutathione-S-transferase homolog 0.8
in nevi Fibronectin 0.6
a3 integrin 0.7
Using the DermArray® DNA microarray, Dooley et al.122 investigated novel 
markers of human melanocytes in two experiments. The DermArray DNA microarray 
contains over 26,000 unique human cDNAs, with a number of them (important in 
dermatology research) spotted in triplicate to aid in statistical analyses. In their first 
experiment, they compared normal melanocyte cells to keratinocytes and fibroblasts. In 
the second experiment, they compared normal melanocytes to two melanoma cell lines; 
one primary (MS7) and one metastatic (SKMel-28).
Clark et al.123 devised a clever study to identify novel genes specific for 
melanoma metastases. Starting with weakly metastatic parental cell lines (mouse and 
human melanomas), they performed an in vivo serial selection scheme in mice to derive a 
robust metastatic cell line. The gene expression profiles of subsequent metastatic
23
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pulmonary tumors were compared to the primary tumors. The table below demonstrates 
the thirty-two out of approximately 7000 genes with enhanced expression levels (>2.5 
fold) in the metastatic tumors.
24
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Table 6. (adopted from Clark et. al123). Enhanced gene expression in metastatic
melanomas
Fluman A3 7 5 Mouse B16
Pulm. Pulm. Pulm. Pulm. Pulm. Pulm.
Gene Name Met #1 Met #2 Met #3 Met #1 Met #2 Met #3
Fibronectin 10.1 3.2 4.0 2.8 2.8 2.8
RhoC 4.7 3.1 4.0 2.9 4.9 2.5
Thymosin (34 3.3 3.6 3.5 4.1 3.5 3.5
t-PA 5.2 9.6 5.2
Angiopoietin 1 4.3 9.4 3.3
IEX-1/Glu96 9.1 3.3 4.5 0.4 0.6 0.5
RTP/NDR1 8.6 5.4 4.7 A 0.7 1.5
Fibromodulin 8.3 4.7 8.2 2.0 2.0 1.1
Hsp70 7.8 4.2 5.0 2.1 1.8 1.8
IL13 Receptor 7.6 2.9 3.1
Sec61J3 3.8 4.7 3.3
snRNP, polypep C 3.8 5.3 3.2
Collagen Ia2 2.5 3.6 3.6 3.1 2.3 3.7
UBE21 3.6 3.4 3.4
TGF|3 superfamily 3.4 3.4 3.0
Surfactant protein C 32 12 16
Lysozyme M 20 10 22
KIAA0156 3.6 3.4 3.4
Matrix Gla protein 3.2 4.4 1.1 12 11 5.4
Tsa-1 9.7 6.1 7.2
Collagen Illa l 8.2 5.6 5.5
Biglycan 3.7 3.7 3.8 4.4 6.9
a-catenin 1.3 1.0 1.9 3.4 3.0 5.7
Valosin-cont. protein 3.0 3.9 5.9
ERK-1 2.6 2.6 3.0
a-actinin 1 3.6 3.3 7.3
calmodulin 4.8 6.7 5.5
EIF4y 4.7 3.2 2.6
a-centractin 2.9 3.8 3.6
IQGAP1 3.6 3.5 3.2
cathepsin S 2.8 2.8 3.1
EF2 2.6 2.5 2.9
The most interesting genes expressed in the highly invasive tumors included 
genes involved in cytoskeletal organization and cell migration (an observation also 
observed in Bittner et al.). Three of the genes identified by Clark et al. — those encoding 
fibronectin, thymosin 04 and RhoC — showed increased expression in all of the human
25
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and mouse melanoma-derived metastases. Anne Ridley suggests in a News and Views 
article that these genes operate in a coordinated fashion to attain metastatic status.124
Cell movementContractile 
actomyosin: RhoC?
Adhesion-site Matrix deposition:
turnover: RhoC? Fibronectin
Figure 6.124 Molecular model for melanoma invasion and metastasis. Cell migration involves 
protrusion of the plasma membrane (lamellipodium extension) at the leading edge of the cell; the 
formation of new sites of adhesion to the extracellular matrix at the front; the release of old 
adhesion sites at the back; and contraction of actomyosin-based cytoskeletal filaments in the cell 
body to move the bulk of the cell forward. Rho proteins regulate actomyosin-based contractility 
and adhesion turnover, implicating it in these steps of cell migration. Thymosin beta4 buffers 
monomeric actin in cells, and could act to provide actin monomers for rapid polymerization into 
actomyosin filaments in lamellipodia. Fibronectin is an extracellular matrix protein, and 
deposition of fibronectin by the cell could promote migration by signalling through specific 
receptors on the cell surface.
A recent study published in Cell by McGill et al.125 used cDNA microarrays to 
identify the transcriptional targets of the micropthamia gene, Mitf, a transcription factor 
essential for melanocyte development. Mitf also appears to be a highly sensitive and 
specific histopathological melanocyte marker for melanoma.126,127 In their article,
McGill et al. demonstrate that Bcl-2, an antiapoptotic factor, is one of the major targets of 
Mitf, and is critical for melanocyte and melanoma survival. A number of histopathologic 
studies have evaluated the relevance of Bcl-2 expression in melanomas, and although its 
association with aggressive potential is unclear128'143, it has been targeted in clinical trials 
using Bcl-2 antisense oligonucleotides144.
Another recent study be de Wit et al.145 used the Affymetrix Hu6800 and Hu35K 
array set to identify genes associated with metastasis by comparing the mRNA expression 
of two human melanoma cell lines with different metastatic behavior; 1F6 is poorly
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metastatic, leading to metastases in only 4% of mice, while Mel57 leads to metastases in 
all injected mice. Among known genes (-5000 on the Hu6800), 29 were up-regulated 
and 62 were down-regulated, using a 3.5-fold cutoff. Of the 35,000 EST sequences on 
the other array, 94 were up-regulated and 133 were down-regulated. Based on the results 
of this study, it appears that a relatively small number of genes are responsible for the 
differences between these two cell lines. They were able to validate most of their results 
in the cell lines, by Northern blot or RT-PCR analysis, but could not always show the 
same correlations in human tissue. Regarding in vivo melanocytic tumor progression 
they were able to validate the array results for five selected genes: APOCII, TGFp, and 
PACE4 show up-regulation, whereas hCDCIO and DYRK1A are down-regulated. The 
graph below displays the up- and down-regulated genes categorized by cellular function.
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Figure 7.145 Categorization of differentially expressed genes. Genes showing differential 
expression in 1F6 and Mel57, identified with the Affymetrix Hu6800 array, were subdivided into 
categories representing particular cellular processes or specific function of proteins. A positive 
average fold change correlates with upregulation in Mel57, and a negative average fold change 
with downregulation.
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Brem et al.146 performed an experiment very similar to that described above.
They compared the expression profile of metastatic (NMCL-1) versus non-metastatic 
(530) melanoma cells. They used the Affymetrix HuGene FL array, containing 6800 
genes. They found that genes involved in a multitude of processes (e.g., transcriptional 
control, cell cycle regulation, proteolysis, cell adhesion, immune response, and signaling) 
were differentially expressed. They especially note that genes involved in MHC- 
interactions and cell adhesion were down regulated.
Somewhat unrelated to the scope of this project, as it focuses on treatment 
response prediction, Wang et al.147 utilized gene expression profiling in melanoma to 
search for molecular predictors of treatment outcome. The authors compared the gene 
expression profiles of subcutaneous melanoma metastases before and after various 
immunotherapy treatments. They were unable to demonstrate subsets of melanoma 
predictive of clinical outcome, based on gene expression profiles. It seems that the extent 
of immune responsiveness may be predetermined and not dependent on the level of 
immune response elicited by a particular therapy. They did show that melanoma 
metastases express a heterogeneous array of cytokines, growth factors, and 
metalloproteinases; a number of which have chemotactic properties (e.g., BLC, eotaxin, 
IL-1, IL-8, IL-16, lymphotactin, MCP-1, MCP-3, MCP-4, RANTES) or inflammatory 
action (e.g., IL-6, M IP-la, MIP-ip, MIP-2a, TNF-y).
Time and testing will reveal the accuracy and clinical relevance of these various 
genes in melanoma progression. These experiments are yielding new insights into the 
molecular genetics of this truly unpredictable disease. The results will be important for a
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complete understanding of melanoma, and equally important for the development of new 
treatments.116
It is unfortunate that most cDNA microarray studies have been performed on cell 
lines instead of fresh human melanocytic tumor lesions. However, it is difficult to run 
cDNA array analyses on these tissues because the amount of mRNA required for these 
studies would be inadequate in most cases. In addition, even with the specificity of laser 
capture microdissection, it is difficult to distinguish expression in the stroma versus 
tumor tissue. This is a major problem with all forms molecular biological analysis that 
require homogenization of tissue.
The findings from these studies provide ‘potential’ biomarkers. They must be 
validated by another method (i.e., quantitative RT-PCR or Northern blots at the RNA 
level, and immunodetection by ELISA or Western blots). In addition, further evaluation 
must be performed to determine their clinical significance on human tissues. This is the 
place for TMAs, allowing one to screen hundreds of markers on hundreds of tissues.
Although DNA microarray technology is becoming omnipresent in research 
laboratories, the results require rigorous evaluation by competent biologists, with 
expertise in molecular biology, cell biology, biochemistry, genetics, and bioinformatics.
In this ‘post-genomic’ era, it is important to avoid over-interpretation of the significance 
of data obtained through DNA microarray experiments. However, these tools still remain 
a valuable tool for identifying the genes altered in the metastatic progression of tumor 
cells.
Selection of markers from cDNA microarray expression profiles incorporated the 
known biological significance of genes and their products, as well as cross-validation of
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multiple studies. Comparison of “Melanoma vs. Normal Nevus” and “Benign Melanoma 
vs. Aggressive Melanoma ”, as well as a marker type stratification system was developed. 
DNA microarray studies, such at those detailed above and our own work led by Dr. 
Halaban117, have identified numerous very promising markers which are just beginning to 
be validated. From these lists, as well as recommendations from experts in the melanoma 
field148 and functional studies on individual genes and gene products, a series of 
approximately 50 markers were selected based on the availability of good antibodies and 
their performance in validation studies.
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Tissue Microarray Technology
Tissue microarray (TMA) technology was first described by Kononen and 
Kallioniemi in 1997.149 Consisting of an ordered array of tissue cores—up to 2,000—on 
a single glass slide, tissue microarrays provide a mechanism for the maximal use of 
scarce tissue resources.149 Most tissue microarrays are currently constructed from 
pathology tissue block archives, and the coordinate clinical data can be correlated with 
experiments performed on these tissues. TMAs allow for the validation of new concepts 
in cell and molecular biology on human tissue.150’151 They are the ultimate step in the 
association of gene expression information with human tissues and human disease.
Tissue microarrays supply a mechanism for conservation of tissue, while 
providing the ability to evaluate hundreds of archival tissue specimens on one microscope 
slide. As illustrated in the figure below, tissue microarrays are constructed from 
formalin-fixed, paraffin-embedded tissues. Under the guidance of a pathologist, the 
target tissues are core-biopsied with a 0.6 mm diameter needle, and the cores are placed 
in a ‘recipient’ paraffin block. The maximum number of specimens one block can hold 
varies from 600 to 2000 (with new smaller diameter needles). The block containing the 
array is sectioned in an identical fashion to any paraffin tissue block. The maximum 
number of sections a block can provide ranges from 100 to 200, depending on the size of 
the original tumors and the skill of the histotechnologist.149-151
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Figure 8.152 Tissue microarrray construction. Cores are removed from paraffin-embedded tissue 
“donor” blocks, and placed into a “recipient” block. A grid format is created, and the position of 
each “donor” specimen is recorded for later analyses. The recipient block is then sliced at a 
thickness of 5um on a digital microtome, and transferred onto a slide. A sample of a stained tissue 
microarray is shown in the inset.
In addition to providing a means of preserving human tissues, which are always in 
limited supply, the ability to examine many histological specimens on a single slide is of 
great value. By exposing all tissues to precisely the same conditions, the slide-to-slide 
variability inherent to immunohistochemistry and in situ hybridization is minimized.
Unlike DNA microarrays, where each microscopic spot represents a unique 
cloned cDNA or oligonucleotide, the spots on tissue microarrays are larger and contain 
histologic tissue sections from unique patients or tumors. This technology reverses the 
typical array paradigm. Instead of testing one sample for expression of thousands of
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genes, tissue microarrays allow testing of one gene (or more typically a protein) on 
hundreds or thousands of samples (patients).
It is estimated that there are over 30,000 genes within the human genome, 
encoding over 100,000 proteins. Researchers are currently beset with the task of filtering 
through the vast number of gene and protein targets to identify those with clinical 
relevance and diagnostic/prognostic/therapeutic potential. Target validation is a critical 
step in sifting through such targets. Traditionally, target validation was done with static 
assays such as Northern blot analysis, RT-PCR, macroarray, microarray, and gene chips. 
These technologies simply provide evidence of differential expression of specific genes 
and only rudimentary clinical information is obtained. For most techniques in molecular 
biology, tissue is homogenized to isolate RNA or protein for expression analysis. 
Unfortunately, the tissue obtained is not necessarily composed solely of the cells of 
interest. The tissue homogenate can contain normal cells, tumor cells, blood cells, 
muscle cells, and other cell types that may result in misleading information. Critical 
spatial information is lost in these studies, convoluting the results and making truly well- 
informed mechanistic explanations nearly impossible. Tissue microarrays provide an 
optimal venue for establishing the clinical importance of various gene products.
A key criticism of tissue microarrays is that the small tissue disk is not 
representative of the entire tumor. This is particularly problematic when the tumors are 
highly heterogeneous, on both a morphological and a molecular level. To evaluate this 
issue, numerous studies have compared IHC findings on TMAs with their corresponding 
traditional whole tissue sections153'172, with the vast majority revealing a high level of 
concordance.154'166,168,169,171 Most of these studies used multiple cores from donor
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blocks in order to determine how many samples are needed to obtain results on TMAs 
that are concordant with whole tissue sections. It has been generally found that two to 
three samples are needed to achieve a good concordance level. However, this number is 
highly dependent on the tumor type and the design of the study. In our effort on breast 
cancer, Camp et al. analyzed estrogen and progesterone receptors and HER2 on 2-10 
cores per breast cancer donor block. It was found that analysis of two cores was 
sufficient to obtain identical results as compared with the corresponding whole tissue 
sections in 95% of cases; four cores yield a concordance of 99%.161 It is important to 
recognize that these studies are based on the assumption that traditional whole tissue 
sections, the current gold standard for molecular tumor tissue analysis, are representative
173 • •of an entire tumor. A section from a tumor that measures 3 x 2  cm in diameter, cut 3 
pm thick, has a volume of 0.0018 cm3. This volume is only 1/19,000 of a tumor with a 
diameter of 4 cm or 1/150,000 of a tumor with a diameter of 8 cm. A TMA sample 
measuring 0.6 mm in diameter represents a tumor volume of 0.00000108 cm3, which is 
1/1600 of a 3 cm x 2 cm x 3 pm whole section tissue slice. Based on these numbers, the 
representivity problem is about 100-times greater between the entire tumor and a 
traditional large section than comparing results obtained on large sections and TMA 
sections.173 In addition, it should be noted that the tissues on the TMA are carefully 
selected to be representative of tumor on the whole tissue section.
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Quantitative Immunohistochemistry
Oxidation and Storage
Tissue microarrays have facilitated the evaluation of large cohort studies with the 
use of formalin-fixed, paraffin-embedded tissues that can sometimes be almost a century 
old. The current method of archival storage of tissues—formalin fixation followed by 
paraffin embedding—is a remarkably resilient method of specimen and antigen 
preservation. However, once the samples from such blocks are cut into 5 micron sections 
and deparaffmized, the tissue is exposed to ambient air and the potential effects of 
oxidation. Several studies have demonstrated the detrimental effects of storing pre-cut 
tissue slides under ambient conditions.174'178 For some proteins (i.e., estrogen receptor), 
pre-cut slides stored in room air lose all detectable antigenicity in one month, with a 
statistically significant difference from fresh cut seen by 6 days179; demonstrated in 
Figure 9. Unfortunately, there is not a universally accepted method for storing slides that 
reduces the loss of antigencity. Cold storage of slides at 4°C has shown some promise, 
but still results in significant loss of antigenicity.176,177 One method of antigen 
preservation that has demonstrated moderate success is paraffin coating of pre-cut 
slides.176 Non-formalin-based fixatives have been tested and have some benefits, but 
they do not reduce the loss of antigenicity due to oxidation.180'185 While these fixatives 
show great promise in overcoming some of the deleterious effects of formalin-based 
fixation, they are not useful for retrospective studies on paraffin-embedded archival 
tissues, the vast majority of which are formalin-fixed.
The advent of tissue microarrays as a tool for the study of immunohistochemical 
stains has renewed interest in finding methods for cut-slide preservation. To avoid
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repeatedly facing the paraffin block containing a TMA, serial sections are typically cut at 
one time and stored as individual slides. While this procedure increases the quantity of 
high quality slides that can be cut from a particular TMA block, it necessitates rigorous 
slide storage techniques that will ensure antigen preservation. Our laboratory has 
developed a reliable method for the long-term storage of TMA slides that entails paraffin-
1 7 0coating of slides followed by (long-term) storage in a nitrogen dessication chamber.
This method of cut-slide storage maintains tissue antigenicity comparable to fresh-cut 
slide for up to 3 months.
Fresh-cut Day 2 Day 6 Day 30
Figure 9.186 Effects of oxidation on tissue antigenicity. Estrogen receptor immunohistochemistry 
is abrogated by storage under ambient air conditions. Matched histospot of breast cancer from 
freshly-cut slide, as well as slides stored for 2, 6, and 30 days in ambient air. Slides were stained 
for ER and visualized with DAB. Staining is localized to the tumor nuclei when assayed under 
high power.
Fixation and Antigen Retrieval
For over 100 years, pathologists have relied upon formalin—a 37% solution of
187formaldehyde gas in water—for fixation of tissue specimens. Formalin has several 
advantages over alcohol and other precipitative (non-cross-linking) fixatives, in that it 
maintains excellent preservation of morphologic detail. Quick and effective fixation of 
fresh tissue is necessary to fix antigens in situ, prior to the onset of autolytic changes. 
Although the biochemical mechanisms of the fixation process are not entirely understood,
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it is clear that formaldehyde-based fixation involves the formation of cross-links of amino 
groups188' 190, among other reactions, recently summarized by Shi et al.191 These 
formalin-induced protein cross-linkages can result in partial or complete loss of 
immunoreactivity of various antigens, either through intramolecular crosslinks within the 
epitope region of the target antigen, or cross-linking of unrelated proteins to the epitope.
Although formalin fixation will allow some epitopes to emerge unchanged 
(formalin-resistant), others will undergo substantial changes (formalin-sensitive).
Despite the loss of immunoreactivity by many antigens as a result of formalin fixation, 
formalin-fixed paraffin-embedded (FFPE) tissue remains the medium of choice for 
clinical and research studies because of the superior preservation of morphology.
Various alternatives to formalin have been tested, and it is likely that an ideal 
fixative will never be found.192,193 To counteract, or ‘reverse’, the effects of formalin 
fixation—to improve the immunoreactivity of FFPE tissues—a number of unmasking 
techniques, such as enzymatic digestion and heat-induced antigen retrieval, were 
introduced. The first attempts to ‘improve’ IHC involved the use of tryptic digestion 
prior to immunofluorescent staining.194 Other proteolytic enzymes (e.g., bromelain, 
chymotrypsin, ficin, pepsin, pronase) were tried for restoration of immunoreactivity to 
tissue antigens with varying degrees of success.195 Proteolytic digestion compensates for 
the impermeable nature of the non-coagulant fixatives by “etching” the tissue and 
allowing hidden determinants to be exposed. Use of these enzymes may however also 
entail the risk of destroying some epitopes.
Currently, the principle of antigen retrieval is based upon the application of heat 
for varying lengths of time to FFPE tissue sections in an aqueous medium. The
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technique, initially developed by Shi et al. in 1991, is a high-temperature heating method 
to recover the antigenicity of tissue sections that has been masked by formalin fixation.196 
A number of modalities for heat generation have been tested, including microwave oven, 
pressure cooker, steamer and autoclave. The advantages and disadvantages of various 
heating modalities and retrieval solutions are the subject of ongoing experiments.191 
Alternate terminology used for “antigen retrieval” includes epitope retrieval, heat- 
induced epitope retrieval, target retrieval and target unmasking. The latter two versions 
have more generic appeal and have also been applied to the retrieval of nucleic acid 
targets for in situ hybridization. In general, antigen retrieval refers to a technique, used 
widely in pathology and other fields of morphology, which improves IHC staining on 
archival FFPE tissue sections by reducing detection thresholds of immunostaining 
(increases sensitivity) and retrieval of some antigens (e.g., Ki-67, ER-1D5, androgen 
receptor, many CD markers) that are otherwise negative in IHC. Antigen retrieval serves 
as a pre-treatment amplification step, in contrast to amplification in the phases of 
detection (e.g., multistep or polymeric detection systems) or post-detection (i.e., 
enchanced substrated such as DAB using metal, imidazole, CARD, anti-end product, 
gold-silver enhancement).197
Although the molecular mechanism of antigen retrieval is not entirely clear at this 
time, it is apparently influenced by the pH of the antigen retrieval solution as well as 
temperature and time of heating.191 A number of hypotheses have been proposed, 
including: loosening or breaking of the formalin-induced cross-links198,199; protein 
denaturation200; hydrolysis of Schiff bases201; chelation of cage-like calcium complexes,
202 203which may develop during formalin fixation ’ ; heat-induced reversal of chemical
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modification to protein structure that occurs during formalin fixation199. This topic has 
been most recently characterized by the Mason group in a series of papers that look at the 
biophysical effects of formalin on RNAse.204,205
The technique of antigen retrieval, a heat-induced remodification of formalin- 
induced modification of protein conformation, may contribute to standardization of IHC 
staining of FFPE tissue by equalizing the intensity of IHC staining under variable 
conditions of fixation and processing.197 While the molecular mechanisms of antigen 
retrieval are the subject of intense investigation, the main concern is that the procedure 
works and provides reproducible results. Importantly, antigen retrieval has become 
increasingly more useful in research and diagnostic pathology, as it provides increased 
sensitivity for the demonstration of molecular markers not previously demonstrable in 
standard tissue sections. A number of different antigen retrieval techniques are in 
development, and it is essential that scientists and pathologists focus on standardization 
of antigen retrieval, which will likely entail optimization for individual antigens.206
Standardization of Immunohistochemistry
The Biological Stain Commission (BSC) was founded in 1944 as a nonprofit
207organization to address the problem of standardization of chemical stains in pathology. 
The BSC was able to achieve considerable success with regard to biological dyes, but the 
introduction of immunohistochemistry brought new challenges. The origins of 
immunohistochemistry date back to 1941, when Coons et al. established an 
immunofluorescence technique for detection of bacteria. It was many years before it 
became a common part of diagnostic pathology. In 1977, the National Cancer Institute 
held a workshop to address the standardization of immuno-reagents in diagnostic
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pathology.209 From its inception and until recently, the use of IHC was limited to 
qualitative assessments of expression. The major application of the method in pathology 
was in the detection of cellular lineage markers to diagnose poorly differentiated 
malignancies. Interpretation of results was a matter of positive or negative, present or 
absent. Little attempt was made to distinguish degrees of staining, or differences in 
intensity.210
The introduction of immunoperoxidase methods and increasingly sensitive 
detection systems in the mid-1970s provided the ability for broad application of IHC on 
routine FFPE tissues. With the promise of unparalleled specificity, IHC transformed
histopathology from something resembling an art into something more closely
211 ■ resembling a science. The application of IHC to routinely processed tissues
represented a new era for the demonstration of antigens in situ, allowing pathologists to
correlate immunologic findings directly with traditional cytologic and histologic
criteria.212
Immunohistochemistry typically follows a series of universal steps. A) 
Pretreatment (antigen retrieval), often with pressure-cooking of tissue in citrate buffer to 
unmask antigens hidden by formalin cross-links or other fixation. Other agents used for 
antigen retrieval include proteases, such as pepsin, trypsin, bromelain. B) Application of 
primary antibody; antibody binds to antigens of interest. C) Wash off excess primary 
antibody. D) Application of labeled anti-IgG antibody (secondary antibody), which binds 
to the primary antibody. The secondary antibody is typically conjugated to biotin or 
horseradish peroxidase. E) Application of detection chemicals, including a chromagen 
(color changing reagent), usually 3, 3’ diaminobenzidine (DAB). It is necessary add an
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avidin-biotin-peroxidase complex prior to DAB in the case of biotinylated antibodies. 
The slide is then counterstained with hematoxylin to identify all nuclei. This is the 
standard method for the ‘brown stain’.
While immunohistochemistry has become an established method in research and 
clinical pathology, a surprising lack of standardization and reproducibility exists among 
different laboratories. Enormous variability has developed in terms of the reagents 
available, the detection methods used, and, most importantly, the interpretation and 
reporting of immunohistochemical findings.213 Although efforts have been made to 
standardize immunohistochemistry, difficulties remain.
Recently, the need for IHC standardization has expanded due to the inception of 
bio-specific therapies that are approved with partner pharmco-diagnostics. Quantitative 
(or at least semiquantitative) IHC is likely to become more critical as pathologists are 
required to accurately distinguish expression levels of markers to determine whether or 
not a patient is a candidate for a specific therapeutic. The classic example is the 
evaluation of HER2-2/neu expression to aid in prognosis of breast cancer. Although this 
marker is an “easy one”, there has still been considerable literature on the inaccuracy of 
of the pathologist-based test. More recently, market forces have resulted in standardized 
test kits, such as the HerceptTest (DAKO, Carpinteria, CA) and INFORM DNA probe 
test (Ventana Medical Systems, Tucson, AZ), that have been approved by the FDA. 
None-the-less, the accuracy and comparability of these methods is somewhat 
controversial.214
Efforts to standardize immunohistochemistry have focused on three areas: (1) 
antibodies and reagents, (2) technical procedures, and (3) interpretation of IHC findings
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for research and diagnostic uses. There has been recommendation for a Total Test 
Approach to standardization of IHC213, requiring that the pathologist pay close attention 
to each and every step of the procedure: from excision of the biopsy, including the type 
and duration of fixation, through the antigen retrieval method and detection procedure, as 
well as interpretation of the resulting stain. Much of the variability in staining is
215introduced by differences in fixatives or fixation times , and these can be reduced, if not
210eliminated by the use of an optimized antigen retrieval protocol . In addition to 
optimization of antigen retrieval, the authors suggest simplification of IHC staining 
method, and the implementation of quantitative IHC.
Quantitative Immunohistochemistry
Although the current gold standard for diagnosis amongst pathologists relies upon 
morphological criteria, histochemistry—immunohistochemistry in particular—has 
provided a more accurate mechanism for diagnosis, as well as the ability to assess 
molecular interactions in situ. The primary usage has been as an ancillary test to assist in 
classifying tumors or in making a diagnosis. But there is now a trend toward increased 
usage of this test as a mechanism to predict response to therapy. This trend, as well as 
advances in computation power, is driving numerous efforts toward quantitative 
assessment of expression. The critical information that makes techniques such as 
immunohistochemistry and in situ hybridization so valuable is that they provide 
molecular information within the architectural context of tissues. This information, 
including architectural and subcellular localization, can be critical for classifying tumors, 
or providing prognostic or predictive information. This information needs to be 
maintained as a unique part of the molecular information package that now includes
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various molecular-based techniques, which typically rely on suspensions or extracts of 
cells or tissues, such as PCR, DNA sequencing, FACS and ELISA assays.
Quantitative immunohistochemistry (QIHC) is composed of two general 
methodologies, manual and automated analysis. Pathologists typically perform the 
manual method of QIHC. After identifying the region of interest within a tissue section 
(i.e., tumor or other diseased tissue), estimation of intensity or percentage of IHC staining 
is determined. This method is presently more commonly used, and is well recognized in 
the literature. However, this approach is relatively subjective, based on visual estimation 
of the intensity and percentage of positive staining of IHC. The immunoreactive grading 
system provides a visual aggregate of intensity/percentage, denoted by "0, 1+, 2+, 3+", 
representing negative, weak, moderate, and strong staining, respectively. Semi- 
quantitative systems have been invented and some have seen extensive usage, including 
the H-score system216 and the Allred system.217 Both are based on the product of staining 
intensity and the percentage of positive cells. Though widely used, the manual system of 
QIHC is imperfect, based on human fallibility, which suffers from a high degree of inter-
7 1  R 9 1  Qand intra-observer variability. ’
Automated systems for QIHC begin with acquisition and storage of digital
images, followed by image correction and enhancement, segmentation of objects within
220  ■ the images, and ultimately image measurement. Several commercial systems are
currently available for image analysis of brown stain IHC slides. Among these systems,
221the CAS system, originally invented by James Bacus , was perhaps the most popular as 
judged by the number of units sold, although now it is outdated. The CAS 200 system, 
and its successor, the BLISS system, is designed for quantitative analysis of “brown”
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stained IHC material. The optical density of the reaction product is determined through 
conversion of the light transmission, or gray level, and the relative area of the staining 
reaction is also determined. Other systems with similar functionality are listed below.
T ab le  7. C om m ercia lly  A va ilab le  A u tom ated  A n alysis System s
System Source
Bliss Bacus Laboratories, Inc. http://www.bacuslabs.com
Chromavision ACIS® Clarient http://www.chromavision.com
IVision and GenoMx™ Biogenex http: //www .bio genex .com
Scanscope® Systems Dako Cytomation httn ://www. aperio. com
Ariol SL-50 Applied Imaging http://www.aicom.com
PATHIAM Bioimagene, Inc. http://www.bioimagene.com
Discovery Molecular Devices http://www.moleculardevices.com
TissueAnalytics Tissue Informatics, Inc. http://www.tissueinfomiatics.com
LSC CompuCyte Corporation http://www.compucvte.com
AQUA™ HistoRx http://www.historx.com
These systems generally cost between $200,000 and $300,000. In addition, some
222 223investigators have developed analysis systems on their own ’ or using commercially 
available software.224,225
Because these systems are designed to analyze brown stain IHC, they rely upon 
absorbance (i.e., optical density) to compute an intensity score. In spectrophotometry, 
Beer's Law (A = e 1 c) states that the absorbance (A) of a species at a particular 
wavelength of electromagnetic radiation, is proportional to the concentration (c) of the
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absorbing species and to the length of the path (1) of the electromagnetic radiation 
through the sample containing the absorbing species. The extinction coefficient (s), also 
known molar absorptivity, is dependent upon the wavelength of the light and is related to 
the probability that the species will absorb light of a given wavelength. When A equals 
zero, no photons are absorbed; when A equals 1.0, 90% of photons are absorbed, i.e.,
10% detected; when A equals 2.0, 99% of photons are absorbed, i.e., 1% detected. Most 
brown stains are optimized by eye for signal to noise such that the absorbance of a 
‘positive’ case is over 1.0 and often over 2.0. Thus, only a tiny percentage of the light is 
detected, which decreases the dynamic range of the assay and makes co-localization more 
challenging. Fluorescence-based imaging could circumvent these problems, but that 
imaging modality has other problems. As a result, very few companies have developed 
quantitative analysis on the basis of this platform.
Fluorescence-based Platforms for Quantitative Analysis
Although fluorescence-based methods have numerous advantages with respect to 
dynamic range and co-localization, they have not been broadly used for numerous 
reasons. Firstly, formalin fixed tissue generally has a substantial amount of auto­
fluorescence, especially in the wavelengths of the most common fluorophores. Red cells 
are a particular problem. A second issue is the higher cost and limited accessibility of 
epifluorescent microscopy equipment. Perhaps the greatest barrier is the inability of the 
pathologist to judge the surrounding tissue and architectural context. This can be seen as 
a huge disadvantage, or, arguably, an advantage if the goal is to reduce subjectivity. In 
flow cytometry, pathologists do not see any cells, but that is not seen as a disadvantage. 
Furthermore, recent studies suggest that pathologists tend to select non-representative
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regions when they select an area to score (Gann et al, personal communication). This can 
decrease the overall accuracy of assessment of protein expression levels.
A small number of laboratories have now begun developing analysis systems for 
fluorescence-based quantification. The following paragraphs describe our lab’s efforts in 
this area.226 The assembly consists largely of off-the-shelf microscopy equipment based 
on an Olympus AX51 automated microscope, with a Cooke digital camera, and 
computerized image acquisition based on the DP Lab software (v3.54, Scanalytics, Inc.). 
The imaging system captures stacks of images that are then analyzed on custom software 
developed in our laboratory, written by Robert Camp called AQUA (Automated 
Quantitative Analysis, Figure 3). The underlying principle behind the software is that 
spatial information is maintained, but that all localization is based on molecular 
information, rather than feature identification or morphology. Thus, the steps for analysis 
of each image include identification of a mask to separate tumor from non-tumor, 
followed by definition of compartments on the basis of other molecular interactions. For 
example, keratin may be used as a mask (for cells of epithelial origin) and DAPI to define 
a nuclear compartment. Then, the target of interest is measured (for example estrogen 
receptor) in a quantitative fashion only in the pixels that are within the mask and 
compartment defined by the previous markers. The intensity then divided by the area of 
the compartment to define a normalized value that is directly proportional to the protein 
concentration of the target. The following is a detailed description of the process.
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Figure 10. AQUA software. The windows of the AQUA software are shown including the 
algorithm description window, the settings window, score window and 4 image windows for the 
images of different raw images or processed images. For example the upper left image is the 
keratin immunofluorescence image from which the upper right mask image was constructed.
Image acquisition: Images of microarrays are obtained using an Olympus Motorized 
Reflected Fluorescence System and software (IP lab v3.54, Scanalytics, Inc.), with an 
attached Cooke Sensicam QE High Performance camera through an Olympus BX51 
microscope with automated x, y, z stage movement. Low power images of microarrays 
are stitched together using multiple low-resolution images of the microarray (64 x 64 
pixel) at approximately 7-micron resolution.
Histospots are identified using a custom written spotfinder algorithm (written by 
Robert Camp) based on the signal from DAPI or other tags. This signal is gated (i.e., a 
threshold of pixel intensity is set) to create a binary image of the microarray. Histospots
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are identified using size criteria. Rows and columns of histospots are then identified, and 
missing histospots filled in, allowing each histospot to be identified based on its 
row/column grid position. The coordinates of each histospot are then recorded.
Subsequently, monochromatic, high-resolution (1024 x 1024 pixel, 0.5-micron 
resolution) images are obtained of each histospot, both in the plane of focus and 8 
microns below it, and recorded in an image stack as bitmaps. This depth, slightly below 
the bottom of the tissue, was determined to be optimal for 5-micron histologic sections.
A resolution of 0.5 microns is suitable for distinguishing between large subcellular 
compartments such as the cell membrane and nuclei. Efforts are underway to 
accommodate smaller subcellular compartments (for example, mitochondria, nucleoli) 
using high power objectives. Images are obtained using a pixel intensity dynamic range 
o f 0-255.
RESA/PLACE algorithmic analysis o f images: Through the use of two algorithms, RESA 
(rapid exponential subtraction algorithm) and PLACE (pixel-based locale assignment for 
compartmentalization of expression), AQUA carries out the following functions:
• Identification of the tumor locale within the histospot (“tumor mask”)
• Identification of subcellular compartments (nuclei, membranes, 
cytoplasm, etc.)
• Defines the localization and intensity of the “target”
First, a tumor-specific mask is generated by thresholding the image of a marker 
that differentiates tumor from surrounding stroma and other non-tumor material. This
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creates a binary mask (each pixel is either ‘on’ or ‘off). Keratin is the most common 
mask used for epithelial neoplasms and SI00 protein is used for melanocytic lesions. As 
formalin-fixed tissues can exhibit autofluorescence, analysis may give multiple 
background peaks. The RESA/PLACE algorithms determine which of these peaks is 
predominant and sets a binary mask threshold at a slightly higher intensity level. This 
provides an adaptive (unique to each histospot) thresholding system that ensures that only 
the target signal from the tumor and not the surrounding elements is analyzed. 
Thresholding levels are verified by spotchecking a few images and then automated for 
the remaining images. This binary mask can be modified using standard image 
manipulations. In most cases this involves filling holes of a particular size (for example, 
less than 500 pixels, to fill in tumor nuclei that do not stain for S I00) and removing 
extraneous single pixels. Once set, these image manipulations are performed 
automatically on all images. All subsequent image manipulations involve only image 
information from the masked area.
Next, two images (one in-focus, one slightly deeper) are taken of the 
compartment-specific tags and the target marker. A percentage of the out-of-focus image 
is subtracted from the in-focus image, based on a pixel-by-pixel analysis of the two 
images. This percentage is determined according to the ratio of the highest/lowest 
intensity pixels in the in-focus image -  representing the signal-to-noise ratio of the image. 
By using an exponential scale, this allows RESA to subtract low intensity pixels in 
images with a low signal-to-noise ratio less heavily than low intensity pixels from images 
with a high signal-to-noise ratio. The overall degree of subtraction is based on a user- 
defined percentage for each subcellular compartment. For most applications this is
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empirically set to 40% of the total signal, and remains constant for images from an entire 
microarray. RESA thus eliminates nearly all of the out-of-focus information. The 
algorithm has the added benefit of enhancing the interface between areas of higher 
intensity staining and adjacent areas of lower intensity staining, allowing more accurate 
assignment of pixels of adjacent compartments. In contrast to the compartment-specific 
tags, the RESA subtraction of the target signal is uniform and not based on overall 
intensity o f the image intensity. This ensures that the same amount of subtraction occurs 
with the target signal from all specimens.
Finally, the PLACE algorithm assigns each pixel in the image to a specific 
subcellular compartment. Pixels that cannot be accurately assigned to a compartment to 
within a user-defined degree of confidence (usually 95%) are discarded. This is 
accomplished iteratively by determining the ratio of signal from two compartment- 
specific markers that minimizes the spillover of marker from one compartment into 
another. Once each pixel is assigned to a subcellular compartment (or excluded as 
described above), the signal in each location is added up. This data is saved and can 
subsequently be expressed either as a percentage of total signal or as the average signal 
intensity per compartment area. The score is expressed on a scale of 1 to 1000 as the 
total intensity divided by the area of the compartment to 3 significant figures. A step by 
step illustration of this process is illustrated in the schematic in figure 4. These 
algorithms are described in further detail in a patent of this technology owned by Yale 
University.
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Figure 11. The schematic above demonstrates a step-by-step methodology for RESA and PLACE 
algorithms used by AQUA in the assessment of P-catenin expression in colon cancer.226 A) Anti- 
cytokeratin is used to distinguish colon carcinoma cells from the surrounding stroma. B) Gating 
of that image creates a binary mask. C) The mask is enhanced by filling holes and removing small 
objects. D) Anti-a-catenin serves as a membrane tag. E) The membrane tag image is 
exponentially subtracted using RESA. F) DAPI identifies the nuclei. G) The nuclear tag image is 
exponentially subtracted using RESA. H) The membrane and nuclear tag images are merged, and 
overlapping pixels are removed. White pixels represent overlap. J) Anti-P-catenin is the target 
marker of interest. K) The target marker image is exponentially subtracted using RESA. L) The 
intensity of the marker is divided into the various subcellular compartments. Graphically, this is 
represented by red (membrane), green (cytoplasm), and blue (nuclei). In this tumor, P-catenin is 
predominantly localized to the membrane (red).
The results of this assay (or other quantitative microscopy systems) are a 
“number” that represents an objective continuous variable for subsequent analysis. This 
allows statistical analysis of histologic data in a manner more similar to other quantitative
52
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
areas o f medicine (blood glucose, liver enzymes, or drug levels). Although these systems 
remove the subjectivity in assessment, there are still other issues that must be 
systematically addressed, including sample selection (the region analyzed) and a 
multitude of steps related to processing. However, the addition of quantitative analysis 
removes the most subjective step and allows the typical rigorous QC and QA of 
laboratory tests. It is easy to envision future application of these technologies in the 
clinical lab. Specifically a likely application is the assessment of biopsy tissue for the 
qualification of cancer patients for new biospecific therapies, based on quantitatively 
assessed levels of target protein expression.
Statistical Approaches to Tissue Microarray Data
Survival analysis: Kaplan-Meier
In medical research, we often seek to display a summary of the survival 
experience of a group of patients. Typically, the most convenient method for 
demonstrating a survival function is by graphical presentation. In this form, it is typically 
referred to as a survival curve. The horizontal axis usually represents time since 
diagnosis and the vertical axis represents the probability or chance of survival (or any 
other well-defined end-point, such as recurrence), expressed as a percentage.227
First proposed by Kaplan and Meier in 1958228, the Kaplan-Meier (K-M) estimate 
can also be called an actuarial estimate. The Kaplan-Meier method is a nonparametric 
(actuarial) technique for estimating time-related events. It is a univariate analysis and is 
an appropriate technique for determining the association of a single variable with 
survival. It estimates the proportion of individuals alive at a particular time, starting from
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the time of diagnosis (time zero). It is especially applicable when length of follow-up 
time varies from patient to patient, and takes into account those patients lost to follow-up 
or not yet event-free at the end of study (censored patients, assuming the censoring is 
non-informative). Since the estimated survival distribution for the cohort study has some 
degree of uncertainty, 95% confidence intervals may be calculated for each survival 
probability on the “estimated” curve.
A variety of tests (log-rank, Wilcoxan and Gehen) may be used to compare two or 
more Kaplan-Meier “curves” under certain well-defined circumstances. Median 
remission time (the time when 50% of the cohort has reached remission), as well as 
quantities such as three, five, and ten year probability of remission, can also be generated 
from the Kaplan-Meier analysis, provided there has been sufficient follow-up of patients. 
In summary, the Kaplan-Meier technique is a useful method of evaluation for individual 
nominal (or categorical) markers.
Survival analysis: Cox Proportional Hazard Analysis
In some cases it is necessary to determine whether survival is influenced by one 
or more factors, called "predictors" or "covariates", which may be categorical (such as the 
kind of treatment a patient received) or continuous (such as the patient's age, weight, or 
the dosage of a drug). For simple situations involving a single factor with just two values 
(such as drug vs. placebo), the method of Kaplan-Meier analysis followed by log-rank 
testing will suffice for comparing the survival curves of two groups of subjects. For more 
complicated situations, a special type of regression is required; one that provides 
assessment of the effect of each predictor on the shape of the survival curve.
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To understand the method of proportional hazards, first consider a "baseline" 
survival curve. This can be thought of as the survival curve of a hypothetical "completely 
average" subject—someone for whom each predictor variable is equal to the average 
value of that variable for the entire set of subjects in the study. This baseline survival 
curve doesn't necessarily have any particular formula representation; it can have any 
shape whatever, as long as it starts at 1.0 at time 0 and descends steadily with increasing 
survival time. The baseline survival curve is then systematically "flexed" up or down by 
each of the predictor variables, while still keeping its general shape.
The proportional hazards method computes a coefficient for each predictor 
variable that indicates the direction and degree of flexing that the predictor has on the 
survival curve. Zero means that a variable has no effect on the curve (i.e., it is not a 
predictor at all); a positive variable indicates that larger values of the variable are 
associated with greater mortality while a negative variable indicates that larger values are 
associated with improved survival. Knowing these coefficients, it is possible to construct 
a "customized” survival curve for any particular combination of predictor values. More 
importantly, the method provides a measure of the sampling error associated with each 
predictor's coefficient. This allows for assessment of which variables' coefficients are 
significantly different from zero, in turn, providing a determination of which variables are 
significantly related to survival.
Cox analysis incorporates proportional hazards regression to predict relative risk. 
When incorporating several variables into a Cox model, the relationship between the 
variables is assessed by multiple regression, taking into account multiple variables and 
the proportional changes in the dependent variable (survival time and censor status) that
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can be expected related to changes in explanatory variables (clinical parameters, protein 
expression levels). Relative risk is a measure of how much a particular risk factor (say 
cigarette smoking) influences the risk of a specified outcome (say, death by age 70). For 
example, a relative risk of 2 associated with a risk factor means that patients with that 
risk factor have a 2-fold increased risk of having a specified outcome compared to 
persons without that risk factor. One overall p-value tests the overall null hypothesis that 
the relative risk of the population is 1.0 and that none of the variables influence patient 
prognosis. Individual p-values for different markers or clinical variables each have their 
own p-value that tests the null hypothesis that a variables’ particular relative risk is 1.0 in 
light of other variables.
Hierarchical Cluster Analysis
A major method for analyzing and demonstrating data from gene expression 
profiling experiments, the use of cluster analysis has increased dramatically over the past 
few years. Cluster analysis includes a diverse collection of techniques that can be used to 
classify objects, with the goal of finding subgroups of data within a larger dataset. All 
cluster analysis algorithms seek to maximize the similarity of “within-cluster” 
observations while maximizing differences between clusters. The underlying 
mathematics of most clustering methods are relatively simple but large numbers of 
calculations are needed. Classification depends on the particular method used, and there 
are many ways to measure similarity and dissimilarity.
Hierarchical clustering methods attempt to create groups of observations through 
merging or dividing, with the resultant classification consisting of an increasing number 
of nested classes. The result resembles a phylogenetic classification, in which
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hierarchical tree dendrograms denote the relatedness between genes/samples; branch 
length denotes the level of similarity. There are two main categories of hierarchical 
clustering: agglomerative and divisive. Agglomerative clustering methods begin with 
each observation representing a single cluster. At each step, two clusters are merged until 
only one cluster remains. The researcher determines the step to stop clustering and, thus, 
how many clusters to retain. Divisive clustering methods begin in an opposite manner. 
Initially, all the observations begin in one large cluster, and at each step a cluster is 
divided until all members represent their own cluster. Again, the researcher determines 
the number of clusters to retain.
The results of clustering analysis are typically displayed as a two-color heat map,
demonstrating both the direction of fold change (indicated by color) and the magnitude of
the change (indicated by the intensity/brightness of the color). The phytogenies (one for
genes and one for patients/specimens) are displayed adjacent to the heat map. The most
popular pieces o f software for these analyses—CLUSTER and TREEVIEW—were
118developed in Michael Eisen’s laboratory in order to demonstrate genome-wide 
expression data from DNA microarray hybridization experiments; standard statistical 
algorithms are used to arrange genes according to similarity in pattern of gene expression.
Unfortunately, this use of gene expression data does not always identify cancer 
subtypes that are related to patient survival. There are two main approaches in the 
literature to identify cancer subtypes. The first approach, described above (e.g., 
hierarchical clustering), is called “unsupervised” as it does not use any of the clinical 
information about the patient. There have been a few studies that have demonstrated 
success in identifying clinically relevant cancer subtypes through unsupervised
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229 233hierarchical clustering analysis. ' However, unsupervised learning procedures, by 
definition, do not use clinical data to identify subtypes, and thus, there is no guarantee 
that the subtypes they identify will be correlated with clinical outcome. The second 
approach to identifying subtypes of cancer is based exclusively on clinical data. For 
example, patients can be assigned to a “low-risk” or “high-risk” subgroup, depending on 
whether they are alive or their tumor has metastasized after a certain time period. This 
approach has been used successfully to develop procedures to diagnose patients based on
' j ' l A  - y 'i '7
their gene expression profile. " Unfortunately, this process of grouping patients may 
not be biologically meaningful, leading to the misclassification of patients in future 
applications of the model. A third, less commonly used procedure—semi-supervised 
clustering—was recently proposed by Bair and Tibshirani238, in which both gene 
expression data and clinical data is used to identify cancer subtypes. The crux of the idea 
is to use the clinical data to identify a list o f genes that correlate with the clinical variable 
of interest and then apply unsupervised clustering techniques to this subset of genes.
In summary, hierarchical clustering is a useful tool for visualizing large datasets 
and generating hypotheses about the relationship of markers and tumors. While it has 
been the cornerstone of DNA microarray analyses, in which the expression of thousands 
of genes is simultaneously evaluated in a small cohort of specimens, the procedure is 
gaining ground in tissue microarray studies, where the expression of a few genes are 
evaluated in hundreds to thousands of patients. A few groups have demonstrated the 
ability to immunoprofile cancer through hierarchical clustering of TMA data, including 
classification by binarized ER, HER2, COX-2, p53 and VEGF expression , analysis of 
breast cancer expression of neuroendocrine markers240, the relationship between
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differential protein expression and cytogenetic alteration patterns241, and prognosis 
prediction242’243. Unfortunately, most of these attempts have been made in breast 
carcinoma and none have been reported for melanoma.
Genetic Algorithms
First introduced by John Holland in 1975244, Genetic algorithms (GA) are a novel 
tool for the investigation of combinatorial optimization problems. A number of books 
have been published in recent years that review the application of genetic algorithms to 
optimization problems.245'247 Briefly, genetic algorithms represent a type of cooperative 
search method, in which a number of searches are run in parallel and information is 
exchanged between them. They are a class of algorithms that mimic some of the major 
characteristics of Darwinian evolution. That is, mutations, cross-overs and replication 
operating on strings, are ultimately subjected to some form of selection. Mutations can 
be thought of as operations within a single search trajectory, and cross-overs provide a 
means of information exchange between trajectories.
A general description of GAs follows. An initial population of trial solutions is 
established, represented by strings. Mutations are introduced independently into each 
string. After some number of mutations has been performed, new strings are created by 
cross-over operations. That is, two new population members are created by joining parts 
of two separate strings. The operation of creating new strings is repeated until a new 
population of accepted strings is established and then another phase of mutations is 
entered. Along the way, the new populations are subjected to a fitness function. Usually, 
only changes that increase fitness are accepted, though, in some cases, less-fit changes 
may be allowed.
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Basic terminology of genetic algorithms, as applied to data in this dissertation, 
includes genes (algorithms) and chromosomes (solutions). In order to avoid confusion 
with the original meaning of these biologic terms, both terminologies will be used 
together.
X-tile Analysis
The ability to parse tumors into subsets based on biomarker expression has many 
clinical applications; however, there is no global way to visualize the best cut-points for 
creating such divisions. Robert Camp, in our laboratory, has developed a graphical 
method, the X-tile plot that illustrates the presence of substantial tumor subpopulations 
and shows the robustness of the relationship between a biomarker and outcome by
7 4 8construction of a two-dimensional projection of every possible subpopulation.
In theory, associations between tumor biomarker expression and patient outcome 
should reveal the existence of biologically meaningful tumor classifications; however in 
practice, there is no universal method for discovering, assessing or displaying such 
associations. Consequently, studies generally group tumors into set divisions (e.g., 
quartiles, deciles), which fails to reflect the underlying biology of most markers. 
Microarray technology has magnified this problem by accelerating the discovery of 
tumor markers for which there is no known biological basis. In such cases, there is no 
foreknowledge about how (or whether) a marker parses a population into subsets.
X-tile plots provide a single, global assessment of every possible way of dividing 
a population into low-, medium-, and high-level marker expression. X-tile data are 
presented in a right triangular grid where each point represents a different cut-point. The 
intensity of the color of each cutoff point represents the strength of the association. The
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X-tile software allows the user to move a cursor across the grid and provides an "on-the- 
fly" histogram of the resulting population subsets along with an associated Kaplan-Meier 
curve. This type of graphical representation can provide insight into the biological nature 
of a marker (e.g., does it show a linear distribution relative to survival, does it reveal 
distinct sub-populations, or does it manifest a U-shaped relationship to outcome).
Because it is statistically invalid to test multiple divisions and accept the best P value, 
rigorous statistical evaluation is achieved by defining divisions in a "training set" and 
then validating them in a separate patient cohort ("validation set"). The X-tile software 
provides a method of dividing a single cohort into training and validation subsets for P 
value estimation when separate training and validation cohorts are not available. In 
addition, the software can perform standard Monte Carlo simulations (e.g., cross- 
validation) to produce corrected P values to assess statistical significance of data assessed 
by multiple cut-points.
In summary, X-tile plots present a new tool for (a) the assessment of biological 
relationships between a biomarker and outcome; and (b) the discovery of population cut- 
points based on marker expression. Clinically, the ability to effectively define such 
subpopulations is important for the development of novel therapeutics that may be 
effective for only a limited subset of tumors. Furthermore, this method may have value in 
other fields (materials testing, actuarial questions, etc.) where cut-point selection is 
complicated by time-dependent assessment of outcome.
Model Selection and Model Assessment
Statistical learning—the process of learning from data (i.e., creating a model for 
outcome prediction)—plays a key role in many areas of science, finance, and industry. In
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its simplest form, a prediction model is used to predict an outcome measurement, which 
can be quantitative (e.g., a stock price) or categorical (e.g., alive or dead), based on a set 
o f features (e.g., diet and clinical measurements). The first step involves a training set of 
data, in which feature measurements and outcome are observed for a set of objects (e.g., 
patients). Using this data, a prediction model, or learner, is developed, with the gaol of 
predicting the outcome for new unseen objects.
The generalization performance of a learning method relates to its prediction 
capability on independent test data. Assessment of this performance is critical, as it 
guides the choice of learning method or model, and provides a measure of the quality of 
the ultimately chosen model. There are, in fact, two separate goals at hand:
Model selection: estimating the performance of different models in order to choose the 
(approximate) best one.
Model assessment: having chosen a final model, estimating its prediction error 
(generalization error) on new data.
In a data-rich situation, the best approach for both goals is to randomly divide the 
dataset into three parts: a training set (typically 50%), a validation set (usually 25%), and 
a test set (also 25%). The training set is used to fit the models; the validation set is used 
to estimate prediction error for model selection; the test set is used for assessment of the 
generalization error of the final chosen model. In many cases, there is insufficient data to 
split into three parts. There is no ‘standard’ regarding how much training data is enough, 
but a major factor in this consideration is the signal-to-noise ratio of the underlying 
function, as well as the complexity of the models being fit to the data. There are a couple 
statistical methods available for approximation of the validation step either analytically
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(e.g., Akaike or Bayesian information criterion, minimum description length, structural 
risk minimization) or by efficient sample re-use (e.g., cross-validation and 
bootstrapping). In addition to assisting in model selection, these methods are also helpful
249m estimating test error.
63
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 2: Subcellular Localization of Activating Transcription Factor 2 in 
Melanoma Specimens Predicts Patient Survival
Abstract
The transcription factor activating transcription factor 2 (ATF2) has been shown to be 
associated with melanocytic oncogenesis and melanoma tumor proliferation in preclinical 
models. The clinical significance of ATF2 expression is unknown. To determine the 
prognostic value of ATF2 in melanoma, we evaluated the pattern and level of ATF2 
expression in a large cohort of melanoma specimens. Immunohistochemical staining was 
performed on a tissue microarray representing 544 patients with a mean follow-up time 
of 60 months. Expression was evaluated semiquantitatively and correlated with overall 
survival and other clinicopathological data. Strong cytoplasmic ATF2 expression was 
associated with primary specimens rather than metastases (P < 0.0001) and with better 
survival (P = 0.0003). Strong nuclear ATF2 expression was associated with metastatic 
specimens (P < 0.0001) and with poor survival (P = 0.0008). Patients who had both weak 
cytoplasmic and strong nuclear ATF2 staining had the worst outcome, both among the 
full cohort of patients (P < 0.0001) and among the patients with localized disease (n = 
269; P < 0.0001). On multivariate analysis of the primary cutaneous specimens, weak 
cytoplasmic staining and strong nuclear staining was an independent predictor of poor 
outcome, as was Clark level. Nuclear ATF2 is likely to be transcriptionally active, 
whereas cytoplasmic ATF2 probably represents an inactive form. These findings support 
other preclinical findings in which transcriptionally active ATF2 is involved in tumor 
progression-proliferation in melanoma. Moreover, our findings suggest that ATF2 might 
be a useful prognostic marker in early-stage melanoma.
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Introduction
The only clinically reliable markers used to predict outcome in malignant 
melanoma are Breslow depth, Clark level of invasion, presence of ulceration and lymph 
node involvement.19 These parameters form the basis of the new American Joint 
Committee on Cancer Staging System. However, within each stage there is significant 
variability in outcome, and while the staging is helpful in determining prognosis and 
therapy at the time of diagnosis, more accurate measures based on tumor biology are 
needed.19 Better predictors of poor outcome in resected melanoma could enhance our 
ability to appropriately select patients in need of adjuvant therapy.
Numerous tissue and serological markers have been studied, as reviewed by Li et 
al 250 Among them, a number of transcription factors, including Activating Transcription
251Factor 2 (ATF2), have been shown to be associated with tumor growth and metastasis ’ 
252 in cell culture and animal models, but their prognostic role in melanoma has not been 
determined. ATF2 is among the primary transcription factors regulated by p38, MAP 
Kinase and JNK signaling pathways.253,254 Phosphorylation of ATF2 by these kinases is 
central in determining its stability255 and transcriptional activity, which is dependent upon 
its heterodimerization with other members of the bZIP family, c-Jun, CREB, NFkB and 
retinoblastoma (Rb).253,256-258 ATF2 plays an important role in acquisition of resistance 
of melanoma cells to chemotherapeutic drugs and radiation.259'261 Inhibition of ATF2 
activity efficiently inhibits melanoma growth, ability to metastasize, and sensitizes 
melanoma to a range of chemotherapeutic agents and radiation.262,263
65
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
In this study, we sought to evaluate the prognostic role of ATF2 by studying the 
pattern and levels of ATF2 expression using a large cohort melanoma tissue microarray, 
and associating expression with clinical and pathologic data.
Materials and Methods
Tissue Microarray Construction:
The tissue microarray was constructed as previously described.150 A total of 570 
tissue cores (553 melanomas with duplicate spots for 9 patients, 17 normal skin) 
measuring 0.6 mm were spaced 0.8 mm apart on a single glass slide. The cohort was 
constructed from paraffin-embedded formalin-fixed tissue blocks obtained from the Yale 
University Department of Pathology archives. The specimens were resected between 
1959 and 1994, with a follow-up range between 2 months and 38 years with a median 
follow-up time of 60 months. Treatment information was not available for the entire 
cohort. Some of the stage III patients were treated with interferon based therapy, and the 
stage IV patients were treated with a range of therapies including chemotherapy, 
biological therapy, vaccine therapy and supportive care. Slides from all blocks were 
reviewed by a pathologist to select representative areas of invasive tumor to be cored. 
The cores were placed on the tissue microarray using a Tissue Micorarrayer (Beecher 
Instruments, Silver Spring, MD). The tissue microarrays were then cut to 5 pm sections 
and placed on glass slides using an adhesive tape-transfer system (Instumedics, Inc., 
Hackensack, NJ) with UV cross-linking.
Immunohistochemistry:
The tissue microarray slide was deparaffmized by rinsing with xylene, followed 
by two changes of 100% ethanol and two changes of 95% ethanol. The slides were then
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boiled in a pressure cooker containing 1 mM EDTA (pH 7.5) for antigen retrieval. 
Endogenous peroxidase activity was blocked with 2.5% methanol in hydrogen peroxide
for 30 minutes at room temperature. After washing with Tris Buffered Saline, the slides
1 2were incubated at room temperature for 30 minutes in 0.3% BSAV1X TBS to reduce 
non-specific background staining. The primary antibody, rabbit polyclonal anti-ATF2 
IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was then added at a dilution of 
1:50, and the slides were incubated overnight at 4°C in a wet chamber, and then rinsed 
three times in IX TBS/0.05% Tween-20. Biotinylated goat anti-rabbit IgG (Vector 
Laboratories, Burlingame, CA) was added for 1 hour, and the slides were washed in 
TBS-Tween as above, incubated for with VECTASTAIN® ABC-AP Reagent (Vector 
Laboratories, Burlingame, CA) for 1 hour, washed again in TBS-Tween as above and 
incubated for 30 minutes with an alkaline phosphatase substrate solution (Vector 
Laboratories). The slides were then rinsed in water, counterstained with hematoxylin and 
mounted with Immunomount (Shandon, Pittsburgh, PA).
Evaluation of the Immunohistochemical Staining:
The regions of most intense staining were scored by eye for each spot. 
Cytoplasmic and nuclear staining of the melanoma cells were scored separately. Because 
of the small size of the histospot (0.6 mm in diameter), no area variable was included in 
the scoring. The staining was graded using the following scale: 0 - no staining; 1 - weak 
staining; 2 - moderate staining; 3 - intense staining. Specimens with no invasive 
melanoma, or specimens that were not interpretable were excluded from the analysis. 
The tissue microarray was scored separately by two independent observers (A.B. and
1 Bovine Serum Albumin
2 Tris Buffered Saline
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H.K.), with a very high correlation between scorers (PO.OOOl). A consensus score was 
determined for spots with discrepant scoring between the observers.
Statistical Analysis:
JMP 5.0.1 and Statview 5.0.1 (SAS Institute Inc., Cary, NC) software were used 
for data analyses. The correlation between the consensus score and the relationship of 
ATF2 expression and clinicopathological parameters were done using the Chi Square 
test. The prognostic significance of the parameters was assessed for predictive value 
using the Cox proportional hazards model with overall survival as an end point. Survival 
curves were calculated using the Kaplan-Meier method, with significance evaluated using 
the Mantel-Cox long-rank test.
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Results
Immunohistochemical Staining of Melanoma Tissue Microarrays
Of the 553 melanoma tumors on the tissue microarrays, 479 (87%) were 
interpretable for cytoplasmic and nuclear ATF2 staining. Spots that were deemed 
uninterpretable had insufficient tumor cells in the spot, loss of tissue in the spot or an 
abundance of necrotic tissue. Of the 479 interpretable specimens, 400 (84%) also had 
associated survival information. Figure 12 demonstrates histospots representative of 
scores 3+ for cytoplasmic and for nuclear staining. The cases included 269 primary 
cutaneous melanoma specimens, 20 local recurrences, 18 melanomas originating in 
mucous membranes (vulva, anus, nasal mucosa and rectal), 118 lymph node metastases, 
68 cutaneous metastases and 51 distant metastases. The site was not known for 4 of the 
patients. There was a strong correlation between nuclear ATF2 expression and lymph 
node or metatstatic sites (chi squared test PO.OOOl), while cytoplasmic ATF2 expression 
correlated with primary lesions (P<0.0001).
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Figure 12. Immunohistochemical staining on representative histospots showing strong cytoplasmic ATF2 
staining (A) and strong nuclear ATF2 staining (B). The Figures are at 10X magnification, and the insets at 
60X magnification.
Survival Analysis
The cytoplasmic and nuclear ATF2 expression levels were each evaluated for 
association with overall survival. Kaplan Meier survival curves generated for 
cytoplasmic and nuclear ATF2 were split by ordinal score, as shown in Figure 13. These 
curves show that increased cytoplasmic expression was correlated with better outcome 
(P=0.0005). Conversely, increased nuclear ATF2 staining was associated with worse 
outcome (P=0.0013). Although these data are only semi-quantitative, the curves suggest 
a splitting of the data to define scores of 0 and 1 as “low” or “negative” expression and 2 
and 3 as “high” or “positive” for both nuclear and cytoplasmic staining. The curves for 
scores of 0 and 1 overlap each other, likely secondary to the difficulty in determining the 
difference between absent or very weak staining by eye, particularly for weak or absent 
nuclear staining in the presence of strong cytoplasmic staining and vice versa. Therefore
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the designations of “high” or “low” expression are used for the remainder of the analyses. 
This result is shown in a Kaplan Meier plot in Figure 13.
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Figure 13. Kaplan-Meier survival curves for ATF2 staining for the entire cohort of patients over a 30 year 
period, with time given in months: (A) The four intensities of ATF2 cytoplasmic staining (0,1,2,3) (B) The 
four intensities of ATF2 nuclear staining (0,1,2,3) (C) High and low cytoplasmic staining for ATF2 (D) 
High and low nuclear staining for ATF2.
There were a relatively large number of patients that had high cytoplasmic ATF2 
expression with low nuclear expression and vice versa. Therefore to further stratify the 
patients, they were divided into three risk groups: 1) high cytoplasmic expression, low 
nuclear expression, 2) low cytoplasmic expression and high nuclear expression and 3) 
high cytoplasmic and nuclear expression or low cytoplasmic and nuclear expression. The
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Kaplan Meier survival curves for these three groups of patients are shown in Figure 
14(A).
For clinicians treating melanoma patients, perhaps the greatest need for 
determining prognosis occurs at initial presentation, when patients have a biopsy 
performed on a changing skin lesion. Therefore, further survival analysis was performed 
using the primary skin lesions only. When dividing the primary skin lesions into the 
three ATF2 prognostic groups mentioned above, patients with high cytoplasmic, low 
nuclear ATF2 expression did better than those with low cytoplasmic, high nuclear 
expression, and the group with low cytoplasmic, low nuclear or high cytoplasmic, high 
nuclear expression demonstrated intermediate overall survival (PO.OOOl), as can be seen 
in Figure 14(B).
O  High Cyt, Low NucATF2 
H  High Cyt, High Nuc or 
Low Cyt, Low Nuc ATF2 
X Low Cyt, High NucATF2
Qg> OP fOCl 080 Q Q—
O  High Cyt, Low Nuc ATF2 
B  High Cyt, High Nuc or 
"  Low Cyt, Low Nuc ATF2 
X Low Cyt, High NucATF2
Survival Months Survival Months
Figure 14. Kaplan Meier survival curves for 3 risk groups of patients: low risk patients (high cytoplasmic 
and low nuclear ATF2 expression), intermediate risk patients (high cytoplasmic and high nuclear or low 
cytoplasmic and low nuclear ATF2 expression) and high risk patients (low cytoplasmic and high nuclear 
ATF2 expression) as shown in the figure legend. Curves include (A) all patients and (B) primary cutaneous 
lesions only.
Univariate analysis was performed using the Mantel Cox test. High cytoplasmic 
ATF2 expression was associated with good overall survival; hazard ratio=0.618 (95%
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C.I.3 0.474-0.806, P=0.0003). High nuclear ATF2 expression was associated with poor 
overall survival; hazard ratio=1.25 (95% C.I. 1.1-1.4, P=0.0009), and the combination of 
low cytoplasmic ATF2 and high nuclear ATF2 was associated with worse survival, 
hazard ratio 1.33 (95% C.I. 1.15-1.53, PO.OOOl). The pattern of ATF2 expression for 
primary and regional/metastatic disease and its association with survival is shown in 
Table 8. The ATF2 expression pattern was only predictive of survival among the primary 
specimens, and not the regional/metastatic specimens.
Confidence Interval
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Table 8. Univariate analysis of ATF2 expression by tumor site and subcellular localization.
Location of . . . . , , , , , ,  „  , Median Survival Hazard ratio „  .r • Cytoplasmic ATF2 Count x ,, P valueLesion r  Months (Range) (95% confidence interval)
Primary Low 70 47(1-463)
O M i I'D ^ 9 - 0  X M 0.001Lesions
High 157 97 (0-444)
Metastatic Low 138 47 (1-305) 1 0 9  ( ( \  R 6  1 0.80
lesions High 93 39(1-415)
Location of 
Lesion Nuclear ATF2 Count
Median Survival 
Months (Range)
Hazard ratio 
(95% confidence interval) P value
Primary Low 153 83 (0-463) 1.37(1.08-1.74) 0.011
Lesions
High 74 77 (1-377)
Metastatic Low 98 44(4-415) 1.03 (0.88-1.23) 0.70lesions High 133 42(1-387)
Location of 
Lesion ATF2 Risk Count
Median Survival 
Months (Range)
Hazard ratio 
(95% confidence interval)
P value
Low 111 93 (0-444)
Primary
Lesions Intermediate 88 77 (1-463) 0.81 (0.57-1.13) 0.0004
High 28 52 (1-309) 2.14(1.46-3.04)
Low 38 41 (6-415)
Metastatic
lesions Intermediate 115 46 (1-387) 0.90 (0.71-1.13) 0.64
High 78 43 (1-305) 1.04 (0.81-1.33)
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Clinicopathological Correlations and Multivariate Analyses
Using the Cox Proportional Hazards Model, we performed multivariate analyses 
to assess the independent predictive value of ATF2 expression among the primary 
cutaneous lesions. We included the following prognostic variables for melanoma,; 
Breslow depth, Clark level, ulceration, microscopic satellites and tumor infiltrating 
lymphocytes at diagnosis. We used a combined cytoplasmic and nuclear ATF2 risk 
grouping with low cytoplasmic and high nuclear ATF2 staining presenting the highest 
risk group. Our high risk ATF2 pattern remained an independent prognostic indicator in 
primary lesions, as did Clark level. Results of the multivariate analysis are shown in Table 
9.
Table 9. Multivariate Analysis of ATF2 Expression Pattern and Other Histopathological 
Variables among Primary Lesions
V ariab le
H azard  R atio  
(95%  con fid en ce  
in terval)
L ik e lih ood -R atio
x2 P value
C lark  L eve l 
(I-III vs. IV -V ) 
B reslow  
(< lm m  vs. > lm m )  
T IL s  
(p resen t vs. absen t) 
U lceration  
(p resen t vs. absen t)  
M icroscop ic  Sate llites  
(p resen t vs. absen t)  
A T F 2 R isk  
(h igh  vs. in term ed ia te+ low )
1.67(1.17-2.47) 8.25 0.0041
1.28 (0.80-2.07) 1.08 0.30
1.13 (0.83-1.51) 0.63 0.43
0.83 (0.63-1.10) 1.73 0.19
0.75 (0.57-1.01) 5.00 0.025
1.81 (1.34-2.40) 13.6 0.0002
Correlation between clinicopathological variables and the ATF2 risk pattern was 
further examined. The high risk ATF2 pattern was most strongly associated with thick 
lesions (P < 0.0001), and had a weaker association with Clark level (P = 0.01). There was
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no significant association between the pattern of ATF2 expression and the site of primary 
lesion, age or gender.
Discussion
Numerous preclinical studies have shown that ATF2 contributes to melanoma 
growth and metastasis, tumor cell survival and resistance to chemotherapy and radiation. 
Here we demonstrate, for the first time, that the ATF2 expression pattern is associated 
with patient survival.
Our data show that strong nuclear ATF2 expression was more frequent in 
metastatic sites (lymph nodes, bone metastases or visceral metastases) than in primary 
cutaneous specimens (PO.OOOl). Furthermore, our data show that nuclear ATF2 
expression is a strong predictor of poor survival and that cytoplasmic ATF2 expression is 
a strong predictor of good outcome in melanoma patients. Among the primary cutaneous 
specimens, patients that had weak cytoplasmic and strong nuclear staining had poor 
survival (P<0.0001), and vice versa for strong cytoplasmic and weak nuclear staining. 
The expression pattern of ATF2 retained independent prognostic value on multivariate 
analysis, as did Clark level. Breslow depth was predictive of outcome on univariate 
analysis. However, when evaluated in multivariate analyses with ATF2, it was not an 
independent predictor of survival. This is likely due to the correlation between Breslow 
depth and ATF2 expression.
Our data suggest that subcellular ATF2 localization might be a very useful 
prognostic marker in primary cutaneous melanoma, and might affect decisions regarding 
patient management, such as the appropriateness of staging evaluation and adjuvant 
therapy for patients with early stage melanoma.
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ATF2 has been primarily implicated as a transcription factor which 
heterodimerizes with c-Jun and mediates transcriptional activities by Jun responsive 
elements.253,264 ATF2 is among early response genes that are activated following stress 
and DNA damage, depending on its phosphorylation by upstream kinases, including JNK 
and p38. ATF2 has been identified as one of the primary transcription factors that bind to
9  SOJun2-like elements in human melanoma cells. Earlier studies that elucidated the 
possible role of ATF2 in human melanoma have established it plays an important role in 
the acquisition of resistance to chemotherapy and radiation therapy.259"261 ATF2 alters 
melanoma susceptibility to undergo apoptosis, in part, due to its ability to alter the 
balance between TNF and Fas signaling.261 Inhibition of ATF2 activities, either by co­
expression with its dominant negative forms or via short peptides that out-compete the 
endogenous protein, was found to be an efficient mechanism for sensitizing human and 
mouse melanoma cells to radiation-induced apoptosis. Furthermore, expression of a 
small peptide that abolishes ATF2 transcriptional activities inhibited melanoma growth in 
several mouse tumor models.262,263 Collectively, these studies suggest a critical role for 
ATF2 in melanoma progression and resistance to therapy.
The current findings are compatible with the preclinical data and provide insight 
into the importance of this transcription factor in the development of melanoma. Of 
particular interest is the finding that nuclear localization of ATF2 correlates with poor 
prognosis. As a transcription factor, ATF2 is active within the nuclear compartment, 
where it elicits its transcriptional activities. Strong nuclear staining of ATF2 therefore 
suggests that ATF2 is constitutively active in these tumors. These findings are consistent
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with the notion that it is necessary to inhibit ATF2 activities in order to sensitize these 
tumors to treatment.
ATF2 phosphorylation is a prerequisite for its stability and transcriptional 
activities. ’ ATF2 kinases are often active in melanoma cells , thereby enabling its 
constitutive phosphorylation and activity. Interestingly, ERK has been shown to be 
capable of phosphorylating ATF2 on the same residues as Jnk263, thereby establishing a 
possible link between B-RAF, which is constitutively active in a large percentage of 
human melanoma tumors266, and the activation of ATF2. Nevertheless, the possible 
existence of another kinase which may be activated in the course of melanoma 
progression, and which would trigger the nuclear localization of ATF2, cannot be 
excluded.
In summary, our data suggest that the level and localization of ATF2 expression 
may be clinically useful for assessing prognosis, particularly in primary cutaneous 
melanoma specimens, warranting prospective confirmation. Furthermore, our findings 
suggest that ATF2 might be a useful target for new drug development.
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Chapter 3: Automated Quantitative Analysis (AQUA) of HDM2 Expression in 
Malignant Melanoma Shows Association with Early Stage Disease and Improved 
Outcome
Abstract
The incidence of cutaneous malignant melanoma continues to increase every year, and 
this disease remains the leading cause of skin cancer death in industrialized countries. In 
spite of the aggressive nature of advanced melanoma, there are no standard biological 
assays in clinical usage that can predict metastasis. This may be due, in part, to the 
inadequacy of reproducible assessment of protein expression using traditional 
immunohistochemistry. We have previously described a novel method of quantitative 
assessment of protein expression (AQUA) with the continuity and accuracy of an ELISA 
assay but with maintenance of critical spatial information. Here, we modify this 
technology for the evaluation of protein expression in melanoma. Using a tissue 
microarray cohort of 405 melanoma lesions and 17 normal skin samples, we analyzed 
expression of HDM2, the human homolog of MDM2 (murine double minute 2) with 
AQUA. We show that expression levels in the nucleus are significantly higher in 
primary melanomas than in metastatic lesions. Furthermore, high levels of expression are 
predictive of better outcome. This study demonstrates that quantitative assessment of 
protein expression is useful in melanoma to validate potential tissue biomarkers, and 
suggests that HDM2 may be a valuable prognostic tool for management of malignant 
melanoma.
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Introduction
Malignant melanoma is currently the malignancy with the most rapid increase in 
incidence in the United States.1,267 The fifth most common cancer2, melanoma is the 
most common fatal malignancy among young adults3 with 53,600 new cases diagnosed in 
2002268. Current estimates predict that 1 in 71 individuals will develop melanoma during 
their lifetime, up from an initial estimate of 1 in 600 in 1960 and 1 in 150 in 1985.1
A number of clinical and pathologic factors have been described as markers of 
prognosis in cutaneous malignant melanoma, however, there are currently no routinely 
used, broadly accepted molecular, or immunohistochemical markers to define subsets of 
this neoplasm15 or predict outcome. The current methods of prognosis in cutaneous 
melanoma have not changed much since the 1970s when Breslow28 and Clark29 first 
published reports indicating the importance of dermal invasion in prognosis. The models 
of Breslow and Clark remain the most powerful and reliable predictors of survival in 
primary melanoma42, in spite of the molecular “revolution” of the past 30 years.
To develop a better understanding of melanoma biology and development, as well 
as discover molecular markers of potential benefit in melanoma prognosis, a number of 
studies have evaluated immunohistochemical (IHC) markers on an individual basis and in 
numerous relatively small cohorts. Very few, however, have been performed on
*)f\Q 9 7 f)melanoma tissue microarrays ’ and none have made use of quantitative analysis. 
Differences in expression levels in the tissues have been limited to those that are easily 
detectable by the human eye. The current IHC technology is susceptible to high levels of 
inter- and intra-observer variability and fraught with variability as a function of the lack 
of standardization of antibody-based techniques.218
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Tissue microarrays provide a highly efficient and economical way to evaluate 
hundreds of tumors on a single slide.149 The use of tissue microarray (TMA) technology 
eliminates the slide-to-slide variability inherent to IHC as all tissues are present on the 
same slide and are exposed to the same experimental conditions. The use of archival 
tissues allows for a retrospective study with the benefit of long-term patient follow-up.
In addition to improving our understanding of key molecular events in cancer 
progression, TMAs provide an excellent mechanism for the discovery of outcome 
predictor models, particularly when coupled with quantitative analysis.
We have developed a system for compartmentalized, automated quantitative 
analysis of histological sections (AQUA).271 AQUA provides highly reproducible 
analysis of target signal expression in tissues on a continuous scale, while preserving 
spatial information, particularly subcellular localization. Quantitative analysis enables 
precise discrimination of expression levels in tissues, providing measurements on a 
continuous scale not previously attainable by traditional, or manual, scoring methods.
The use of this technology was originally described in colon cancer271, and has since been
7 7 7  7 7 7applied to breast and prostate carcinoma. Briefly, the system identifies and tags 
tumor tissue within each histospot, based on the expression of tissue specific proteins, 
such as cytokeratin in carcinomas, and then evaluates the expression level of a target 
antigen within the ‘tumor mask’ and inside user-defmed subcellular compartments. For 
this study, the AQUA system was modified to accommodate melanoma by substituting 
SI 00 protein for cytokeratin (Figure 15). A review of the pertinent literature 
demonstrated that SI 00 is expressed in 97.4% of all melanomas274, and some 
investigators suggest this number may exceed 98%275. Here, we validate the technology
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by assessing the expression of HDM2 (human homologue of ‘murine double minute 2’) 
and demonstrate its utility in evaluating a prognostic marker in a large retrospective 
cohort.
HDM2 is a transcriptional target of the tumor suppressor protein p53, that, in turn,
" i n f .  0 '7 0
marks p53 for degradation. ' It is predicted that disruption of this negative feedback 
loop, through either p53 mutation or overexpression of HDM2, would be a negative 
prognostic marker for cancer progression. The association between HDM2 and clinical
279 • ■ •outcome has been investigated intensively in a number of cancers with the anticipation 
of using HDM2 as a clinical prognostic marker. However, only a handful of studies have
9  FiQ Of) T O  1evaluated HDM2 expression in melanoma. ’ In the largest study, Polsky et al. 
demonstrated that over-expression of HDM2 in a cohort of 134 melanoma patients 
unexpectedly correlated with improved clinical outcome, having a statistically significant 
association with longer disease free- and overall survival.109 The quantitative assay we 
describe in the work confirms and extends these observations.
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Materials and Methods
Tissue Microarray Construction:
i c a  282The tissue microarray was constructed as previously described. ’ A total of 
570 tissue cores representing 542 total melanoma cases and a small series of controls 
measuring 0.6 mm were spaced 0.8 mm apart on a single glass slide. The cohort was 
constructed from formalin-fixed paraffin-embedded tissue blocks obtained from the 
archives of the Department of Pathology at Yale University School of Medicine. A 
pathologist examined each case to select the region for inclusion in the TMA. Core­
biopsies from the specimens were placed on the tissue microarray using a Tissue 
Micorarrayer (Beecher Instruments, Sun Prairie, WI). The tissue microarrays were then 
cut to 5-pm sections and placed on glass slides using the adhesive tape transfer system 
(Instumedics, Inc., Hackensack, NJ) with UV cross-linking. The specimens were all 
drawn from archives of tumors resected between 1959 and 1994, with a follow-up range 
of 2 months and 38 years (median follow-up time, 60 months). The cohort characteristics 
are demonstrated in Table 1. For the primary cutaneous lesions (269), a single reviewer 
measured Breslow depth, Clark level, microscopic satellites, tumor infiltrating 
lymphocytes, and the presence of ulceration. Treatment information was not available 
for the entire cohort. Some of the stage III patients were treated with Interferon-based 
therapy, and the stage IV patients were treated with a range of therapies including 
chemotherapy, biological therapy, vaccine therapy, and supportive care.
Immunohistochemistry:
The tissue microarray slide was stained as described previously.271 In brief, the 
slides were deparaffinized by rinsing with xylene, followed by two changes of 100%
83
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ethanol and two changes of 95% ethanol. Antigen retrieval was performed in a pressure 
cooker containing 1 mM EDTA (pH 7.5), and endogenous peroxidase activity was 
blocked with 2.5% hydrogen peroxide in methanol for 30 min at room temperature. The 
slide was washed with TBS, incubated in 0.3% BSA/1X TBS for 30 min at room 
temperature to reduce nonspecific background, and then stained with the a combination 
of anti-MDM2 mouse mAb 1B10 (1:100, Novocastra, Ltd., Newcastle upon Tyne, UK) 
plus anti-SlOO rabbit polyclonal (1:6,000, DAKO Corporation, Carpinteria, CA) diluted 
in BSA/TBS, at 4°C overnight. The IB 10 mAb was chosen because it was validated by 
numerous studies in which HDM2 expression was assessed in tumors relative to normal 
tissues.283'285 The secondary antibodies Alexa 488-conjugated goat anti-rabbit (1:100, 
Molecular Probes, Eugene, OR) plus Envision anti-mouse (neat, DAKO) diluted in 
BSA/TBS were applied for 1 hour at room temperature. DAPI (4, 6-Diamidino-2- 
phenylindole) was included with the secondary antibodies to visualize nuclei. The slide 
was washed with BSA/TBS (3X for 5 min), and then incubated with Cy5-tyramide 
(Perkin Elmer Life Science Products, Boston, MA), activated by HRP resulting in the 
deposition of numerous covalently associated Cy5 dyes immediately adjacent to the 
HRP-conjugated secondary antibody. Cy5 was used because its emission peak (red) is 
well outside of the green-orange spectrum of tissue autofluorescence. The slides were 
sealed with cover-slips with an antifade-containing mounting medium (with 0.6% n- 
propyl gallate)
Automated Image Acquisition and Analysis:
The AQUA automated image acquisition and analysis was performed as 
described.271 Briefly, images of the TMA were captured through an Olympus BX51
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microscope with automated x, y, z stage movement using an Olympus Motorized 
Reflected Fluorescence System and software (IP lab v3.54, Scanalytics, Inc.), equipped 
with Cooke Sensicam QE High Performance camera. Low power images of the 
microarray were stitched together using multiple low-resolution images of the microarray 
(64 x 64 pixel) at approximately 7-micron resolution. Histospots were identified 
employing the signal from DAPI and/or SI 00 tags. Rows and columns of the histospots 
were then identified, missing histospots filled in, allowing each histospot to be identified 
by its coordinates, and recorded based on its position in the grid. Subsequently, 
monochromatic, high-resolution (1024 x 1024 pixel, 0.5-micron resolution) images were 
obtained of each histospot, both in the plane of focus, and 8 microns below it, recorded in 
an image stack as bitmaps. A resolution of 0.5 microns is suitable for distinguishing 
between large subcellular compartments such as the cell membrane/cytoplasm and nuclei. 
Images were obtained using a pixel intensity dynamic range of 0-1024.
A visual demonstration of the AQUA analysis process is depicted in Figure 15. 
For each histospot, areas of tumor are distinguished from stromal elements by creating a 
tumor mask from the S I00 protein signal, visualized under the Alexa 488 fluorophore. 
The tumor mask is determined by ‘gating’ the pixels in this image, in which an intensity 
threshold is set by visual inspection of histospots (ranging from lowest to highest 
intensity), and each pixel is recorded as “on” (tumor) or “o ff’ (non-tumor) based on the 
threshold. In addition, small objects (<50 pixels) are removed and small holes filled.
The DAPI image, used to identify the nuclei, is subjected to RES A (rapid exponential 
subtraction algorithm), which improves signal-to-noise ratio by subtracting the out-of­
focus image from the in-focus image, in order to clearly define the nuclear
85
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
271compartment. Removal of the pixels assigned to the nuclear compartment from the 
tumor mask provides a designation of the cytoplasmic compartment. After application of 
RESA, the signal intensity of the target antigen, acquired under the Cy5 signal (HDM2), 
is scored on a scale of 0-1024, and the AQUA score within the sub-cellular compartments 
(i.e., nucleus, cytoplasm) is calculated by dividing signal intensity by the area of the 
specified compartment. This score has three significant figures and is directly 
proportional to the number of molecules per unit area.
•Binary Gating 
•Holes Filled 
•Small O bjects 
Removed
S10Q P ro te in  (Cy2) C ytop lasm ic  C om partm en t
•RESA
•Pixels "inside**
Mask
N uclei (DAPI) N u c le a r  C o m p a r tm e n t C o m p a rtm e n ts
Target/H D M 2 (Cy5) T a rg e t  a f te r  RESA
T a rg e t L ocalization
Red * N uclear 
G reen = Cytoplasm ic
Figure 15. Schematic demonstration of AQUA protocol applied to melanoma. Images on the left are raw. 
Images on the right have been generated by AQUA. The top horizontal set of panels demonstrates tumor 
mask in a melanoma histospot, based on S I00 protein expression (Alexa 488), distinguishing tumor cells 
from stroma. The S I00 image is gated to form a binary mask. This binary image is enhanced by filling 
holes and removing small objects. DAPI is used to tag the nuclei, and after application of RESA (Rapid 
Exponential Subtraction Algorithm) and identification of only those pixels within the tumor mask, this 
image designates the nuclear compartment. After application of RESA to the Alexa 488 image, the nuclear 
compartment is subtracted from the tumor mask to provide a designation of the cytoplasmic compartment. 
An image of the target-specific marker, HDM2, is taken (Cy5), and after exponential subtraction using 
RESA, the intensity of the marker is divided into the subcellular compartments by pixel-based locale 
assignment for compartmentalization of expression (PLACE algorithm). An AQUA score (intensity/area) is 
generated for the target within the subcellular compartments. This information is graphically represented by 
the target localization image.
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Data Analysis:
Histospots containing <10% tumor as assessed by mask area were excluded from 
further analysis. Previous studies have demonstrated that the staining from a single 
histospot provides sufficient representative sample to judge outcomes. ’ In the case 
of HDM2, staining was always nuclear; analyses using the nuclear-specific AQUA score 
of HDM2 yielded parallel results to analyses using the total AQUA score. Univariate 
survival analyses were assessed using the Kaplan-Meier method for nominal variables 
and the Cox regression method for continuous variables. Multivariate analyses were 
performed with the Cox proportional hazards model. Mantel-Cox log-rank score was 
used to assess statistical significance. Analyses were performed with JMP 5.0.1 (SAS 
Institute Inc., Cary, NC). Patients were deemed uncensored if they died of melanoma 
within 30 years of their initial date of diagnosis.
Results and Discussion 
Validation of Microarray Cohort:
We sought to validate our tissue microarray cohort of 542 melanomas using 
several traditional histopathological markers of malignancy. As described previously282 
and demonstrated in Table 10, unique patient-specific cases on the TMA include 287 
primary specimens, 233 metastatic specimens, and 20 local recurrences. Using univariate 
analysis of long-term disease-related survival, primary versus metastatic status predicted 
improved survival (p<0.0001). (Figure 16A) For the primary cutaneous specimens, we 
found that tumor depth (Breslow and Clark) (pO.0001), ulceration status (p=0.0028),
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microscopic satellitosis (p<0.0001), tumor infiltrating lymphocytes (TILs) (p=0.0007), 
and histologic subtype were all significant predictors of survival (Figure 16B-F).
Table 10. Tissue Microarray Characteristics
Primary Lesions (287) 269 Cutaneous 18 Mucosal
Metastatic Lesions (233)
118 Lymph Node 
65 Cutaneous & Subcutaneous 
11 Lung 
8 Bone
2 Brain
26 Other Distant
3 Unknown
Local Recurrences (20)
Unknown (2)
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Figure 16. Melanoma TMA characteristics. Kaplan-Meier survival curves demonstrating disease-specific 
survival based on lesion location (i.e., primary versus metastatic), as well as the role of standard 
histopathological criteria on survival in this cohort, which includes Breslow depth (T1-T4), Clark levels (II- 
V), the presence or absence of ulceration, the presence or absence of microscopic satellites and presence of 
infiltrating lymphocytes.
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Automated Analysis of HDM2 Expression in Melanoma:
After image acquisition for each histospot, AQUA was performed to establish the 
intensity of HDM2 expression per unit area within each histospot (Figure 15). HDM2 
expression was confined to the cell nuclei, and analysis of AQUA scores of HDM2 
within the nuclear compartment yielded similar results to analysis of HDM2 expression 
within the overall tumor mask, suggesting nearly all of the expression is in the nucleus.
AQUA score calculation results in a continuous scale in contrast to manual 
scoring, which is based on an ordinal scale with arbitrary values. Regression analysis has
• 271 272previously demonstrated a good correlation between the two methods. ’ Of the 542
total histospots, 405 contained sufficient tumor tissue to provide an AQUA score for 
HDM2. The loss of histospots is random, but reduces the number of cases available for 
analysis in remainder of this study. Of the 405 cases analyzed, 200 were primary lesions 
and 190 were metastases, 13 were local recurrences, and 2 were of unknown origin. 
AQUA scores in the melanoma-specific nuclear compartment of all specimens ranged 
from 19.62-150.72 and from 21.84-145.98 within nuclear compartment of primary 
lesions. The histogram in Figure 17A demonstrates the continuous nature and bell­
shaped distribution of the AQUA scores for all of the specimens. Note that in other 
systems, we have evidence that the scores are directly proportional to the number of 
molecules per unit area. This is probably also true for F1DM2, but purified protein 
standard controls were not available to validate this prediction.
HDM2 expression in the primary lesions was compared to expression in 
cutaneous metastases, lymph node metastases, and distant metastases. Figure 17B shows 
that loss of HDM2 is more common in later stage disease. This may be related to specific
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classes of tumor with low expression having a great propensity for progression. The 
significance of the difference between the means of the AQUA scores for each tissue type 
(i.e., skin metastases, lymph node metastases, distant metastases) from the AQUA scores 
of primary lesions was determined by t-tests, demonstrated in the Table 11.
Table 11. HDM2 Protein Expression within Tumor Nuclei by AQUA Analysis
n Mean SE 95% Cl
Comparison with Mean of Primaries
Difference Std Error t test DF p value
Primaries 200 65.73 1.57 62.63-68.83
Skin Mets 52 58.37 3.24 51.98-64.76 7.36 3.64 2.02 250 0.0445
LN
Mets 98 53.72 2.28 49.23-58.21 12.01 2.78 4.31 296
<0.0001
Distant
Mets 40 49.22 3.52 42.28-56.15 16.51 3.86 4.28
238 <0.0001
All Mets 190 54.05 1.63 50.85-57.24 11.68 2.27 5.15 388 <0.0001
Mets, metastatic tumor; LN, lymph node; Cl, confidence interval
Survival Analysis:
Since the AQUA scores are of a continuous nature, the HDM2 expression scores 
were analyzed by univariate Cox regression. This univariate parametric survival analysis 
demonstrated that high HDM2 expression was associated with improved survival in all 
specimens (p=0.0154), and in the primary lesions alone (p=0.0318). However, when 
HDM2 expression was evaluated in only the metastatic specimens, it did not show a 
significant association with survival (p=0.9330). To graphically depict the influence of 
HDM2 on survival in melanoma, the scores were divided into quartiles and Kaplan-Meier 
survival curves were constructed for HDM2 expression. The p values for these curves 
were determined by the Mantel-Cox log-rank method. Assessment of survival in all
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specimens demonstrated that high expression of HDM2 is associated with better disease- 
specific survival (p=0.0382) (Figure 17C). Examination of HDM2 expression in relation 
to survival in only the primary specimens followed the same trend, revealing improved 
outcome for high expressers (p=0.0211) (Figure 17D). The quartile cut-points 
established for AQUA scores in all specimens were maintained in evaluation of the 
primary lesions.
Clinicopathologic Correlations:
Table 11 and Figure 17B demonstrate that decreased expression of FIDM2 is associated 
with metastasis. Within primary lesions, there is a relationship between HDM2 
expression and lesion progression. Table 12 demonstrates that HDM2 exhibits an 
association with Breslow thickness, Clark level, and tumor infiltrating lymphocytes, but 
not with microscopic satellites, ulceration, primary tumor location, age, or sex. These 
data indicate that HDM2 expression decreases as lesions progress deeper into the dermis 
(Breslow thickness and Clark level). Multivariate analysis revealed that HDM2 is not 
independently predictive presumably due to its tight association with variables defining 
depth of invasion (data not shown).
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Table 12. HDM2 Expression and Clinicopathologic Features of Primary Lesions
HDM2 Expression within Tumor Nuclei (Quartiles)
Factor
Bottom 25% 
(n=31), 
No. (%)
25-50% 
(n=48), 
No (%)
50-75% 
(n=55), 
No (%)
Top 25% 
(n=66), 
No (%) P value
Breslow Thickness
< lm m (T l) 0(0) 10(17.9) 16 (28.6) 30 (53.6)
1.01-2.Omm (T2) 7(15.6) 10(22.2) 15 (33.3) 13 (28.9)
<0.0001
2.01-4mm (T3) 9(18.8) 16(33.3) 13 (27.1) 10 (20.8)
>4mm (T4) 12(30.8) 9(23.1) 8 (20.5) 10 (25.6)
Unknown 3 3 3 3
Clark Level
I 0(0) 0(0) 0(0) 0(0)
II 0(0) 0(0) 8 (38.1) 13 (61.9)
III 10(14.7) 19(27.9) 18 (26.5) 21 (30.9) 0.0029
IV 14(17.5) 19 (23.8) 23 (28.8) 24 (30)
V 3(15) 8(40) 4(20) 5(25)
Unknown 4 2 2 3
TILs
Brisk/Diffuse 1 (2.1) 11 (23.4) 14 (29.8) 21 (44.7)
N onbrisk/N ondiffuse 20 (20.2) 26 (26.3) 26 (26.3) 27 (27.3) 0.0392
Absent 7 (16.3) 9(21.0) 13 (30.2) 14 (32.6)
Unknown 3 2 2 4
Age
<60 9 (8.9) 27 (26.7) 30 (29.7) 35 (34.7)
0.1797
>60 17 (20.2) 20 (23.8) 22 (26.2) 25 (29.8)
Unknown 5 1 3 6
Ulceration
Present 12 (20.3) 15 (25.4) 17 (28.8) 15 (25.4)
0.2585
Absent 14(11.4) 28 (22.8) 35 (28.5) 46 (37.4)
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HDM2 Expression within Tumor Nuclei (Quartiles)
Factor
Bottom 25% 
(n=31), 
No. (%)
25-50% 
(n=48), 
No (%)
50-75% 
(n=55), 
No (%)
Top 25% 
(n=66), 
No (%) P value
Unknown 5 5 3 5
Sex
Male 12(14.3) 19 (22.6) 27 (32.1) 26 (31.0)
0.5304
Female 15 (15.3) 25 (25.5) 22 (22.5) 36 (36.7)
Unknown 4 4 6 4
Microscopic Satellites
Present 7(18.0) 9(23.1) 8 (20.5) 15 (38.5)
0.5535
Absent 19(13.5) 33 (23.4) 44 (31.2) 45 (31.9)
Unknown 5 6 3 6
Primary Tumor Location
Axial 12 (15) 20 (25) 24 (30) 24 (30)
0.5701
Extremity 9 (9.5) 26 (27.4) 25 (26.3) 35 (36.8)
Unknown 10 2 6 7
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Discussion
HDM2 overexpression correlated positively with poor prognosis in sarcoma, 
glioma, and pediatric acute lymphocytic leukemia, but negatively for non-small cell lung 
cancer, ERa-positive breast carcinoma, and melanoma.279 Pathologist-based, traditional 
analysis of HDM2 expression in a melanoma cohort of 134 patients demonstrated that 
HDM2 over-expression was unexpectedly associated with improved survival.109 The 
method of scoring used by Polsky et al. was based on a scale of nuclear 
immunoreactivity, ranging from undetectable (0%) to homogeneous staining (100%). 
Their choice of cut point was based on prior experience with this antibody in other 
cancers (i.e., bladder, prostate, squamous cell carcinomas, and sarcomas), in which the 
20% cut point stratified patients in a clinically relevant fashion, but they acknowledged 
that the appropriate cut points for cutaneous melanoma remain to be established.109 
The continuous nature of AQUA scores makes it difficult to determine a cut-point for 
survival analyses; however, expression of HDM2 diminished as lesions became more 
invasive (Table 11 & Table 12, Figure 17B). Therefore, the AQUA scores of HDM2 
expression were stratified into quartiles and survival curves were plotted to predict 
outcome. In concordance with Polsky et al., we also found that high expression of 
HDM2 predicted a favorable prognosis (Figure 17C). The ability to predict survival was 
more apparent when the analysis was limited to primary lesions (Figure 17D).
The apparent paradox of HDM2 over-expression having a protective effect, was 
suggested to indicate the presence of a functional p53 exerting an inhibitory effect on 
tumor proliferation and activating the HDM2 promoter as part of its normal 
autoregulatory feedback loop.109 The p53 tumor suppressor plays a critical role in the
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cellular response to DNA damage, preventing altered, pre-malignant cells from 
progressing to cancer. In response to DNA damage, the p53 protein initiates a variety of 
stress-specific transcriptional response programs that lead to growth arrest, apoptosis, or 
senescence.276 In addition to inducing these response programs, p53 also tightly regulates 
its own intracellular level via an autoregulatory feedback loop with HDM2.
Transcription of HDM2 is stimulated by p53, and HDM2, in turn, directly ubiquintinates 
p53 and targets it to proteasomal degradation.278 Recent experiments by Lahav et al. on 
the dynamics of the p53-MDM2 feedback loop demonstrate that this negative-feedback 
system functions in a ‘digital’ fashion, in which expression of repair enzymes occurs in 
defined linear quanta rather than a binary switch-like (all-or-nothing) response.288 Cells 
probably express frequent pulses of HDM2 induction when exposed to damage, and 
histologic sections may represent a snapshot of this dynamic result. That is, a set of cells 
undergoing pulses that are more frequent would be more likely to be expressing HDM2 at 
the time of excision and fixation.
However, in light of all the examples demonstrating the regulatory functions of 
MDM2/HDM2 on p53, there is mounting evidence demonstrating p53-independent 
functions of HDM2.289 This protein has been shown to interact with multiple factors 
(e.g., ARF, MDMX, ATM, c-abl, HIF-la, RB, PML, E2F) that can play a role in 
transformation, affecting cell cycle control, differentiation, DNA synthesis, RNA 
biosynthesis, transcription, and cell surface receptor turnover.290 Like p53, which plays
291roles in both transcriptional regulation and mediation of apoptosis in mitochondria , 
HDM2 may also have a second role, unrelated to its interaction with p53. It should also
292 293 294 295be noted that a number of other oncoproteins, such as Ras ’ , Raf-1 , and Bcl-2 ,
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have recently been shown to possess secondary, growth inhibitory functions. These dual­
function oncoproteins, including HDM2, may be essential to the proliferation of normal 
cells equipped with growth suppressor activities that have not been fully characterized.296
The AQUA system provides a unique method for the analysis of tissue 
microarrays not previously possible using standard pathologist-based techniques. The 
system is precise, highly reproducible and quantitative resulting in continuous 
measurements similar to that obtained from ELISA assays. In addition, AQUA allows 
for accurate subcellular localization, with the ability to discriminate between the 
cytoplasmic and nuclear compartments in melanoma cells. With increased resolution, the 
analyses will expand to include additional ‘virtual’ compartments (e.g., mitochondria, 
lysosomes, endoplasmic reticulum, Golgi, etc.). The system has been effectively
271 272 273demonstrated on colon , breast , and prostate carcinomas. The automated nature of 
this technology can allow high-throughput screening of tissue microarrays, facilitating 
their use in discovery of chemotherapeutic targets and biomarker validation.
In summary, AQUA-based analysis was used to demonstrate that HDM2 is a 
marker of melanoma progression. As might be expected of a marker of progression, it is 
also useful for prognostication independent of all conventional histologic markers except 
those related to tumor depth of invasion. In primary lesions, this biomarker may 
represent a mechanism to predict survival in a tumor type without standard molecular 
tools for prediction of outcome.
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Chapter 4: Automated Quantitative Analysis of AP-2 subcellular expression in 
Melanoma Tissue Microarrays Correlates with Survival Prediction
Abstract
The activator protein-2a (AP-2) transcription factor plays a key role in regulating the 
expression of many genes involved in tumor growth and metastasis of human melanoma. 
Loss of AP-2 expression has been shown to result in the deregulation of several genes 
with AP-2 binding motifs such as c-Kit, MCAM/MUC18, MMP-2, and PAR-1 
expression, all of which contribute to the increased metastatic potential of human 
melanoma. In this study, we sought to assess the prognostic significance of AP-2 
expression and its role in the transition of nevi to radial growth phase (RGP) and to 
vertical growth phase (VGP, metastatic phenotype) in human melanoma. Two cohorts 
were analyzed using the tissue microarray format. The first was a “progression” array 
containing melanoma specimens from M.D. Anderson Cancer Center representing 168 
melanocytic cores (84 individual cases) from benign nevi (BN, 19), dysplastic nevi (DN, 
21), radial and vertical growth phase melanoma (MM, 22) and metastatic melanoma 
(MMM, 27). The second array was a retrospective cohort collected at Yale University 
representing 214 primary melanomas and 293 metastases with long term clinical follow 
up. The MDCC array was analyzed using Laser Scanning Cytometry (LSC) and Yale 
array was analyzed using Automated Quantitative Analysis (AQUA) systems for analysis 
of AP-2 expression, respectively. Both systems permit the continuous and quantitative 
analysis of protein expression at the single cell level, including sub-cellular localization, 
in tissue sections. Analysis of total AP-2 expression using two, independent quantitative 
systems revealed no correlation with diagnosis group (i.e., BN, DN, MM, or MMM).
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Laser Scanning Cytometry (LSC)-mediated sub-cellular analysis demonstrated that the 
nuclear expression of AP-2 was highest in the BN group (11.85%) and significantly 
decreased in each phase of melanoma progression to 0.39% in the MMM group. Using 
Automated Quantitative Analysis (AQUA™)-based analysis, neither nuclear nor 
cytoplasmic expression levels correlated with outcome. However, the ratio of 
cytoplasmic over nuclear AP-2 was highly predictive of outcome in the entire population, 
as well as in the primary tumors alone. Furthermore, the AP-2 ratio directly correlated 
with other clinicopathological factors such as Breslow depth (R=0.334, p < 0.001). 
Employing two different automated quantitative systems, we demonstrate that a high 
level of AP-2 expression in the cytoplasm relative to the nucleus correlates with poor 
prognosis. Together, these results confirm the biological hypothesis and provide 
quantitative evidence that the loss of AP-2 expression in the nucleus is associated with 
malignant transformation and progression of melanoma.
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Introduction
The incidence and mortality rate of melanoma has increased significantly over the
297last fifty years, with more than 59,000 new cases expected this year. This increase in 
incidence combined with the lack of effective therapy for advanced melanoma 
emphasizes the need to develop better markers that correlate with clinical outcome.
Since the 1970s, the Breslow depth and Clark level of invasion remain the most widely
298 299used and reliable predictors of survival in primary melanoma. ’ However, withm 
each stage of melanoma there is a significant variability in outcome. Thus, more accurate 
molecular markers for melanoma progression are needed to stratify and treat patients with 
malignant melanoma.
Previously, our collaborators have shown that the 52-KDa transcription factor 
Activator Protein 2-a (AP-2) is involved in the progression and metastasis of human 
melanoma through the regulation of several target genes such as c-KIT, MCAM/MUC18, 
E-cadherin, p 21, PAR-1 and MMP-2 genes.300'305 The loss of AP-2 results in the 
suppression of endogenous AP-2 transactivator function that may inhibit melanoma cells
^ A A  A A H
to respond to growth and differentiation-regulatory signals. ’ Furthermore, 
inactivation of AP-2 by means of dominant-negative AP-2 gene resulted in an increase of
302tumorigenicity and metastasis potential in primary cutaneous melanoma cells. Indeed, 
screening human melanoma cells in vitro for AP-2 protein expression has shown that the 
majority of highly metastatic cells express low levels of nuclear AP-2.
Few studies have evaluated AP-2 immunohistochemical staining in melanoma 
prognosis.306,309 These studies, however, were based on individual cases or on small 
patient cohorts using semiquantitative methods. Manual quantification is limited by the
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pathologist’s ability to detect low level staining patterns with the eye, rapidly and 
reproducibly score on a continuous scale, and accurately quantify subcellular expression 
levels. In addition, the analysis of histological sections is complicated by the fact that 
tumor tissue contains a heterogeneous mixture of cell types, necrotic regions and 
extracellular material. Better research tools are needed to facilitate discovery of 
molecular markers of prognosis that reduce variability often observed using antibody- 
based techniques.
Tissue microarrays provide a high-throughput approach to simultaneously screen 
hundreds of patient samples in a uniform fashion.310,311 Analysis of tissue arrays permit 
the molecular profiling of a large number of different molecules at the DNA, RNA, and
'ii')
protein levels that are potentially involved in tumor development and/or progression. ’ 
313 Microarray technology reduces the variability between specimens because all tissue 
cores on the slide are simultaneously exposed to the same technical conditions. Another 
benefit of tissue microarrays is that automated quantitative analysis systems such as LSC 
or AQUA can be used to generate accurate, reproducible measurement of antigen 
levels.314'316 Consistent measurements made across thousands of cells can help identify
317subtle differences in expression that are not easily detectable by the human eye. 
Furthermore, quantitative analysis provides continuous scoring as opposed to pathologist- 
based categorical scoring. This is particularly important when validating putative 
prognostic markers that display large variation in expression, especially when analyzing a 
large cohort as in a tissue microarray.
Here we report two innovative, automated quantitative analysis systems, LSC and 
AQUA, to measure the subcellular expression of AP-2 in two independent melanoma
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tissue microarrays. The LSC platform combines features of both flow and static image 
cytometry analysis. LSC data acquisition captures quantitative information by detecting 
single cell nuclei in tissue sections, eliminating the need to acquire multiple images for 
performing complex algorithms. For this study, LSC-mediated analysis of AP-2 was 
performed by using Melanoma Antigen Recognized by T Cells l(MART-l) to detect 
melanocytic cells. MART-1 or Melan-A is a recently discovered melanocyte
■3 1 O
differentiation antigen recognized by autologous cytotoxic T lymphocytes. The gene 
that encodes MART-1 is expressed in retina, skin, and melanocytic cell lines thereby 
making it an ideal marker for automated detection of melanocytes.319
AQUA uses a pair of novel algorithms that allow highly reproducible analysis of 
target expression in subcellular compartments in tissue sections. Validation using the 
AQUA system has been previously reported.314 This system identifies tumor tissue 
within each histospot based on the expression of tissue-specific proteins (such as SI 00) 
and then evaluates the expression of target antigen, e.g., AP-2, within the tumor mask and 
inside user defined subcellular compartments. Because SI 00 is expressed in 98% of all
320 315 321melanomas , this protein has been used to create the tumor mask in melanoma. ’ 
Recently, AQUA was used to demonstrate that HDM2 is a marker of melanoma 
progression and may be used to predict survival in primary lesions.315 Thus, AQUA is 
designed to read tissue microarrays and optimized for high throughput quantitative 
analysis.
We hypothesized that AP-2 should be active in the nucleus while cytoplasmic 
expression should be associated with loss of function. Employing two independent 
automated quantitative analysis systems, we further demonstrate herewith that the loss of
103
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AP-2 in the nucleus is a crucial event in the progression of human melanoma and that 
subcellular localization of AP-2 is the critical factor in predicting survival.
Materials and Methods 
Patients and Case Selection
Specimens obtained from the Department of Pathology, M.D. Anderson Cancer 
Center consisted of 84 cases comprised of melanocytic lesions including benign nevus 
(19), dysplastic nevus (21), primary melanoma (22, including superficial spreading, 
nodular, acral, and lentigo malignant melanoma, and metastatic melanoma (27) to 
subcutaneous tissue, lymph node and visceral organs, and normal melanocyte controls 
(8). Specimens obtained from the Department of Pathology, Yale University consisted of 
214 primary melanomas, 293 metastases, 14 local recurrences, 22 nevi and 15 cell block 
controls. The specimens were resected between 1959 and 1994, with a median follow-up 
time of 60 months. Both studies involving human tissues were approved by the 
Institutional Review Board at each institution.
Tissue Microarray Construction
Tissue sections from each block were stained with hematoxylin and eosin (H&E) 
and reviewed by a pathologist to define the selective areas to be punched. To preserve 
the original tissue block, either 0.6 mm (biopsies) or 1.0 mm (excision specimens) 
cylindrical cores of tissue were punched out from donor blocks. Selected tissue cores 
were inserted in a standard 4.5 x 2 x 1 cm recipient block using a Tissue Microarrayer 
(Beecher Instruments, Silver Spring, MD, USA) with an edge-to-edge distance of 0.1 or 
0.15 mm.
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The tissue microarrays were then cut to 5 |im sections and placed on glass slides 
using an adhesive tape transfer system (Instumedics, Inc., Hackensack, NJ) with UV 
cross-linking. One section from each array was stained with H&E to verify the presence 
of diagnostic lesional cells and to facilitate case selection for LSC and AQUA-mediated 
quantitative analysis. At least two cylindrical cores from each case were obtained to 
construct the three tissue microarrays evaluated at M.D. Anderson Cancer Center as 
previously described316. Two tissue microarrays were constructed at Yale University, 
with cores (0.6mm) taken from different parts of the tumor for each microarray as
315previously described .
Immunofluorescent Detection of MART-1 and AP-2 for Laser Scanning Cytometry 
Analysis
Sections (5 pm) were prepared from each block, deparaffmized in xylene, 
rehydrated in alcohol, and transferred to PBS. Antigen retrieval was performed by 
steaming using antigen retrieval solution (Dako, Carpinteria, CA) by boiling tissues in 10 
mM citrate buffer, pH 6.0 for 10-20 minutes followed by cooling at room temperature for 
20 minutes. Next, tissues were washed three times for 3 minutes with PBS and incubated 
with protein block (5% normal horse serum in PBS) for 15 minutes at room temperature. 
Protein block was drained, and tissues were incubated with a 1:50 dilution of rabbit anti- 
AP-2 (Serotec, Raleigh, NC) in protein block overnight at 4°C. Tissues were washed 
with PBS three times for 3 min. Avoiding exposure to light, tissues were incubated with 
a 1:400 dilution of secondary goat anti-rabbit conjugated to Alexa 488 for 2 h at room 
temperature. Tissues were washed with PBS containing 0.1% Brij for 3 minutes two 
times, and once with PBS for 3 minutes. Next, tissues were incubated with a 1:200
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dilution of mouse monoclonal anti-MART-1 (Dako) in protein block overnight at 4°C. 
Tissues were washed with PBS three times for 3 min and then incubated with a 1:400 
dilution of secondary anti-mouse conjugated to phycoerythrin (PE). Tissues were washed 
with PBS three times for 3 minutes and incubated with 1 pg/ml propidium iodide for 10 
minutes at room temperature to counterstain total cell nuclei.
Laser Scanning Cytometry Analysis
Laser Scanning Cytometry (CompuCyte Corporation, Cambridge, MA) combines 
flow cytometry, image analysis, and automated fluorescence microscopy to enable 
fluorescence-based quantitative measurements at the single cell level. The LSC consists 
of an Olympus BX50 fluorescent microscope and a computer controlled optics unit 
coupled to an Argon, HeNe, and Violet laser. Multiple lasers are used to simultaneously 
excite different fluorochromes in cellular specimens that emit discrete wavelengths 
detected by a set o f photomultiplier tubes. Together these features permit the ability to 
generate high-content stoichiometric data on heterogeneous populations of large numbers 
of cells. Thus, the LSC was used very much like a fluorescent activated cell sorter 
(FACS) to obtain three-color immunofluorescence intensity information from the tissue 
microarrays.
We selected each fluorochrome based on the experimental endpoint of the study 
and compatibility with the LSC. Importantly, each probe was independently tested to 
ensure non-overlapping emission between filters. Propidioium iodide was used as a 
nuclear counterstain to contour and quantify single cells within each tissue core. To 
determine subcellular expression of AP-2, the peripheral contouring feature was selected 
to simultaneously analyze the cytoplasmic versus nuclear expression level. Using the
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Wincyte™ software, Argon and HeNe lasers were selected with the appropriate filters to 
detect red (cell nuclei), long-red (MART-1) and green (AP-2) fluorescence. Once the 
scan region was selected using the epifluorescent microscope, slides were scanned using 
a 200x objective and detector gain voltages were set so that a maximum of 50% 
saturation was achieved for the brightest maximum pixel event scanned for each 
fluorochrome. The minimum area threshold was set to optimize contouring of single cell 
nuclei. To determine the percentage of MART-l-positive/AP-2-positive cells, a 
scattergram was created to define four quadrants that determined which cells were 
positive. Each gate of the scattergram was set based on the fluorescent properties of the 
negative control sample stained with each fluorescent probe. Once each slide was 
scanned, the data file was replayed to determine the percentages of each cell population, 
e.g., MART-1-positive/AP-2-positive cells for each tissue core. AP-2-positive cells were 
analyzed separately for nuclear or cytoplasmic expression. The relocation feature was 
used to confirm positive cellular expression.
Immunofluorescent Detection of S100 and AP-2 for AQUA Analysis
The tissue microarray slide was stained as described previously.314,315 In brief, 
the slides were deparaffmized by rinsing with xylene, followed by two changes of 100% 
ethanol and two changes of 95% ethanol. Antigen retrieval was performed in a pressure 
cooker containing 6.5 mmol/L citrate (pH 6.0) and endogenous peroxidase activity was 
blocked with 2.5% hydrogen peroxide in methanol for 30 minutes at room temperature. 
The slide was washed with Tris-buffered saline (TBS), incubated in 0.3% BSA/1X and 
TBS for 30 minutes at room temperature to reduce nonspecific background, and then 
stained with a combination of rabbit anti-AP-2 (Cl 8) (1:1600, Santa Cruz Biotechnology)
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and mouse monoclonal anti-SlOO, AM058 (Biogenex, San Ramon, CA) diluted in 
BSA/TBS at 4°C overnight. The secondary antibodies, Alexa 546-conjugated goat 
antirabbit (1:200, Molecular Probes, Eugene, OR) plus Envision antirabbit (neat; DAKO) 
diluted in BSA/TBS were applied for 1 hour at room temperature. 4', 6-Diamidino-2- 
phenylindole (DAPI) was included with the secondary antibodies to visualize nuclei. The 
slide was washed with BSA/TBS (three times for 5 minutes) and then incubated with 
Cy5-tyramide (Perkin-Elmer Life Science Products, Boston, MA) and activated by 
horseradish peroxidase, resulting in the deposition of numerous covalently associated 
Cy5 dyes immediately adjacent to the horseradish peroxidase-conjugated secondary 
antibody. Cy5 was used because its emission peak (red) is well outside of the green- 
orange spectrum of tissue autofluorescence. The slides were sealed with coverslips with 
an antifade-containing mounting medium (with 0.6% n-propyl gallate).
Automated Image Acquisition and Analysis.
The AQUA automated image acquisition and analysis was performed as described 
previously.314 Briefly, images of the tissue microarray were captured through an 
Olympus BX51 microscope with automated x, y, and z stage movement with an Olympus 
Motorized Reflected Fluorescence System and software (IP lab v3.60, Scanalytics, Inc., 
Fairfax, VA) equipped with Cooke Sensicam QE High Performance camera. Low-power 
images of the microarray were stitched together with multiple low-resolution images of 
the microarray (64 X 64 pixels) at ~7-pm resolution. Areas of tumor were distinguished 
from stroma and non-melanoma tissue by creating a mask with the S I00 signal tagged 
with Alexa 546. Expression of SI 00 protein was used to identify the tumor mask and 4', 
6-diamidino-2-phenylindole (DAPI) was used to identify the nuclear compartment.
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Areas of the tumor mask without DAPI were considered 'nonnuclear' or 'cytoplasmic'. 
The target marker, AP-2, was visualized with Cy5 (red). Rows and columns of the 
histospots were then identified, missing histospots filled in, allowing each histospot to be 
identified by its coordinates, and recorded based on its position in the grid. Subsequently, 
monochromatic, high-resolution (1024 X 1024 pixel, 0.5-pm resolution) images were 
obtained of each histospot, both in the plane of focus, and 8 pm below it, and recorded in 
an image stack as bitmaps. A resolution of 0.5 pm is suitable for distinguishing between 
large subcellular compartments such as the cell membrane/cytoplasm and nuclei. The 
AP-2 signal from the cytoplasmic and nuclear compartment within the S100 tumor mask 
was measured on a scale of 0 to 4095 and expressed as target signal intensity relative to 
the respective cytoplasmic or nuclear compartment area.
Statistical Analysis
The number of MART-1 and AP-2 positive cells was compared between the 
diagnosis groups using a Kruskal-Wallis test or a Wilcoxon rank-sum test, as appropriate. 
The M.D. Anderson Cancer Center tissue microarray was designed to assess markers 
along the progression of normal melanocytic lesions to metastatic melanoma and was not 
designed to be a prognostic array. Therefore, sub-cellular localization of AP-2 
expression from the Yale University tissue microarray was used to determine its 
association with melanoma-specific survival. The association between the consensus 
score and AP-2 expression and clinicopathological parameters was assessed using the 
Chi-square test. The prognostic significance of the clinicopathological parameters was 
assessed for predictive value using the univariate and multivariate Cox proportional 
hazards model with melanoma-specific survival as an end point. Survival curves were
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calculated using the Kaplan-Meier method, with significance evaluated using the Mantel- 
Cox log-rank test. All analyses were performed using JMP or SAS (SAS Institute Inc., 
Cary, NC) at a significance level of 5%.
Results
Immunofluorescent staining of Melanoma Tissue Microarrays.
Previously, it has been reported that the progression of human melanoma is 
associated with the loss of nuclear AP-2 expression in metastatic melanoma.301'303’306,309 
Our results have been confirmed by other studies using tumor specimens. These studies, 
however, were based on standard immunohistochemical analyses of total cellular AP-2 
expression in primary tumors or human melanoma cell lines using semiquantitative 
methods.
To simultaneously measure AP-2 expression in MART-1 or SI 00-positive cells 
by LSC or AQUA, respectively, specific labeling conditions were established for optimal 
data acquisition. For LSC, we selected fluorescent probes that were compatible with the 
laser and filter configuration to minimize non-specific emission and false-positive 
signals. Likewise, probes outside the spectrum of tissue autofluorescence were selected 
for use with the AQUA system Tissue microarrays stained with anti-MART-1 (Figure 
18A) or SI00 (Figure 18B) and anti-AP-2 were visually inspected to verify the quality of 
immunofluorescent antigen detection. A serial section from each tissue microarray was 
stained with hematoxylin and eosin (H&E) to pathologically verify the presence of 
diagnostic lesional cells and facilitate selection of the scan region, excluding unwanted or 
necrotic regions from the analysis. Tissue cores deemed uninterpretable had insufficient 
tumor cells in the spot, loss of tissue, or large areas of necrotic tissue.
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MART-1 AP-2 Overlay
B
Strong Nuclear Expression Strong Cytoplasmic Expression
S100 PROTEIN S100 PROTEIN
F igu re  18. Automated detection of AP-2 in melanocytes. Tissue microarrays were immunofluorescently 
stained for A, MART-1 (red) orS , S100 and AP-2 (green) as described in Materials and Methods. A, A  
representative LSC-generated image of a case from a DN reveals optimization of antigen detection for 
MART-1 and AP-2. Co-localization of MART-1 and AP-2-positive cells appears yellow in the overlay 
image. Original magnification, x200. B, Representative images display tissue cores evaluated by the 
AQUA system for compartment-specific expression of AP-2. S100 protein (visualized under the 546 
wavelength; green) defines the melanoma mask and DAPI (blue) defines the nuclear compartment. The 
compartment-specific AQUA scores were determined within the melanoma nuclear and melanoma non­
nuclear (i.e., cytoplasmic) compartments. Note that the primary melanoma displays strong AP-2 nuclear 
expression (nuclear compartment, 842; cytoplasmic compartment, 270) and the metastatic melanoma core 
reveals strong AP-2 cytoplasmic staining (cytoplasmic compartment, 781; nuclear compartment, 490).
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Automated Analysis of AP-2 Expression in Melanoma.
The M. D. Anderson tissue microarray was designed to assess markers in the 
progression of melanoma and not prognosis. Therefore, LSC- and AQUA-based analyses 
were used to characterize the subcellular expression pattern of AP-2 in each diagnosis 
group. Peripheral contouring capabilities of the LSC permit the simultaneous 
measurement of expression in the cytoplasm and nuclear compartment of each cell nuclei 
(Figure 19A). Because expression of MART-1 has been shown to be a prognostic factor 
for cutaneous melanoma 322, we first used the LSC to measure the number of MART-1- 
positive cells in each diagnostic group (Figure 19B, quadrants 2 and 4). Importantly, 
three-color quantitative analysis demonstrated no significant difference in the number of 
MART-1-positive cells between the benign nevi, dysplastic nevi, primary or metastatic 
melanoma groups (Table 13). We therefore used MART-1 as a melanocytic reference for 
LSC automated analysis of AP-2 in each diagnostic group. After scanning each tissue 
microarray, the nuclear and cytoplasmic levels of AP-2 in MART-1-positive cells were 
determined by selecting each case using LSC-generated coordinate position maps and 
replaying the data file (Figure 19B). LSC-mediated analysis revealed a statistically 
significant decrease (p < 0.0001) in nuclear expression of AP-2 in the benign nevi group 
(11.85%) to a complete loss of AP-2 (0.39%) in the metastatic melanoma group (Figure 
19C). In contrast, cytoplasmic expression of AP-2 significantly increased (p < 0.001) 
with melanoma progression (Figure 19D).
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Figure 19. LSC-based quantitative analysis of subcellular AP-2 expression. A, LSC-mediated peripheral 
contour analysis. A representative LSC-scanned image of a single cell indicates the nuclear contour (red 
outline) and peripheral or cytoplasmic boundaries (two yellow lines). During laser scanning, quantitative 
information is acquired for each compartment (nuclear or cytoplasmic) based on the fluorescent intensity of 
each probe. Original magnification, x400, digital magnification 4X. B, Stained tissue microarrays were 
scanned by LSC and individual cases from each diagnostic group were selected from the tissue map to 
determine the number of MART-1 and AP-2 positive cells (quadrants 2). Representative scattergrams from 
a BN and MMM case reveal that the percentage of MART-1-positive cells (x-axis) and AP-2-positive cells 
(y-axis) decreased 8-fold, from 16% in the BN to 1.9% in the MMM group (quadrant 2 ). Gates were set 
based on the negative staining controls. Note that the number of MART-1-positive cells (quadrants 2 and 
4) was similar between the two groups (approximately 17%). C, Nuclear expression of AP-2 from each 
case were analyzed. A box plot displays the median (middle line) and the minimum and maximum range 
(outside lines) of MART-l/AP-2-positive cells by diagnosis group. D, Cytoplasmic expression of AP-2. 
Levels of AP-2 cytoplasmic expression from each case were analyzed using a Kruskal-Wallis test as 
described in Materials and Methods. A box plot displays the median (middle line) and the minimum and 
maximum range (outside lines) of MART-l/AP-2-positive cells by diagnosis group. Note that the median 
levels of AP-2 slightly increased with progression of melanoma.
Table 13. Characteristics of Tissue Cores Analyzed using LSC.
Group n No. of Cells Analyzed per Core No. of MART-1 Cells3
Benign Nevi 18 287 ± 402 18% ±3.53
Dysplastic Nevi 21 265± 196 17% ±2.82
Melanoma 20 1450± 1082 14% ±7.77
Metastatic Melanoma 27 420 ±315 16% ±2.82
aNo significant difference between groups
A different section of the same TMA was analyzed by AQUA, in which S100 was 
used to detect the cells of melanocytic origin and DAPI was used to define the nuclear 
compartment. The melanoma-specific cytoplasmic compartment was defined by 
subtracting the DAPI image from the S I00 image (after appropriate gating). Although 
overall expression of AP-2 tended to increase in the progression from benign nevi to 
malignant melanoma (Figure 20A & B), there were significant differences in the ratio of 
cytoplasmic to nuclear expression relative to lesion progression. Advanced lesions
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demonstrated significantly more cytoplasmic over nuclear AP2 relative to benign nevi 
(Figure 20C and Table 14).
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Figure 20. Box plots demonstrating the AQUA 
scores for compartment-specific (A, nuclear; B, 
cytoplasmic) expression of AP-2 measured on the 
progression TMA, as well as, C, the ratio of 
cytoplasmic/nuclear expression of AP-2.
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Table 14. Subcellular Expression of AP-2 by Tissue Type
Group n Nucleus Cytoplasm Ratio
Mean (SE) P ' P : Mean (SE) p. p ’ Mean (SE) P
B enign rsevi 
Oysplahiiie nevi 
M elan o m a
M eia sla lic  ra d a m im a
15 942,39(4144} 0.1531 642.08 (38228) 0.0007 0.68 ( 0.03) <0.01X11
13 1,032.23 ( 60.28) 0 3 6 1 5
16 1,185.06 (76.08) 0.1550
23 3.041,62 (76,87 ) 0.2055
717.22 (50.95) 0.2-119
912.77 (42.091 0.0059
945.48 (69,80) 0.7213
0.70 (0.02) 0.6772
0.80 (0.04) O.Ot 14
0.91 (0.03) 0.017)
' /  test c-om piired w ith  g ro u p  above. 
*ANOVA.
Survival Analysis and Clinicopathological Correlations.
The decrease in nuclear AP2 and increase in cytoplasmic AP2 with progression 
suggested that the differential expression pattern may be useful as a prognostic marker in 
melanoma. To assess this, we analyzed a cohort of nearly 600 cases of melanoma collected 
retrospectively at Yale University Department of Pathology. In order to assess this large 
cohort, a second fluorescence-based system of automated analysis was used. After image 
acquisition for each tissue core, AQUA was performed to establish the intensity of AP-2 
expression per unit area within each core. Consistent with our LSC-generated results, strong 
nuclear AP-2 expression was noticeable in the primary melanoma cores whereas the 
metastatic cores displayed diffuse cytoplasmic staining (Figure 18B). Therefore, the 
cytoplasmic and nuclear AP-2 expression levels generated from the Yale University tissue 
microarray were used to determine their potential association with melanoma-specific 
survival. Statistical analysis of total AP-2 expression revealed no significant association with 
survival (data not shown). Hazard ratios determined by Cox univarate analysis of the AQUA 
scores for cytoplasmic and nuclear AP-2 expression were 1.000 (95% Cl: 1.000-1.001, 
p=0.4846) and 1.000 (95% Cl: 0.999-1.000, p=0.2969), respectively. When analyses were 
restricted to primary melanoma specimens, the HR’s remained non-significant. In contrast,
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analysis of the subcellular levels of AP-2 (ratio of cytoplasmic to nuclear expression) 
revealed a significant association with metastases (p < 0.01) and survival [HR: 2.795 (95% 
Cl: 1.609-4.857, p=0.0003), Figure 21A and Table 15]. In the primary specimens, the AP-2 
ratio maintained prediction of poor survival [Relative Risk 4.337 (95% Cl: 1.294-14.536, p = 
0.0174), Figure 21B and Table 15]. Analysis of other clinicopathological factors revealed 
that the AP-2 ratio correlated with Breslow depth (R=0.334, p < 0.001, not shown), and was 
associated with microscopic satellitosis (p = 0.0373, not shown). Continuous AQUA scores 
were then divided into quartiles, based on the size of the cohort, reflecting the use of routine 
statistical divisions in the absence of an underlying justification for division of expression 
levels. Kaplan Meier analysis of the cohort is shown in figure 3. Using the ratio of 
cytoplasmic over nuclear AP-2 shows that the ratio is highly predictive of outcome, in both 
the total cohort (Figure 21A) and the subset of only primary lesions (Figure 21B). Log rank 
values for each are highly statistically significant (p<0.0001 and p=0.0094, respectively).
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Figure 21. Melanoma tissue microarray analysis of subcellular AP-2 expression using AQUA. Kaplan-Meier 
survival curves were generated for AP-2 compartmental expression for the A, overall cohort and B, primary 
melanoma, with time given in months, showing the four quartiles of intensities of cytoplasmic to nuclear 
expression.
Table 15. Cox Univariate Survival Analysis o f Continuous Variables.
All Specimens P Primary
Compartmentalized AQUA Score (HR (95% Cl)) value Specimens p value
1.000 0.4846 1.000 0.7540AP2 in Cytoplasm (1.000-1.001) (0.999-1.001)
1.000 0.2969 1.000 0.4927A.P2 in Nucleus (0.999-1.000) (0.999-1.001)
AP2 Ratio (Cytoplasmic 2.795 0.0003 4.337 0.0174
AP2/Nuclear AP2) (1.609-4.857) (1.294-14.536)
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To assess the independent predictive value of the AP-2 ratio, we performed a 
multivariate analysis on the primary cutaneous lesions. In addition to the AP-2 ratio, we 
included the following histopathologic variables in a Cox proportional hazards model: 
Breslow depth, Clark level, ulceration, microscopic satellites, tumor-infiltrating lymphocytes. 
The model (Table 16) demonstrates that the AP-2 ratio maintains prognostic significance 
(p=0.0082) after adjustment for the standard prognostic factors.
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Table 16. Multivariate Suvival Analysis of AP2 Expression Pattern and Standard
Histopathological Variables Among Primary Lesions
Variable Hazard Ratio (95% Cl) p value
Tumor Infiltrating Lymphocytes 
(Absent vs. Present) 3.44(1.52-7.76) 0.003
Breslow Depth 
(>2.00 mm vs. <2.00 mm) 2.18(1.11-4.25) 0.0229
Clark Level 
(IV-V vs. I-III) 1.57 (0.79-3.13) 0.2022
Ulceration 
(Present vs. Absent) 1.29 (0.77-2.17) 0.3267
Microscopic Satellites 
(Present vs. Absent) 0.96 (0.55-1.70) 0.9003
Cytoplasmic by Nuclear AP2 Ratio 
(Top 25% vs. Bottom 75%) 2.14(1.22-3.76) 0.0082
Discussion
Our goal in this study was to quantitatively assess the subcellular expression of AP-2 
on a large cohort of melanoma specimens. Using two independent, automated quantitative 
systems to evaluate localization of AP-2 expression in two independent tissue microarrays 
from two separate institutions, we reached the same conclusion. Specifically, we 
demonstrate for the first time that the ratio of AP-2 cytoplasmic to nuclear expression pattern 
correlates with both progression of melanocytic lesions and survival.
Because AP-2 is a transcription factor, we hypothesized that AP-2 should be active in 
the nucleus, while cytoplasmic expression should be associated with loss of function. 
Analysis of the cohort from The University of Texas M. D. Anderson Cancer Center using 
LSC revealed almost a complete loss of AP-2 nuclear expression in the metastatic melanoma 
group. Our results are consistent with other studies demonstrating that AP-2 is lost in 
metastatic melanoma.306,309 However, most of these studies were based on categorical 
scoring of total cellular expression and were not able to distinguish subtle expression patterns 
between cellular compartments. Application of the LSC and AQUA automated quantitative
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analysis revealed that the ratio between cytoplasmic to nuclear AP-2 expression changes with 
melanoma progression. Together, these data strongly suggest that translocation of AP-2 from 
the cytoplasm to the nucleus is disrupted during melanoma progression by an unknown 
mechanism. Our findings suggest that changes in subcellular AP-2 expression in 
melanocytes, particularly from benign nevi to dysplastic nevi (2-fold decrease), is a critical 
step in the genesis and progression of melanoma. Automated analysis of subcellular AP-2 
expression in melanocytes may serve as a sensitive marker to monitor the progression of 
melanoma. It seems therefore, that the major deficiency in AP-2 activity in metastatic 
melanoma is the loss of nuclear translocation. We hypothesize that this deficiency may be 
due to changes in the nuclear translocation signal within the AP-2 protein itself or 
modifications in other chaperone or ‘cargo’ proteins. The precise mechanism is being 
investigated in the laboratory of our collaborator, Menashe Bar-Eli.
Both the LSC and AQUA systems offer advantages for quantitative analyses of tissue 
microarrays that are not practical using conventional methods. LSC-based quantification lies 
in its analytical power: tens of thousands of cells can be analyzed in a consistent manner 
between each tissue section, as opposed to hundreds of cells typically evaluated using 
conventional immunohistochemistry. Here, we demonstrate the peripheral contouring 
feature of the LSC which allows for accurate quantification of cytoplasmic and nuclear 
protein expression. In addition, the laser platform has the ability to simultaneously quantify 
up to five fluorescent probes and determination of positive and negative is accomplished 
objectively by gating against staining controls.323 Together, these features permit 
investigators to evaluate levels of a protein in specific cell types, e.g., AP-2 in MART-1 or 
S100-positive cells, in a manner that is more reproducible between tissue cores and generates
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consistent results in the hands of different investigators. The PM-1000 device and 
subsequent AQUA analysis is similarly quantitative. AQUA based quantitative analysis of 
AP-2 expression results in continuous scores that are directly proportional to the 
concentration, rather than subjective pathologist-based divisions of staining into categorical 
scores (0-3) or ‘positive’ and ‘negative’. Both automated systems are excellent for analysis 
of subcellular localization, but the PM-1000 does not require laser illumination and has a 
much higher throughput which makes it ideal for analysis of large tissue microarrays as the 
one in this study. Thus, the ability to quantify subcellular localization of markers using 
automated, quantitative-based systems may be crucial in assessing their potential as 
prognostic indicators when analyzing tissue microarrays.
To further confirm whether the changes in AP-2 subcellular expression had any 
potential prognostic benefit, we used the AQUA system to analyze a separate tissue 
microarray containing a much larger cohort of melanoma specimens from Yale University. 
Statistical analyses of nuclear or cytoplasmic AP-2 expression levels alone were not 
significantly associated with survival, suggesting that there may be case to case variability 
that obscures the overall analysis. Intriguingly, the ratio of cytoplasmic to nuclear AP-2 
expression levels correlated with survival, with high levels in the cytoplasm predicting an 
unfavorable outcome. These results illustrate the power of the ratio. Case to case variability, 
either real or artifact, is internally normalized by calculation of a ratio.
Heterogeneity is often an issue that is difficult to assess, but is generally addressed by 
repetition of the analysis with a second set of tissue cores (second fold redundancy). Indeed, 
these results were reproducible using a second melanoma tissue array containing different 
cores from the same patients suggesting that the levels of AP-2 are homogenously expressed
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throughout the tumor. Furthermore, the subcellular expression patterns of AP-2 obtained 
using AQUA were further confirmed by their consistency using LSC to analyze a separate 
cohort.
This study demonstrates two powerful methods for automated, quantitative profiling 
of tissue microarrays. The automated nature of LSC and AQUA-based technology should 
facilitate high-throughput molecular profiling of tissue microarrays for use in a variety of 
applications such as target discovery and prognostic and diagnostic biomarker validation. 
When compared with conventional immunohistochemistry, these methods demonstrate the 
importance of quantifying expression based on fluorescence and subcellular localization.
The ratio-based data would not be achievable using traditional DAB-based staining methods. 
Thus, the LSC and AQUA systems provide a useful tool for quantitative analysis of 
compartmental protein expression in a reproducible fashion, free of the subjectivity 
associated with pathologist-based scoring.
In summary, the data presented here add further support that the loss (or cytoplasmic 
translocation) of nuclear AP-2 is a crucial event in the progression of melanoma. Two 
quantitative methods, AQUA and LSC, were used successfully to demonstrate the 
importance of quantifying compartmental AP-2 expression and provide evidence that the loss 
of nuclear AP-2 correlates with progression in melanocytic lesions and also, when calculated 
as a ratio, predicts survival.
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Chapter 5: Improvement of Outcome Prediction in Primary Cutaneous Melanoma by 
Multiplexed Quantitative (AQUA™) Analysis of Tissue Biomarkers
Abstract
OBJECTIVE: Breslow depth is currently the most reliable predictor of metastatic potential 
and clinical outcome in primary cutaneous melanoma. We hypothesize that multiplexed 
analysis of in situ protein expression in melanoma could augment the prognostic value of 
Breslow depth.
METHODS: A 521-case tissue microarray, including 214 primary melanomas, 293 
metastases, and a series of controls was constructed with complete clinical annotation. 
Candidate biomarkers were selected from previous studies evaluating prognostic potential of 
markers, gene expression profiling studies (cDNA, oligonucleotide, etc.), and functional 
studies on individual genes and gene products. The AQUA™ (Automated Quantitative 
Analysis) technology was used to determine exact expression levels of protein biomarkers 
within nuclear, non-nuclear (i.e., cytoplasmic) and total melanocytic compartments. Several 
statistical methods were then used to build statistical models that improve, or exceed, the 
prognostic value of current methods. Briefly, Cox univariate analysis was used to select 
those markers most closely associated with melanoma-specific survival. Hierarchical 
clustering, multivariate regression models and genetic algorithms (GA) were then used to 
determine the optimal number of biomarkers and the optimal cut-points for each marker. 
Patients were classified by Breslow depth and GA score. Association with melanoma- 
specific death over 20 years was ultimately measured by Kaplan-Meier analysis.
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RESULTS: Thirteen of the 66 variables (derived from 48 independent protein assays) 
analyzed were significantly (p<0.1) associated with outcome (N-cadherin, E-cadherin, p i20, 
Beta-catenin, CD44, Tenascin C, p21, PCNA, Fibronectin, MDM2, ATF2, pl6, AP2). GA 
software was run to convergence (>20X106 generations) multiple times and the runs 
repeatedly resulted in the same five-marker solution: ATF2_ratio of cytoplasm by nuclear; 
nuclear p21; pl6_ratio of cytoplasm by nuclear; Beta catenin; and Fibronectin. In this 
training cohort, limited to 129 primary tumors for which all data points were available, 
Kaplan-Meier analyses show patients with Breslow depth <1.00 mm have a 78.1% 10-year 
survival compared to patients with depth >1.00 mm with a 45.4% 10-year survival(p<0.001). 
Addition of the GA information further stratifies the patients. Patients with Breslow depth 
<1.00 mm are split into “low-risk” (86.4% survival) and “high-risk” groups (60% survival) 
while those with Breslow >1.00 mm split into “low-risk” (80.5%) and “high-risk” (19.6%) 
(pO.0001).
CONCLUSION: These training set data suggest that it is possible to improve upon the best 
prognostic index in primary melanoma (i.e., Breslow depth) by using multiplexed in situ 
measurement of protein expression. We are in the process of validating our results on an 
independent cohort of patients with known sentinel lymph node outcomes to determine if this 
Breslow+GA assay is more accurate than sentinel node biopsy in the prediction of melanoma 
recurrence.
126
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Introduction
Melanoma is the sixth most common cancer in the United States, and its yearly 
incidence is rising faster than that of any other cancer, with 47,700 new cases and 7,300 
deaths in the year 2000; these numbers are estimated at 53,600 and 7,400 for the current 
year.2 Initial management of the primary lesion is by surgery. The surgical treatment of 
melanoma can range from a marginal biopsy to wide local excision with regional 
lymphadenectomy, and advance in some cases to include extraction of distant metastases.
It has been suggested that metastatic melanoma will become a treatable disease in the
148coming years as specific inhibitors are being developed against most major targets.
Whether this does, in fact, occur remains to be seen. What is clear is that genome-wide 
screening approaches at the DNA, RNA and protein levels are yielding an increasing number 
of biomarker candidates that may serve as diagnostic, prognostic, selection of treatment and 
treatment follow-up markers.
Much success has been demonstrated in the genomic assessment of melanoma, with 
the majority of studies evaluating global mRNA expression. This has created a bottleneck in 
biomarker development. Hundreds to thousands of potential biomarkers can be discovered 
through genomic profiling studies. However, the verification and validation of initial 
selections from these screening studies requires demonstration on human tissue specimens. 
The use of tissue microarrays provides the next step in biomarker assessment and evaluation.
While the morphological biology of melanoma progression is well described, the 
genetic changes that take place as lesions invade deeper and ultimately become metastatic are 
not well understood. Work is under way in a number of laboratories to reveal these changes
127
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and use them for their prognostic potential (to help predict aggressive potential) and 
ultimately develop therapies that target these changes.
A number of studies have been published, indicating the prognostic potential of 
various immunohistochemical markers in melanoma. Although some of the studies have 
already demonstrated that the levels of melanoma-associated proteins can serve as markers to 
predict disease outcome, there are a multitude of genes and gene products with prognostic 
potential in patients with localized melanoma. The expression of thousands of genes in 
melanoma tumors and cell lines can be surveyed using cDNA microarrays. It has been 
proposed for various cancers that a discrete and previously unrecognizable cancer taxonomy 
can be identified by assessing the systemized data acquired from gene expression 
experiments.15 Most gene expression studies reported thus far have been based on cell lines, 
which may not be entirely representative of in vivo tumor biology. The data acquired must 
be validated on in vivo models and patient samples.
Melanoma is truly an unpredictable cancer. It is not clear what genetic changes take 
place in melanoma progression. As this cancer remains refractory to virtually every 
pharmacologic treatment, and has an incredible potential for aggressive growth, it is not 
surprising that many melanoma patients submit themselves to toxic and experimental 
therapies.116 The products from cDNA microarray analyses not only provide validation of 
previously identified biomarkers, but also offer new genes that might be useful in molecular 
diagnosis, pathogenesis studies, and possible molecular targets for therapeutic interventions.
Prognosis in melanoma is currently determined by a number of factors unique to the 
primary lesion, as well as the presence of loco-regional (lymph node and in-transit 
metastases) and distant metastatic disease. This information is distilled into the recently
128
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
revised Melanoma Staging System of the American Joint Committee on Cancer (AJCC).
The first published reports of variables to predict survival in primary melanoma came with 
publications from A Breslow ’ and WH Clark in the 1970s. The models they described 
have changed little and remain the most powerful and reliable predictors of survival based on 
characteristics of the primary cutaneous lesion. In addition to Breslow depth and Clark level, 
a number of other histopathological characteristics in melanoma have been observed to 
correlate with disease outcome. The strongest histological predictors of outcome are: tumor 
thickness (Breslow), anatomic depth of invasion (Clark)324, presence of ulceration35’41'46, 
mitotic rate47, presence of microscopic satellites (discrete nests of tumor cells separated from 
the main body of the tumor by normal subcutaneous tissue). Less powerful histopathological 
factors include: histologic subtype (i.e., superficial spreading, nodular, lentigo maligna, acral 
lentiginous, desmoplastic; acral and nodular melanomas may be more aggressive than other 
types4), angiogenesis48, vascular invasion, regression, and tumor infiltrating lymphocytes. Of 
all clinical and pathological criteria, the majority of studies demonstrate that tumor thickness
98 tc iq
(Breslow) is the most reliable independent prognostic factor in cutaneous melanoma. ’ ’ ’
4 0 ,4 2 ,4 3 ,4 9 -5 4
In spite of the fact that these parameters represent the standard of care and the pillars 
of the AJCC staging system, these histopathologic characteristics of the primary tumor may 
not necessarily be indicative of tumor aggressiveness. There are a surprisingly large number 
of cases of melanoma in which tumor thickness does not predict outcome; cases in which 
thin melanoma turns out to be aggressive36,38,44,54-76 or thick melanoma indolent77'80. 
Significant efforts over the past 30 years have sought to discover molecular markers that 
could be used, but no marker has replaced or even matched the physical descriptors above.
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Initially, markers were accrued and tested in a somewhat random fashion, based on success 
in other tumors or a defined role in tumorgenesis in a model system. A long list of these 
markers can be found in the literature and are reviewed by Li et al.250 We have contributed 
to this list282,325"327, yet none have been broadly adopted, most likely due to the lack of 
standardization of these prognostic markers, or more significantly, the lack of a multi-center 
prospective clinical trial for molecular prognostic indicators.
Perhaps the most significant recent change in the management of melanoma is 
sentinel lymph node biopsy. This is a procedure initially developed in the treatment of penile 
cancer where a dye, and/or radiotracer, is injected into the tumor to identify the primary 
nodal drainage of a particular region, and then the identified nodes are removed for histologic 
analysis. This can determine if a patient has metastatic disease—regional or distant—and 
result in more accurate (or at least less morbid) initial staging and management. If the 
sentinel lymph node is negative for disease, it can be assumed that the rest of the regional 
nodes are also negative, and the patient will be spared an “unnecessary”, invasive and 
debilitating procedure. The decision to perform a sentinel lymph node biopsy (in the absence 
of clinically apparent LN disease) is typically based upon the Breslow depth of the primary 
lesion. Generally, the threshold for performing a sentinel lymph node biopsy is a primary 
lesion around 1 mm thick , but the procedure is becoming the standard of care for patients 
with primary melanoma greater than 1 mm in thickness86 or less328. Although this method is 
considered an accurate mechanism for predicting the pathologic status of regional lymph
83nodes, as well as in the prediction of patient outcome , it is far from faultless. However, it is 
now an essential component of the AJCC TNM classification of melanoma.
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Sentinel node biopsies, while valuable, are not perfect. The false negative rate for the 
procedure is around 5-10%, but more significantly, nearly 25% of patients may be ultimately 
upstaged, especially if molecular tests are used.329 Perhaps more importantly, as many as 
90% of the sentinel nodes are negative, suggesting the test was unnecessary. Thus, 
management of melanoma could be improved if there were a method to determine metastasis 
without removing the nodes and without false negative tests.
Many groups have described promising single biomarkers for melanoma. While 
these biomarkers may have value, none have successfully transitioned to standard practice in 
melanoma management. There may be many reasons for this, including the subjective nature 
of assessment of these markers, the non-reproducibility of these assays, and the fact that 
assessment of a single marker has limited potential to describe specific biological disease 
classifications. Even with the addition of quantitative information, it is not clear that a single 
marker is the optimal way to define outcome classes.
Multiplexing of markers and definition of disease classifications has been a strength 
of the cDNA array technologies. The work of the Botstein and Brown group330 and the
234 •group from the Netherlands Cancer Institute in breast cancer or the Trent group m 
melanoma15 has provided a model for this paradigm. In each case (and many others not 
referenced), a series of cDNA markers is used with a hierarchical clustering algorithm to 
produce a relatively small group of disease classifications that show significant differences in 
the disease outcomes. The classes are generally defined by groups of 70-200 or more 
markers. While these (and many other studies) show the power of multiplexing for 
classification, they also illustrate the weaknesses. Perhaps the most significant weakness is 
the difficulty of translating this technology to clinically useful tests. Not only is RNA
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difficult to obtain for routine clinical testing, but the genes discovered by each group show 
relatively little overlap, suggesting that RNA may not be the most appropriate platform for 
multiplexing. Some efforts have been made to do multiplex analysis of protein expression,
269using tissue microarrays. However, the non-quantitative and discontinuous nature of the 
scoring systems has resulted in results that are likely to lack reproducibility, and tend to be 
the subject to the same criticisms leveled at conventional immunohistochemistry. Use of a 
quantitative approach to tissue microarray analysis has the potential to solve this problem. In 
the present study, we assess numerous protein biomarkers on our large-cohort malignant 
melanoma tissue microarrays using our automated quantitative analysis (AQUA) system. 
After establishing biomarkers that are most closely associated with aggressive disease, we 
develop a prognostic model to predict patient outcome.
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Materials and Methods
Tissue Microarray Construction and Cohort Descriptions.
Tissue microarrays were constructed as previously described, with 0.6mm diameter 
cores spaced 0.8mm apart. Representative tumor regions were selected for coring and 
placement in the tissue microarray using a Tissue Microarrayer (Beecher Instruments, Silver 
Spring, MD). The tissue microarrys were then cut to 5 pm sections and placed onto slides 
using an adhesive tape-transfer system (Instrumedics, Inc., Hackensack, NJ) and UV 
crosslinking.
In collaboration with our laboratory, the Yale Cancer Center TMA Facility has 
constructed two melanoma tissue microarrays that were used for this study. Each of these is 
accompanied by a wealth of clinical and pathological data. Long-term follow-up data, 
including recurrence and survival, as well as cause of death, is available for the majority of 
the cases. These data have been acquired from YNHH medical records, the Yale University 
Department of Pathology, and the Connecticut Tumor Registry.
The first array (Melanoma Discovery TMA; YTMA 20 / 59) contains 553 melanoma 
specimens (with redundancy for some specimens), and 17 normal skin biopsies collected 
between 1959 and 1994, as well as nevi, melanoma cell line, and normal melanocyte 
controls. Regarding patient representation, there are 214 primary melanomas and 293 
metastases. Median and mean age at the time of diagnosis were 56 and 55 years, 
respectively. The median follow-up time is 19 years. The value of this array lies in the 
exceptionally large cohort size and the availability of long-term survival data. When 
analyzed for outcome, the specimens collected on this tissue microarray are representative of
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the overall melanoma population in the U.S., conforming to expected results based on current 
staging criteria (refer to Figure 16).
The second cohort {Melanoma Validation TMA; YTMA 76) contains 270 primary 
melanoma specimens with known SLN status, as well as 50 controls from YTMA 20/59, 
including 21 primary specimens, 38 metastatic specimens, 14 cell line controls. All of these 
patients underwent sentinel lymph node biopsy performed by the same surgeon (Dr. Stephan 
Ariyan). As most of these specimens were collected rather recently, the median follow-up 
time on the second cohort is approximately 12 months, with the last follow-up for many of 
the patients being the SLN post-operative visit. However, follow-up data collection on these 
patients occurs continuously and is a work-in-progress.
Biomarker Selection.
Through gene expression profiling studies, we117, and others15’116,120_123’125,146>331>3325 
have sought to identify molecular changes that take place in melanoma progression. Specific 
details of these studies can be found in Chapter 1. Table 17 displays the initial list of 
potential protein biomarkers for assessment of aggressive/metastatic potential in melanoma. 
Many of these markers were selected based on the potential they demonstrate in functional 
(cell biological) or small pre-clinical studies in melanoma. Others were selected from gene 
expression studies, and they were selected based on the significance of differential 
expression, as well as intersection on multiple studies with different experimental designs.
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Table 17. INITIAL LIST OF MELANOMA BIOMARKERS
Selected by gene expression profiling, immunohistochemistry, and/or cell biology
Adhesion Molecules
ALCAM (activa ted  
leukocy te 
ad h es io n  
m o lecu le)/C D 166 
CD 44 
Cyr61 
E -cadherin  
(CDH1)
Fasc in  (FSC N ) 
F ibronectin  (FN1) 
Flyaluronan
1 CAM 
ICAM2 
ILK
Integrins
02)31 
(CD49B) 
a4pi 
(CD49D) a6pi 
avpi 
(CD29) avp3 
(CD61) avp6 
L1 (CD 171) 
LECTINS
HPA
LPHA
Muc1
M uc18 (MCAM)
N -cadherin
(CDH2)
P -cadherin  
(CDH3) 
Skeletroph in  
sy n d e c a n  4 
T e n a sc in  C 
T hrom bospond in  
1
T hrom bospond in
2
VCAM1
V E -cadherin
(CDH5)
V ersican  
a-ca ten in  
3 -ca ten in  
y-caten in  
Apoptosis-related Factors 
ACS/TM S1 
APAF-1 
Bad 
Bax 
Bcl-X 
Bcl-2 
Bid 
DR4 
DR5
FAS (CD 95)
FA S-ligand
(CD95L)
FLIP
Survivin
TRAIL
bHLH
HEY1
Tw ist
Growth Factors/Receptors
CTG F
EG F
E G FR
E ndothelin  recep to r B 
EphA 2 (Ephrin 
R e cep to r  A2)
Ephrin A1 
FG F2 (basic)
FGFR-1 (Fig)
IG FBP3 
IG FBP5 
IG FB P6 
IG FBP7 
KDR (VEGFR) 
Immunoregulatory  
CD 20
C D 26 (D PP4, A D C P2) 
C D 40 (TN FR SF5, B 
cell recep tor)
CD 59 
CXCR4 
HLA C la s s  I 
HLA C la s s  II 
Melanoma-associated  
CD 63 
MAGE-A1 
MAGE-A3 
MART-1 
MiTF
Motility
T ropom yosin  1 (alpha) 
R hoC  
Neural/Neural Crest
Myelin b as ic  protein
GalNAc-T
G FA P
Growth a s so c ia te d  
protein  43 
Pax3
P h o sp h o g ly ce ra te  
m u ta se  1 (brain) 
sy n u d e in , a lp h a
Other
A polipoprotein C-ll 
A polipoprotein D 
H IF1a
Flydroxyacyl-CoA 
D eh y d ro g en ase ; FIADFI 
M etallothionein 
MTAP
(m ethy lth ioadenosin
p h o sp h o ry la se )
Na/K A T P a se , b e ta  1 
O s te o n ec tin  (SPA R C )
PFKL
pirin
Tropom odulin  
D esm oglein  2 
h-CD/CNh1 
F5AB2 
R hoC  
UCHL1 
Proliferation Molecules
AXL re c e p to r  tyrosine
k in ase
CDK2
c-kit
C yd in  D1
GADD
Ki67/MIB-1
p16IN K 4a
P21W AF1
p27kip1
PCNA
SKI
W NT5A 
Proteases/-related Factors
C a th e p sin  B 
C a th e p sin  D 
C a th e p sin  L 
EMMPRIN
FA P (fibroblast activation 
protein)
MMP1 (CLG, fibroblast 
c o lla g e n a se )
MM P13
MMP2 (Type IV 
c o lla g e n a se )
MMP3
MMP9
MT1-MMP (M M P14)
PA  sy s te m  (uPA, tPA, PAI's) 
PAI-1 
PAI-2 
TIMP1 
TIM P2 
TIM P3 
tPA  
uPA  
uPA R  
Regulatory Molecules
A nnexin I (Lipocortin 1)
A nnexin II (Lipocortin 2)
HDM2
M elastatin
MIA
P 5 3
Rb
Signaling
Akt/PKB 
PTEN  
Transcription Factors
A P-2
ATF-1
ATF-2
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When possible, antibodies to the targets listed above were selected based on their 
publication record, or other data supporting their specificity and accuracy in 
immunohistochemisty. In some cases, however, we needed to engage our own antibody 
validation techniques; typically involving various methods (e.g., Western blots, IHC, 
peptide competition assays on positive- and negative- control cell lines). Table 18 
demonstrates target molecules that have been successfully evaluated on our melanoma 
cohort, including clone and species information, as well as source and dilution 
information.
Immunohistochemistry.
Tissue microarray slides were deparaffinized in xylene, followed by rehydration 
through a graded ethanol series and washed with tris-buffered saline (TBS). The slides 
then underwent antigen retrieval, which involved 15-minute heat treatment in a pressure 
cooker containing 6.5 mmol/L citrate, pH 6.0 (except in the cases of ATF2 and HDM2, 
which were boiled in a pressure cooker containing 1 mM EDTA, pH 7.5). Endogenous 
peroxidase activity was blocked with 2.5% hydrogen peroxide in methanol for 30 
minutes at room temperature. After washing with TBS, the slides were incubated at room 
temperature for 30 minutes in 0.3% bovine serum albumin in TBS to reduce non-specific 
background staining.
Immunohistochemical staining was performed on these slides using 50 different 
antibodies (source and concentration listed in Table 18). Antibodies used in this study 
were selected for their potential—or previously reported—role in the prediction of 
melanoma outcome, and/or for their role in key aspects of cell cycle, apoptosis, signal 
transduction, and melanoma differentiation. Prior to staining these antibodies on the
136
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Discovery Melanoma TMA, each antibody was subjected to a series of dilution titrations 
on test TMAs to determine the optimal antibody concentration for detecting differences 
in expression levels. Depending on the species of the antibody, a cocktail was created 
with an anti-SlOO protein antibody of a different species; rabbit polyclonal anti-SlOO 
(1:6,000, DAKO Corporation, Carpinteria, CA) in the case of mouse antibodies or mouse 
monoclonal anti-SlOO, AM058 (Biogenex, San Ramon, CA) in the case of rabbit (or 
other nonmouse species). In all cases, the slides were incubated overnight at 4°C in a 
humidity chamber.
Secondary antibodies, an Alexa 546-conjugated goat antibody directed against the 
anti-SlOO antibody (anti-mouse or anti-rabbit) (1:200, Molecular Probes, Eugene, OR) 
diluted in Envision—an HRP tagged polymer—directed against the ‘target’ antibody 
(neat; DAKO) were applied for 1 hour at room temperature. 4', 6-Diamidino-2- 
phenylindole (DAPI) was included with the secondary antibodies to visualize nuclei. 
Slides were then washed with BSA/TBS (three times for 5 minutes) and then incubated 
with Cy5-tyramide (Perkin-Elmer Life Science Products, Boston, MA) and activated by 
horseradish peroxidase, resulting in the deposition of numerous covalently associated 
Cy5 dyes immediately adjacent to the horseradish peroxidase-conjugated secondary 
antibody. Cy5 was used because its emission peak (red) is well outside of the green- 
orange spectrum of tissue autofluorescence. The slides were sealed with coverslips with 
an antifade-containing mounting medium (with 0.6% n-propyl gallate). Negative 
controls were obtained by omitting the primary antibody.
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Table 18. Antibodies Examined in the Study, indicating Source, Clone, and Dilution
Protein Clone (Cat No.)
Host
Species Source Dilution
FN1 (F ibronectin) a b 2 9 9 R abbit A beam 1 700
SPA R C /O N  (O steo n ec tin ) AON-5031 M ouse H aem ato log icT ech n o lo g ies 1 8000
MMP1 (Matrix m eta llo p ro te in a se  1) IM35L M ouse C alb iochem 1 550
MMP3 (Matrix m e ta llo p ro te in a se  3) A B810 R abbit C hem icon 1 3000
TIM P3 (T issu e  inhibitor o f MMP3) 136-13H 4 M ouse O n c o g e n e  R e se a rc h  P roduc ts
1 10
TIM P2 (T issue  Ihibitor o f MMP2) 3A4 (18-7351) M ouse Z ym ed 1 75
MT (M etallothionein) M 0639 M ouse DAKO 1 400
FSCN  (Fascin) 55K-2 (M 3567) M ouse DAKO 1 250
ANXA1 (Annexin A1) 29  (610066) M ouse T ran sd u c tio n  Labs 1 1000
CDH1 (E -cadherin ) 32  (610182) M ouse T ran sd u c tio n  Labs 1 400
CDH 2 (N -cadherin) 3B 9 (18-0224) M ouse Z ym ed 1 150
CDH 3 (P -cadhe rin ) 56  (610228) M ouse T ran sd u c tio n  Labs 1 250
L1CAM (L1 neura l cell ad h e s io n  m olecu le) L1-11A M ouse Gift of P au l A ltevogt S u p e rn a t
CTNNA1 (a-ca ten in ) aC A T-7A 4 (18-0225) M ouse Z ym ed 1 150
CTNNB1 (P-C atenin) 14 (610154) M ouse T ran sd u c tio n  Labs 1 2500
CTNND1 (p120-ca ten in ) 98  (610133) M ouse T ran sd u c tio n  Labs 1 400
C D 44 (H yaluronic ac id  recep to r) 2C 5 M ouse R&D S y s te m s 1 200
C D 61/ITG B 3 (integrin, b e ta  3) SZ21 (0540) M ouse B eckm an 1 50
ILK (Integrin-linked k in ase) K A P-ST203 R abb it S tre s sg e n 1 300
APAF1 (apop to tic  p ro te a se  activating  factor) H-324 (S C 8339) R abb it S a n ta  C ruz 1 100
Bad (B cl-asso c ia ted  d e a th  prom oter) 4 8  (610391) M ouse T ran sd u c tio n  Labs 1 250
B d -2  (B-cell CLL/lym phom a 2) 124 (M 0887) M ouse DAKO 1 30
Bcl-X (BCL2-like 1) Poly (610211) R abb it T ran sd u c tio n  Labs 1 1600
Bid (BH3 interacting  dom ain  d e a th  ag o n is t) R abb it Gift from  Gil Mor 1 100
clA P (inhibitor of a p o p to s is ) A-13 (S C 12410) G o at S a n ta  C ruz 1 600
XIAP (X-linked inhibitor of a p o p to s is ) M ouse Gift from  Gil Mor 1 100
DR4/TRAILR1 (D eath  re c e p to r  4) 69036  (MAB347) M ouse R&D S y s te m s 1 80
D R 5/TR A ILR 2/TN FR SF10B  (D eath  re c e p to r  5) 152415  (M AB6312) M ouse R&D S y s te m s 1 350
Survivin A F886 R abb it R&D S y s te m s 1 800
Bax (Bcl-2 hom ology protein, pro-apopto tic) A 3533 R abbit DAKO 1 1500
CTG F (C onnective  tis su e  grow th factor) ab 6 9 9 2 R abb it A beam 1 650
EFNA1 (EphrinA I) 1220 3  (SC 911) R abb it S a n ta  C ruz 1 250
EPHA 2 (EPH  recep to r  A2) S C 9 2 4 R abb it S a n ta  C ruz 1 200
TW IST H-81 (S C 15393) R abb it S a n ta  C ruz 1 250
TNC (T en asc in  C) S C 2 0 9 3 2 R abb it S a n ta  C ruz 1 600
MBP (Myelin B asic  P ro te in ) (18-0038) R abb it Z ym ed 1 300
HEY1 (hairy /enhancer-o f-sp lit re la ted  with Y RPW  
motif 1)
R abb it S a n ta  C ruz 1 200
LPHA (L eukoyte phy tohem agglu tin in— re c o g n iz e s  
3 1 ,6 -b ran ch ed  o lig o sac ch a rid es) B-1115
N/A V ecto r 1:10000
CD 63 (M elanom a 1 an tigen ) FC-5.01 (18-7300) M ouse Z ym ed 1:50
MAGEA1 (M elanom a an tig en  fam ily A, 1) MA454 (18-7353) M ouse Z ym ed 1:90
MITF (M icropthalm ia transcrip tion  factor) C 5+D 5 (08-8369) M ouse Z ym ed P red ilu ted
HDM2 (H um an hom ol. of m urine d oub le  m inute 2) 1B10 M ouse N o v o castra 1 100
ATF2 (Activating transcrip tion  fac to r 2) C 19  (SC 187) R abb it S a n ta  C ruz 1 2 5 0
A P 2a K2403 (S C 184) R abbit S a n ta  C ruz 1 1600
PCNA (Proliferating cell n u c lea r  an tigen) P C 10 (18-0110) M ouse Z ym ed 1 10000
Ki-67 B56 (556003) M ouse T ran sd u c tio n  Labs 1 500
c-kit (kit o n c o g e n e ) 2 E 4  (18-0384) M ouse Z ym ed 1 50
p16/CDKN 2A/INK4a (c y d in -d e p e n d e n t k in ase  
inhibitor 2A  (m elanom a, p16, inhibits CDK4) G 175-405 (554070) M ouse
T ran sd u c tio n  Labs 1 500
p21/Cip1/CD K N 1A  (cy c lin -d ep e n d en t k inase  
inhibitor 1A)
S X 118 (556430) M ouse T ran sd u c tio n  Labs 1:100
p27/Kip1/CDKN1B (cy c lin -d ep en d en t k in ase  
inhibitor 1B)
G 173-524  (554069) M ouse T ran sd u c tio n  Labs 1:300
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Automated image acquisition and analysis.
The AQUA automated image acquisition and analysis was performed as described 
previously.314 Briefly, images of the tissue microarray were captured through an 
Olympus BX51 microscope with automated x, y, and z stage movement with an Olympus 
Motorized Reflected Fluorescence System and software (IP lab v3.60, Scanalytics, Inc., 
Fairfax, VA) equipped with Cooke Sensicam QE High Performance camera. Low-power 
images of the microarray were stitched together with multiple low-resolution images of 
the microarray (64 X 64 pixels) at ~7-pm resolution.
Areas of tumor were distinguished from stroma and non-melanoma tissue by 
creating a mask with the S I00 signal tagged with Alexa 546. Expression of S I00 protein 
was used to identify the tumor mask and 4', 6-diamidino-2-phenylindole (DAPI) was 
used to identify the nuclear compartment. Areas o f the tumor mask without DAPI were 
considered 'nonnuclear' or 'cytoplasmic'. The target markers were visualized with Cy5 
(red). Rows and columns of the histospots were then identified, missing histospots filled 
in, allowing each histospot to be identified by its coordinates, and recorded based on its 
position in the grid. Subsequently, monochromatic, high-resolution (1024 X 1024 pixel, 
0.5-pm resolution) images were obtained of each histospot, both in the plane of focus, 
and 8 pm below it, and recorded in an image stack as bitmaps. A resolution of 0.5 pm is 
suitable for distinguishing between large subcellular compartments such as the cell 
membrane/cytoplasm and nuclei. The ‘target’ signal from the cytoplasmic and nuclear 
compartment within the S I00 tumor mask was measured on a scale of 0 to 255 and 
expressed as target signal intensity relative to the respective cytoplasmic or nuclear 
compartment area.
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Data analysis.
Clinical data and immunohistochemistry scores were performed blind, and data 
were compiled only after all analyses were completed. Histospots containing <10% 
tumor, as assessed either subjectively (manual) or by mask area (automated), were 
usually excluded from further analysis. Our previous studies have demonstrated that 
scores from one to two histospots matches the score from an entire tissue section >95% 
of the time.
Hierarchical Clustering.
A general description of clustering methods can be found in Chapter 1. In order 
to perform clustering analyses, Z-score transformation was utilized to normalize 
AQUA data between experiments. Z-score formula:
[(AQUA Score) -  (mean of AQUA Scores on TMA) / standard deviation.]
The computer program CLUSTER118 was used to perform unsupervised average 
linkage hierarchical clustering on unweighted z-score transformed AQUA data. The 
results were then visualized with TREEVIEW118. For the 50-marker clustering, cases 
shown include those with at least 75% of the marker values present.
Univariate logistic regression followed by Classification Error / ROC fitting for 
multivariate logistic regression models .
Tumor thickness (Breslow) has been repeatedly described as the best overall 
predictor of disease survival in melanoma patients. We aim to pair Breslow depth with 
protein expression patterns from tumor tissue microarrays in order to improve the 
prediction of disease outcome. The data consist of 71 tumor microarray variables— 
protein expression levels as well as combination variables—in 211 patients with primary
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melanoma. The outcome variable is 5-year recurrence (binary). Missing values were 
imputed by using the column mean. We used a two-step variable selection approach to 
determine the optimal number of variables to be included in a model to best predict 5- 
year recurrence.
First, we performed univariate logistic regression to find the top scoring variables 
with a P value <0.05. This step resulted in a list of 15 variables.(Table 20)
Then, we then performed an exhaustive search over all variable combinations to 
find the best predictive set of variables using 10-fold cross-validation. We used two 
scoring functions: misclassification error and the area under ROC curve (AUC). The 
model was iteratively trained on 9/10 of the data, and then tested on the remaining 1/10 
of the data. An attempt to build models based solely on traditional clinico-pathologic 
variables (e.g., Breslow depth, Clark level, ulceration, microscopic satellitosis, tumor 
infiltrating lymphocytes), in the absence of molecular marker information, was also 
attempted.
Cox Multivariate Analysis and Aiken Information Coefficient (AIC).
We used survival time as the only end point in this analysis. Firstly, we performed 
univariate Cox proportional hazard regression to assess the statistical significance of each 
candidate potential factor, and the factor was retained if a significance level of p<0.05 
was attained. Factors showing statistical significance as a predictor were further 
analyzed using a multivariate Cox proportional hazard regression model with stepwise 
selection of variables based on the Akaike information criterion (AIC). AIC is a measure 
of the goodness of fit (log likelihood) with a "penalty score" for the complexity of the 
model (number of variables included), defined as: AIC = -2  x (maximum log likelihood)
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+ 2 x (total number of parameters), and the optimum (that is, simplest effective) model 
gives the lowest AIC value.
Genetic Algorithm.
A general description of genetic algorithms can be found in Chapter 1. A genetic 
algorithm was used to develop a multiplex marker assay for separation of prognostic 
groups based on the expression of markers closely associated with outcome. First, those 
markers mostly closely associated with survival in the primary melanoma specimens 
were identified by Cox univariate survival analysis (p<0.1). (Table 21 & Table 22).
These markers were then used as a starting point for the development of a genetic 
algorithm.
The genetic algorithm software (component of X-tile, written by Robert Camp) 
applies the elements of Darwinian evolution to optimization problems (e.g., mutation, 
recombination, selection) in order to the find the best combination of potential solutions 
to a problem. Each gene/algorithm represents an equation that is a true/false statement, 
such that the marker value is either ‘greater than’ (>) or ‘less than or equal to’ (<) a 
particular AQUA score. Each patient is given one point for each ‘true’ statement and a 
zero for ‘false’ statements. A chromosome/solution then consists of the optimal number 
of if/then statements that can be calculated as true or false. Chromosomes/solutions were 
subjected to multiple iterations by mutation (i.e., randomly changing cutpoint) and/or 
cross-overs (i.e., mixing and matching elements of from one gene/algorithm with those of 
another) until the model converged on a maximum predictive value, measured as relative 
risk or chi-square. This process was repeated multiple times until the end-point (relative 
risk or chi-square) values converged. The genetic algorithm repeatedly resulted in a 5-
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member model containing the same five variables: ATF2_ratio, Fibronectin, Beta 
Catenin, pl6_ratio, p21_nuclear. Patients were then assigned to risk group based on the 
genetic algorithm score.
Survival analysis.
Complete follow-up survival data were available for the Discovery cohort.
Overall survival analysis was assessed using Kaplan-Meier analysis and the Mantel-Cox 
log-rank score for assessment of statistical significance. Relative risk was assessed using 
univariate and multivariate Cox-proportional hazards model analyses. All statistical 
analyses were carried out using SPSS v. 13 (SPSS Inc., Chicago, IL).
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Results
Protein Expression Profiling of Melanoma.
The results of expression profiling, in which primary cutaneous melanoma 
specimens were compared to metastatic melanoma specimens is demonstrated in Table 
19. Significant differences (p<0.05) were observed for the following markers: Higher 
expression in primary specimens: Beta-catenin, MMP3, TIMP2, ATF2, HDM2, E- 
cadherin, P-cadherin, N-cadherin, CD61, HEY1, MAGE1, pl6, Bcl-2; Higher expression 
in metastatic specimens: Fibronectin, CTGF, TIMP3, Ll-CAM, alpha-catenin, Bad, Bax, 
Bcl-X, Bid, XIAP, Survivin, EphA2, Twist, Fascin, PCNA, Thioredoxin, LPHA, p21, 
Metallothionein.
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Table 19. Comparison of Protein Expression Levels in Primary versus Metatstatic Specimens
Primary
Specimens
Metastatic
Specimens
Protein Mean ± SD Mean ± SD MeanDifference t value p value
F N 1 47 .59± 14 .79 63 .10124 .11 15.51 7 .55 <.0001
C TG F 66 .07118 .12 72 .9 3 1 1 8 .2 3 6 .86 3.64 0 .0003
SPA R C /O N 20 .53115 .33 21 .3 8 1 1 7 .4 0 0 .85 0 .5 0 .6177
MMP1 37 .41119 .88 3 7 .28122 .80 -0 .136 -0 .06 0 .9524
MMP3 2 0 .44111 .52 1 3 .7816 .89 -6 .66 -6 .474 <.0001
TIM P3 40 .9 4 1 1 6 .6 6 4 7 .18+ 17 .54 6 .24 3.67 0 .0003
TIM P2 5 6 .40116 .07 50 .6 7 1 1 2 .3 5 -5 .73 -3 .39 0 .0008
HDM2 5 2 .38118 .06 43 .2 6 1 1 6 .8 4 -9 .12 -5 .25 <.0001
ATF2 6 9 .21140 .24 60 .3 6 1 3 9 .7 8 -8 .85 -2 .52 0.0121
E -cad 37.46119.51 2 9 .8 5 1 1 8 .0 5 -7.61 -3 .43 0 .0007
P -cad 35 .6817 .23 3 2 .7015 .74 -2 .97 -4 .38 <.0001
N -cad 19 .00114 .77 13 .38112 .96 -5 .62 -3 .92 0.0001
L1 6.5213 .35 8 .17 1 4 .2 9 1.65 3.71 0 .0002
a -ca ten in 11 .6012 .15 14.5517.21 2 .95 4 .3 6 <.0001
P-C atenin 48 .25115.81 4 0 .7 4 1 1 2 .2 8 -7 .50 -5 .15 <.0001
p120 18 .59110 .32 18.26+9.23 -0 .327 -0.31 0 .7569
APAF1 32 .21120 .03 31 .6 6 1 1 7 .5 9 -0 .544 -0 .209 0 .8344
Bad 40 .8 9 1 1 5 .3 5 4 8 .7 1 1 2 2 .8 2 7.83 2 .9 7 0 .0033
Bax 1 0 .6015 .75 13 .0519 .09 2 .45 2 .2 7 0 .0 2 4
Bcl-2 19 .61120 .19 15 .43117 .16 -4 .17 -1 .9 8 0 .0484
Bcl-X 17 .5018 .10 2 1 .2 3 1 1 2 .3 2 3.73 2 .84 0 .0049
Bid 14.3617 .57 2 0 .2 1 1 1 0 .2 9 5 .86 4 .1 9 <.0001
clAP 3 9 .58120 .64 44 .9 3 + 2 1 .7 9 5.36 1.88 0 .0608
XIAP 10.5517 .98 13 .6119 .64 3.06 2 .5 4 0 .0116
DR4 3 5 .80111 .83 34 .01+ 11 .03 -1 .79 -1.11 0 .2675
DR5 5 3 .64115 .33 54 .34116.21 0 .70 0 .29 0 .7706
Survivin 3 6 .26118 .20 4 3 .3 2 1 1 5 .4 9 7 .06 3 .55 0 .0005
CD61 3 0 .52111 .18 2 6 .2 5 1 7 .5 4 -4 .27 -4.01 <.0001
ILK 43 .20+ 14 .00 4 4 .86+ 14 .30 1.65 1.13 0 .2612
EphrinA I 45 .8 5 1 1 6 .3 0 4 3 .6 7 1 1 4 .7 5 -2 .18 -1.31 0 .1897
EphA2 49 .8 2 1 1 6 .4 5 54 .1 9 1 1 4 .1 3 4 .37 2 .53 0 .012
Twist 2 4 .64111 .82 28 .8 1 1 1 5 .1 0 4 .17 2 .82 0.0051
T en asc in  C 26 .1 1 1 2 1 .6 6 29 .45129 .11 3.33 1.21 0 .2275
MBP 45 .2 4 1 1 7 .3 2 4 3 .2 7 1 1 5 .7 5 -1.97 -1 .04 0 .3006
A nnexin 1 40 .43+ 20 .80 4 0 .04+ 25 .85 -0 .384 -0 .16 0.8741
MITF 16 .74113 .59 13 .41113 .05 -3 .33 -2 .27 0.0241
Fascin 2 2 .97122 .38 30 .9 4 1 2 6 .8 6 7 .97 2 .7 7 0 .0059
HEY1 59 .2 1 1 2 3 .6 5 4 6 .3 2 1 2 5 .4 4 -12 .89 -4 .90 <.0001
PCNA 2 0 .05+ 14 .12 28 .2 5 1 1 6 .7 3 8.2 4 .5 2 <.0001
Ki-67 18 .8916 .80 2 0 .3 5 1 8 .1 7 1.46 1.91 0 .0564
Thioredoxin 4 .3 3 1 2 .3 6 5 .92+ 5 .12 1.59 2 .84 0 .005
LPHA 21 .4 0 1 2 1 .6 5 2 7 .9 4 1 1 6 .1 0 6.54 2 .9 0 .004
MAGE1 14 .45113 .08 11 .1117 .16 -3 .34 -2 .87 0 .0044
A P2 2 1 .74112 .33 2 0 .6 4 1 1 1 .3 4 -1.1 -0 .87 0 .3842
CD 63 15 .16117 .07 1 5 .58114 .67 0.421 0 .23 0 .8 1 5
c-kit 3 2 .71116 .89 34 .5 3 1 1 5 .3 3 1.82 0 .9 9 0 .322
p16 29.44123 .11 2 3 .8 8 1 1 9 .2 2 -5 .57 -2 .65 0 .0084
P21 1 3 .0114 .90 13 .8515 .46 1.84 3 .578 0 .0004
P27 3 8 .89119 .55 4 0 .6 4 1 2 1 .3 3 1.75 0 .8 6 0 .3948
M etallothionein 3 1 .00125 .65 3 7 .2 1 1 3 0 .8 6 6.21 2 .0 0 0 .0459
C D 44 5 1 .03115 .63 4 9 .1 4 1 1 6 .5 0 -1 .89 -1.01 0 .3113
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Clustering Analysis.
Clustering models are a good preliminary method of analysis to potentially detect 
molecular subclasses of disease that may not be recognized otherwise. Although they 
may not necessarily produce prognostically relevant classifications, the analysis 
illustrates the strength of multiplexing of quantitative values of protein expression, and 
may provide some clues to melanoma biology.
We have performed AQUA analysis on 50 proteins using our 521 case Discovery 
Melanoma Tissue Microarray. When subsets of these proteins are clustered using 
unsupervised hierarchical clustering algorithms, the patient population can be divided 
into smaller subclasses (Figure 22A). However, these subclasses tend not to be 
prognostically relevant (Figure 22B & C). One method for improving our understanding 
of molecular subclasses, while using clinical information already available to us is semi­
supervised clustering analysis. Semi-supervised clustering analysis involves the use of 
clinical data to identify a list of genes that correlate with a clinical variable of interest 
(melanoma-specific survival in this case) and then applying unsupervised clustering 
techniques to this subset of genes. After using Cox univariate survival data to identify 
those markers most closely associated with survival, unsupervised clustering analysis was 
used to identify groups of patients that have significantly different rates of melanoma- 
specific survival (Figure 23).
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Figure 22.Unsupervised hierarchical clustering of protein expression. Average linkage cluster 
analysis of protein expression, measured by AQUA analysis, in melanoma patient specimens. A, 
Clustergram. The rows represent patients and the columns represent proteins. Scores were 
normalized to the mean by Z-score calculation. B, Kaplan-Meier plot demonstrating survival for 
the highest level of classification. C, Kaplan-Meier plot demonstrating survival for the second 
highest level of classification.
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Figure 23. Semi-supervised hierarchical clustering. Molecular markers closely associated with 
survival by Cox regression analysis (p<0.1) were subjected to unsupervised hierarchical 
clustering. Clades were established and examined by Kaplan-Meier analysis. A, Clustergram.
The rows represent patients and the columns represent proteins. Scores were normalized to the 
mean by Z-score calculation. B, Hierarchical clustering of proteins. C&D, Kaplan-Meier plots (C, 
all patients; D, primary specimens only) demonstrating survival for the clades identified in 
clustergram.
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Univariate logistic regression followed by Classification Error Determination for 
multivariate logistic regression models.
We have found 15 variables that show prognostic value using univariate logistic 
regression analysis for death (as a surrogate marker of recurrence). These are listed in 
Table 20.
Table 20. Top scoring variables in univariate regression
Variable Name coefficient P  value
BRESLOW -0.823 1.38e-06
ATF2inCyto 0.549 0.00234
Ecadherin 0.499 0.0039
N cadherin 0.601 0.00424
ATF2 0.501 0.00568
PCNA Nuclei -0.405 0.0086
CD44 0.438 0.00869
PCNA Tumor Mask -0.373 0.0148
Fibronectin -0.353 0.0205
ATF2 nucbycyto -0.405 0.032
ATF2inNuc 0.348 0.038
Tenascin C -0.302 0.0415
Beta catenin 0.314 0.0473
Bid -0.327 0.0477
Survivin 0.325 0.049
Multivariate prognostic models were then constructed and tested through 10-fold 
cross-validation. Each possible model was trained on 9/10 of the population, followed by 
testing on the remaining 1/10 of the population; this process was then repeated 10 times. 
The results of these analyses (i.e., the ability of the model to correctly classify those 
patients who will ‘recur’ versus those who will not) can be measured as a classification 
error.
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Model Including Clinicopathologic Factors Alone
-  Input: 15 variables
• BRESLOW
• ATF2_Cytopl 
asm
• E-cadherin
• N-cadherin
• ATF2
• PCNANuclei
• CD44
PCNA_Tumor Mask
Fibronectin
ATF2_nucbycyto
ATF2_Nuclei
Tenascin C
Betacatenin
Bid
Survivin
0.45
0.4
0.35
0.3
0.25
0.2
variable se t size
F igu re 24 . Missclassification error and 95% Cl for Models including Molecular Markers + Breslow Depth
A plot of misclassification error (Figure 24) demonstrates the 
generalization/prediction error for models of different variable set sizes. As 
demonstrated in Figure 24, a prognostic model with 5-7 variables results in a 
misclassification error of about .26, down from .34 when using only one variable alone. 
This demonstrates that the addition of variables to Breslow depth improves the ability of 
the model to determine which patients will ‘recur’ up to a point, after which, the addition
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of variables convolutes the picture. However, the direct utility of these markers is not 
entirely clear, or easy to apply to a prospective cohort, as they remain continuous 
variables in the constructed models.
Model Including Clinicopathologic Factors Alone 
-  Input: 11 variables
• Breslow
• Clark
• Ulceration
• TILs
Microscopic Satellites
Histologic subtype
Lesion site
Sex
Age
MISS.CLASSIFICATION ERROR MELANOMA 5 YEAR RECURRENCE
0.31
0.305
0.3
0.295
0.29
0.285
0 2 3 4 5 6
NUMBER OF MODEL VAR IAB LES 
Figure 25. Missclassification error and 95% Cl for Models including Clinicopathologic Variables
For a point of reference, and to determine the economic reality of the molecular 
assay, the same process was performed on the available standard clinicopathologic 
variables alone, in the absence of molecular markers.(Figure 25) The analyses
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demonstrate that models constructed using only clinicopathologic variables do not 
dramatically improve the prediction of recurrence by Breslow alone.
Cox Proportional Hazard and AIC.
Univariate Cox proportional hazard analysis of the training data set revealed that 
13 factors were significantly associated with prognosis of melanoma patients (Table 22). 
We included Breslow, which showed remarkable significance (p<0.0001), and performed 
multivariate analysis on the 14 factors with stepwise selection of variables using the AIC. 
Not surprisingly, a Cox multivariate modeling system produced similar results to those 
obtained with multivariate logistic regression, demonstrating that 5-8 markers provide the 
most reliable estimate of survival. (Figure 26)
AIC COX MULTIVARIATE ANALYSIS FOR MELANOMA SURVIVAL
935
925
920
915
910
Number of mode! variables
Figure 26. Plot of Akaike Information Coefficient (AIC) score by number of variables included in 
Cox multivariate models.
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Table 21. Univariate Prediction of Melanoma-Specific Death at 20 year follow-up:
Associated with good outcome:
Relative Risk
Marker
cont. p- 
value
10%
vs
90%
25%
vs
75%
50%
vs
50%
ATF2 0 .0 0 0 5 9 2.40 2 .06 1.45
B eta ca ten in 0 .0007 3 .49 1.68 1.43
N cadherin 0 .0013 1.97 1.95 1.61
CD 44 0.0071 2 .0 8 ^ 1.58 1.22
E cadherin 0 .0087 1.28 1.88 1.69
MDM2 0.01 2.41 1.79 1.27
ATF2 N uclear 0 .013 2 .00 1.65 1.33
MDM2 N uclear 0 .018 2 .52 1.57 1.22
CD61 0.023 2 .15 1.39 1.29
p16 _ N u clear by 
p16 C ytop lasm 0.026 1.33 1.63 1.49
p16 N uclear 0 .033 1.92 1.57 1.38
P cadherin 0 .067 1.41 1.04 1.22
p1 2 0 ca ten in 0 .083 1.75 1.43 1.18
MDM2 C ytop lasm 0 .09 1.73 1.47 1.33
TIM P2 0 .0 9 7 1.18 1.33 1.22
MMP3 0.1 2 .05 1.47 1.22
EphA2 0 .12 1.85 1.16 1.05
A P2 N uclear 0 .13 1.71 1.45 1.08
p16 T um or M ask 0 .13 1.42 1.41 1.43
EphrinAI 0 .1 5 1.11 1.45 1.24
ckit T um or M ask 0 .2 1.22 1.34 1.44
MBP 0.2 2 1.47 1.28 1.14
p16 C ytop lasm 0 .2 6 1.31 1.29 1.32
LPHA 0.27 1.14 1.05 1.05
MITF N uclear 0 .2 9 1.66 1.09 1.29
CD63 0.41 0 .74 1.26 1.20
MAGE1 0.51 1.59 1.11 1.34
Hev1 0 .54 1.60 1.23 1.00
p27 N uclear 0 .64 1.42 1.07 1.03
A paf 1 0 .6 9 1.60 1.31 1.06
A P2 T um or M ask 0 .7 5 1.72 1.07 0 .97
Bel x 0 .77 0 .80 1.08 1.33
ILK 0 .83 0.81 1.14 1.11
Thioredoxin 0 .8 8 1.10 0 .98 0 .85
L1 0 .9 8 0 .58 0 .69 0 .79
Associated with poor outcome:
Relative Risk
Marker
cont. p- 
value
10%
vs
90%
25%
vs
75%
50%
vs
50%
BRESLOW 6.0 0 E -1 3 11.95 7.33 4.10
A T F2_nuc lear by 
ATF2 cy top lasm 3 .20E -7 2.29 1.74 1.39
A P 2_C ytop lasm  
b y A P 2  N uclear 2 .20E -5 1.62 2.09 1.83
Fibronectin 0 .00071 1.62 2.13 1.57
PCN A  N uclear 0 .0 0 9 5 2.43 1.51 1.36
O steonectin 0 .0 2 6 1.04 1.22 1.22
p 16_C ytop lasm  
b y p 1 6  N uclear 0 .0 2 6 1.33 1.62 1.54
M etallothionein 0 .0 4 8 1.12 1.49 1.34
p21 N uclear 0 .0 5 8 1.48 1.12 1.30
p21 C ytop lasm 0 .0 6 6 1.20 1.73 1.27
Ki67 N uclear 0 .0 8 1.45 1.35 1.15
F asc in 0.091 1.29 0.97 1.08
p27_C ytop lasm  
by p27  N uclear 0.1 1.09 1.37 1.31
p21 T um or M ask 0.11 0.97 1.34 1.29
MMP1 0.14 1.35 1.31 1.06
C TG F 0 .14 1.88 1.10 1.29
Bax 0 .23 1.88 1.28 1.32
Bid 0 .29 1.66 1.29 1.06
p 21 _ N u clear by 
p21 C ytop lasm 0.3 0 .99 1.01 0 .99
TIM P3 0 .34 1.14 1.40 1.05
XIAP 0 .3 5 1.21 1.09 1.00
Twist 0 .43 1.25 1.16 1.29
A P 2 C ytop lasm 0 .4 9 0 .80 1.04 1.07
Bad 0 .5 1.39 0 .97 1.09
p 27  C ytop lasm 0 .52 1.04 1.02 1.06
Survivin 0.57 1.17 1.24 1.08
T e n a sc in  C 0 .57 0.90 0.94 0.90
clA P 0 .62 0.89 1.06 1.07
DR4 0 .88 1.05 1.07 0.88
p27 T um or M ask 0 .94 0.91 0.95 0 .99
a lp h a  ca ten in 0 .9 8 1.01 0.98 0.90
TRAIL DR5 0 .9 8 1.03 0.95 0 .90
A nnexin 1 0 .9 9 0 .52 0.92 1.07
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Table 22. Univariate Prediction of Melanoma-Specific Death at 20 year follow-up
(Only Prim ary Specimens):
Associated with good outcome:
Relative Risk
Marker
cont. p- 
value
10%
vs
90%
25%
vs
75%
50%
vs
50%
A TF2 C ytop lasm 0.00041 6.34 3 .56 2 .06
ATF2 0 .0012 5.75 2 .90 2.04
E cadherin 0.0031 3.32 2 .20 2.17
N cadherin 0 .0033 4 .85 3 .23 2 .28
B eta  caten in 0 .0048 5.89 2 .89 1.61
C D 44 0 .0095 2.57 2 .32 1.63
A TF2 N uclear 0 .019 2 .55 2 .24 1.82
MDM2 0.027 3.44 2 .23 1.20
MDM2 N uclear 0 .033 3 .08 2 .04 1.15
p 16 _ N u clear by 
p16 C y top lasm 0 .033 0.81 1.55 1.82
MDM2 C y top lasm 0 .056 2.72 1.86 1.46
p 1 2 0caten in 0 .087 2 .15 2 .28 1.17
a lp h a  ca ten in 0.11 2 .95 1.39 1.26
ckit T um or M ask 0 .13 1.43 2 .20 1.96
EphrinA I 0 .16 1.62 1.56 1.52
p16 N uclear 0.21 1.81 1.61 1.27
P  cadherin 0 .23 3 .19 1.01 1.09
EohA2 0 .28 1.91 0 .97 1.08
MBP 0 .38 1.63 1.26 1.13
MITF N uclear 0 .42 1.04 1.56 1.27
MMP3 0 .46 1.23 1.52 1.58
p16  T um or M ask 0 .47 1.18 1.23 1.41
Survivin 0.5 1.26 1.41 0 .87
LPHA 0.53 2.23 0 .88 1.28
p27 N uclear 0 .53 1.76 0 .96 1.01
CD61 0 .58 1.65 1.04 1.01
A paf 1 0 .58 2 .12 0 .97 1.11
A P2 N uclear 0 .58 1.59 1.28 0 .99
p16  C y top lasm 0 .6 1.31 1.38 1.32
ILK 0 .72 0 .77 1.43 1.36
Hey1 0 .74 0.95 0 .90 1.15
Thioredoxin 0 .85 2 .88 1.11 0 .82
CD 63 0 .8 6 0 .68 1.25 1.13
p27 T um or M ask 0 .8 8 1.23 1.04 1.01
TIM P2 0 .95 1.12 1.01 0 .86
A P2 T um or M ask 0 .96 1.64 0 .95 0 .97
Associated with poor outcome:
Relative Risk
Marker
cont. p- 
value
10%
vs
90%
25%
vs
75%
50%
vs
50%
BRESLOW 9.00E -12 9 .48 9.58 4.14
A T F2_nuc lear by 
A TF2 cy top lasm 4 .10E -05 1.91 2 .06 1.43
PCNA N uclear 0 .0012 4 .2 4 2 .74 1.28
Fibronectin 0 .0087 2 .8 8 1.65 1.17
A P 2_C ytop lasm  
b y A P 2  N uclear 0 .018 1.66 2.00 1.63
Bid 0 .065 5.11 1.27 1.09
p16_C ytop lasm  
b y p 1 6  N uclear 0 .088 0 .99 1.63 1.85
T e n a sc in  C 0 .093 1.29 1.18 0.89
p21 N uclear 0 .093 1.54 1.25 0.91
p 27_C ytop lasm  
by p27 N uclear 0.11 1.50 1.41 1.35
p 21_T um or_M as
k 0 .12 2 .05 1.31 0.93
O steo n ec tin 0 .18 1.44 1.65 1.14
p21 C ytop lasm 0.22 1.57 1.19 0 .89
M etallothionein 0 .24 0 .7 8 1.20 1.43
MMP1 0 .25 1.89 1.50 1.13
Fascin 0.31 0.91 0.90 0 .78
Tw ist 0 .32 1.71 1.26 1.36
A nnexin 1 0 .35 1.07 1.55 1.16
Ki67 N uclear 0 .35 1 .29 1.29 1.20
L1 0 .38 1 .29 1.65 1.61
p 2 1 _ N u clear by 
p21 C ytop lasm 0.38 1.46 1.04 0.94
DR4 0 .6 1 .45 1.12 0 .95
Bax 0.61 2 .0 2 1.16 0.78
XIAP 0.67 0 .47 0.50 0.81
TRAIL DR5 0.68 1.23 1.01 0 .89
A P 2 C ytop lasm 0.68 0 .6 9 1.06 1.13
CTG F 0.74 1.45 0.82 0 .89
clA P 0 .79 1.40 1.08 0 .85
MAGE1 0.81 1.10 0 .76 0 .78
p27  C y top lasm 0.81 0 .93 1.01 1.13
p2 1 _ C y to p lasm  
by p21 N uclear 0 .83 0 .77 0.93 1.02
TIM P3 0 .85 1 .66 1.13 0.90
B ad 0.93 1 .09 0.69 0.87
Bel x 0 .95 1 .54 0.60 0.72
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Genetic Algorithm.
In order to develop a prognostic model with results that can be applied to future 
cohorts, or be used in a prospective trial, we applied genetic algorithm software to 
determine the optimal combination of markers, as well as optimal outpoints for each 
marker. Thirteen of the 66 variables (derived from 50 independent protein assays) 
analyzed were significantly (p<0.1) associated with outcome (N-cadherin, E-cadherin, 
p i20, Beta-catenin, CD44, Tenascin C, p21, PCNA, Fibronectin, MDM2, ATF2, p i6, 
AP2) by Cox univariate analysis. GA software was run to convergence (>20X106 
generations) multiple times (Figure 27A) and the runs repeatedly resulted in the same 
five-marker solution: ATF2_ratio of cytoplasm by nuclear; nuclear p21; pl6_ratio of 
cytoplasm by nuclear; Beta catenin; and Fibronectin (Figure 27B).
It is interesting to note that the genetic algorithm resulted in a similar number of 
genes (five) in the ‘optimal model’ to optimal models derived from logistic and Cox 
multivariate regression models, which consider the variables in a linear fashion. The 
application of the GA model to the training set (Discovery cohort) is depicted in Figure 
28. The groups were pooled 0-3 (high risk) and 4-5 (low risk) based on similar outcomes 
amongst the groups.
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A Molecular Markers Alone
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Figure 27. A, Plot of risk ratio by generation number amonst genetic algorithms, demonstrating 
progressive improvement of chi-square as generation number increases. B, Optimal gene set with 
optimal cut-points for each biomarker. The patient is assigned 1-point for each condition that is 
true, in an additive fashion.
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Figure 28. Kaplan-Meier plot of genetic algorithm applied to primary melanoma specimens. Risk 
groups were assigned based on stratification seen when plotting each individual score category.
In this training cohort, limited to 129 primary tumors for which all data points 
were available, Kaplan-Meier analyses show patients with Breslow depth <1.0 mm have 
a 78.1% 10-year survival compared to patients with depth >1.0 mm with a 45.4% 10-year 
survival (p<0.001). Addition of the GA information further stratifies the patients.
Patients with Breslow depth <1.00mm are split into “low-risk” (86.4% survival) and 
“high-risk” groups (60% survival) while those with Breslow > 1.00mm split into “low- 
risk” (80.5%) and “high-risk” (19.6%) (p<0.0001). This information is presented in 
Figure 29.
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Figure 29. Kaplan-Meier plot demonstrating stratification of patients by Breslow depth (1.00 mm 
cut point; the ‘standard’ used by surgeons in determination of which patients receive sentinel 
lymph node biopsy) and genetic algorithm risk score.
This training set data suggests that it is possible to improve upon the best 
prognostic index in primary melanoma (i.e., Breslow depth) by using multiplexed in situ 
measurement of protein expression.
We are in the process of validating of our results on an independent cohort of 
patients with known sentinel lymph node outcomes to determine if  the genetic algorithm 
(GA) assay is more accurate than sentinel node biopsy in predicting 
recurrence/metastasis. The preliminary data follow.
In the Validation cohort of 270 primary melanoma specimens, all patients 
underwent sentinel lymph node biopsy (SLNB). The mean time from wide local excision 
(WLE) to SLNB was 47 days. Patient and tumor characteristics include the following. 
There are 112 female and 158 male patients. The mean age at diagnosis is 58 years ± 17
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years (range: 5 years -  98 years). The mean follow-up time is 23 months ±18 months 
(range: 21 days -  74 months). The results of SLNB were positive in 33 cases (12.2%).
The majority of these patients received their SLNB within the last year and a half. 
As a result, recurrence/metastasis data on this cohort is somewhat limited. Using the 
restricted recurrence data available to us, we seek to examine the ability of Breslow 
depth, SLN status, and our GA risk test to predict metastasis. However, we first 
demonstrate the ability of Breslow depth to predict SLN status (Figure 30).
l r  °-6~
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Figure 30. Receiver-operator characteristic curve for prediction of SLN status by Breslow depth.
Regarding recurrence, there are currently 30 patients (10.8%) who have 
developed metastases. Only seven of these patients had positive SLN results. In terms of 
prediction of recurrence, Kaplan-Meier plots demonstrate that Breslow depth (Figure 31), 
SLN status (Figure 32), and the GA risk test (Figure 33) are able to predict metastasis.
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Figure 31. Prediction of metastasis by Breslow depth in SLN (YTMA 76) cohort. Time to recurrence is 
measured in days.
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Figure 32. Prediction of metastasis by SLN status in SLN (YTMA 76) cohort. Time to recurrence is 
measured in days.
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Figure 33. Prediction of metastasis by GA risk test on SLN (YTMA 76) cohort. Time to recurrence is 
measured in months.
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Discussion
We have demonstrated a set of molecular markers that can be used as an 
independent predictor of survival, to potentially be used on a regular basis to aid in 
patient prognosis. It should be recognized, however, that these prognostic models should 
be tested on an independent validation set before being applied in a prospective clinical 
trial. We hope that these models will serve as an initial assessment to aid clinicians in the 
prognosis of their patient’s disease, and possibly provide therapeutic guidance. Though 
the current aim of this project is to define aggressive melanoma from ‘benign—less 
aggressive’ melanoma, a number of molecular targets have been identified that may have 
therapeutic potential.
Tissue microarray technology, uniquely, provides the capacity for detecting 
multiple proteins in large series of patients. To our knowledge, only one study has 
demonstrated evidence of the feasibility of protein expression profiling for the prognosis
269 • • 109 282 325-of melanoma , and only a few papers based on the expression single proteins ’
I ' ) ’!  ' I 1  'X have been published. Bom out of the unparalleled ability to control many of the 
ambiguities of immunohistochemistry, tissue microarray technology combined with 
automated quantitative analysis allows one to approximate molecular concentration 
measurements of a particular protein without loss of spatial information.
Many of the genes (i.e,. gene products) that demonstrate closest association with 
outcome in this study have an established role in melanoma progression. Others have a 
purported role that requires further investigation at the cellular and molecular biology 
level. All of them, however, are potential therapeutic targets in the treatment of 
melanoma.
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Cyclins and cyclin-dependent kinases (CDKs) are evolutionarily conserved 
proteins that are essential for cell-cycle control in eukaryotes. Cyclins (regulatory 
subunits) bind to CDKs to form complexes that regulate the progression of the cell cycle. 
The activity of these complexes is modulated by activating and inhibitory 
phosphorylation events, as well as interactions with small regulatory proteins, including 
p i6, p21, p27 and others. These proteins, referred to as inhibitors of CDK activity 
(CDKIs), bind to cyclins, CDKs, or their complexes.334
The pi 6INK4a gene, found at 9p21, is a tumor-suppressor gene that has long been 
known to be involved in familial and sporadic melanoma. The p l6  protein has been
335identified as a specific inhibitor of CDK4, blocking CDK4 substrate phosphorylation. 
Deletion of the INK4a/ARF (CDKN2a) locus is a common genetic lesion, detected in 
-50% of primary tumors and nearly all melanoma cell lines.336,337 Work on mouse 
models has suggested that p ld 11'*43 plays an important role in limiting inappropriate or 
aberrant cellular proliferation.338 Previous studies have demonstrated that loss of nuclear 
p l6  occurs more commonly in melanomas than benign nevi339,340, and that this 
occurrence in primary melanoma is also associated with increased proliferation 
(measured by Ki-67) and poor prognosis.341
Most papers approach the cytoplasmic localization of p i 6 as a nonspecific 
artifact. However, recent studies have suggested that cytoplasmic localization of p i 6 
may represent prognostically-relevant subclasses of cancer. Emig et al. reported that in 
breast cancer, cytoplasmic accumulation of p i 6 identifies a subset of tumors with 
accelerated proliferation and other unfavorable parameters.342 Another study 
demonstrated that nuclear and cytoplasmic p i6 overexpression in breast cancer was
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associated with a highly malignant tumor phenotype.343 On the other hand, cytoplasmic 
p l6  localization in colon cancers is associated with a good prognosis.344 In an attempt to 
elucidate whether cytoplasmic p i6 staining is specific or an artifact due to tissue fixation 
and/or nonspecific binding of the applied antibodies, Evangelou et al. used 
immunoelectronmicroscopy to demonstrate that p i6 can, in fact, be present in the 
cytoplasm.345
An abundance of nuclear factors in the cytoplasm likely represents a defect in the 
cytoplasmic-nuclear shuttling system.346 However, the mechanism is not fully 
understood. As p l6  lacks Nuclear Location Signals (NLS) and Nuclear Export Signals 
(NES), the defect may lie in the nuclear chaperone group of proteins. The significance of 
these proteins has been shown in cases of APC and BRCA1 where destruction of NLS 
does not impede shuttling in the nucleus.345 An alternative explanation is that 
cytoplasmic p i6 may represent a protective response to over expression of CDK4. 
According to this scenario, a portion of p i 6 binds to CDK4 in the cytoplasm and inhibits 
its passage into the nucleus due to the large size of the complex, whereas the unbound 
protein enters the nucleus to exert its oncosuppressor activity.344 In any event, based on 
our results, an aggressive phenotype is expected in melanoma when cytoplasmic 
concentrations of p l6  exceed those in the nucleus.
The WAF1 gene, which encodes the p21WAF1 protein, is located at 6p21. It is has 
been shown to be under the transcriptional control of p53, and the p21 protein is known 
to inhibit progression of the cell cycle at the Glto G2 phase.347 The WAF1 gene is rarely 
mutated in metastatic melanoma, and expression is not always correlated with p53 
expression.348 Regarding melanocytic lesions, expression of p21 is found to be
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low/undetectable in benign melanocytic lesions, while higher expression seen in 
malignant melanomas.349 Additionally, increasing expression of p21 has been found to 
correlate with Clark level and Breslow thickness.349,350 However, the association of p21
• • 351with patient prognosis is not entirely clear or intuitive.
Fibronectin is an extracellular glycoprotein that serves as a ligand for the integrin 
family of cell adhesion receptors and regulates cytoskeletal organization. Previous 
studies have demonstrated that fibronectin expression is associated with tumorigenesis352 
and metastasis353. Enhanced expression of extracellular matrix (ECM) proteins, such as 
fibronectin, may promote tumor cell survival or angiogenesis.354 Experiments by Clark et 
al. demonstrate that metastatic transformation of relatively indolent cell lines is 
associated with upregulation of several genes that encode ECM proteins.123 We have also 
previously demonstrated, through genomic analysis, that fibronectin expression is 
significantly increased in melanoma cell lines relative to normal melanocytes.117 This is 
the first time, to our knowledge, that anyone has demonstrated that fibronectin expression 
by melanoma cells is associated with an invasive phenotype and poor prognosis.
The cadherin/catenin complex is critical for the formation and maintenance of 
cell-cell adhesion. E-cadherin, a calcium-dependent intercellular adhesion receptor, is 
the primary epithelial cell adhesion regulator.355 Its functional role in melanocytes is to 
maintain melanocyte-keratinocyte adhesion.356 The extracellular domain works like a 
molecular zipper, while the cytoplasmic tail is linked to the actin cytoskeleton via 
catenins.357 Loss of E-cadherin expression has been implicated in tumor progression for 
a variety of tumor types, including malignant melanomas.358"364 Recent studies show that 
E-cadherin is not only involved in cell-cell contact but multiple signaling pathways are
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activated or repressed by E-cadherin. The most commonly discussed pathway is the (3- 
catenin/LEF/TCF signaling cascade.365,366 However, E-cadherin is also involved in the
'K fn  TSRregulation of other pathways as well, including MAP kinase and NFkB pathways.
N-cadherin, the neuronal equivalent of E-cadherin, is also expressed by melanoma 
and has been reported to be upregulated in melanoma cell lines when E-cadherin is
T SOdownregulated. Additionally, strong N-cadherin expression in single melanomas has 
been reported in the literature.362 These observations suggest that this shift in cadherin 
profiles may endow melanocytic cells with new adhesive properties that favor 
uncontrolled proliferation, migration, and invasion. However, examination of a larger 
cohort of tumor specimens demonstrates that only a minor percentage of invasive 
melanomas demonstrate N-cadherin expression.368 Based on previous data and our 
results, it is unlikely that the E- to N-cadherin “switch” actually takes place in vivo. The 
role of cadherins as causative factors in melanoma tumor progression remains to be 
proven. It is likely, however, that overall cadherin expression, in general, is indicative of 
the differentiation status of a tumor. Based on our results, it is clear that maintenance of 
E- and/or N-cadherin expression is an excellent predictor of outcome in melanoma.
Regarding the cadherins, our results indicate that it does not matter which 
cadherin is present at the cell surface. Both E- and N-cadherin are significantly 
associated with survival in a positive fashion. That is, it is unlikely that the E- to N- 
cadherin shift is an actual in vivo phenomenon. The mere presence of one of these 
cadherins at the cell surface is probably sufficient to stabilize melanoma cells and retard 
their invasion.
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Catenins are the cytoplasmic proteins that regulate and effect cadherin function.
P- and y-catenin bind directly to the cytoplasmic carboxy-terminal domain of E-cadherin, 
forming mutually exclusive complexes, while a-catenin links the bound P- and y-catenin 
to actin microfilaments of the cellular cytoskeleton.369 The catenins are thought to have a 
signaling role through the cytoplasmic adenomatous polyposis coli (APC) protein, which 
is the product of a tumor suppressor gene mutated in colorectal and other cancers. They 
are also known to interact with the epidermal growth factor (EGF) and hepatocyte growth 
factor (E1GF) receptors, becoming tyrosine phosphorylated upon activation by these
7 7 0 771growth factors. ’ A fourth member of the catenin family is pl20-catenin (pi 20). 
Although it was originally identified as a Src substrate, p i20 regulates cell-cell adhesion 
through its interaction with the cytoplasmic tail of cadherins. It is purported to regulate 
cadherin turnover at the cell surface, thereby controlling the amount of cadherin available 
for cell-cell adhesion, p i20 also modulates the activities of RhoA, Rac, and Cdc42,
7 7 9suggesting that along with other Src substrates, p i20 regulates actin dynamics. Thus, 
p i20, a regulator of cadherin abundance and activity, likely participates in regulating the 
balance between adhesive and motile cellular phenotypes.
Very little data is available regarding expression of the catenins in melanoma. A 
relatively small study performed by Zhang et al. demonstrated that there is no correlation 
between the expression of a-, (3-, y-catenins. However, P- and pl20-catenin showed 
coordinated expression levels, a-catenin exhibited an inverse correlation with tumor 
thickness, as well as lower expression levels in advanced primary melanoma and 
metastases.373 Studies also show that expression of P-catenin is reduced in metastatic
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compared with primary melanoma lesions,100’362,374 and reduced (3-catenin expression in 
superficial spreading melanomas is associated with a poor prognosis375.
Based on our results, all members of the catenin family are associated with 
improved disease-specific survival. However, expression of P-catenin is most closely 
associated with outcome. This likely corresponds to the presence of functional cadherin- 
catenin complexes, representing ‘stable’ melanoma cells. However, it has also been 
suggested that P-catenin participates in induction of apoptosis in early lesions and that the 
expression is lost or down-regulated in the more advanced tumors.375
Transcriptional regulation of the genes that are critical in melanoma progression 
is beginning to be elucidated. Transcription factors that have been implicated in 
melanoma progression include AP-2, ATF-2, SNAIL, MITF, and NFkB.376 A s 
demonstrated in chapters two and four, the transcription factors ATF-2 and AP-2 are
9 8 9  9 7 7closely associated with outcome in melanoma. ’ These are likely master regulators 
in the development of melanoma, with AP-2 inhibiting tumorigenicity and metastasis and 
ATF-2 promoting these qualities. In fact, AP-2 has been shown to directly affect 
transcription of c-KIT, MCAM/MUC18, MMP-2, and PAR-1,378'380 and also influence 
expression of E-cadherin, p21, HER2, PAI-1, Bcl-2, VEGF, and IGFR-1.376 ATF-2 has
251 252been shown to be associated with tumor growth and metastasis ’ in cell culture and 
animal models, and its prognostic role in melanoma is demonstrated in this dissertation. 
MITF, the microophthalmia transcription factor, plays an important role in the 
differentiation of melanocytes and other neural crest-derived cells. Although its role in 
this process is still poorly understood, MITF has multiple functions.381 In the Appendix 
(Garraway et al. publication in Nature382) , we show that although protein levels of MITF
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are not significantly associated with patient outcome, genetic aberrations (i.e., gains in 
DNA copy number of the MITF gene detected by fluorescence in situ hybridization) 
predict a poor outcome in metastatic malignant melanoma.
Many factors influence tumor initiation, proliferation, invasion, and metastasis, 
including alterations in multiple genes affecting cell cycle regulation, cell-cell interaction, 
adhesion to extracellular matrix, and vascularization. Using an objective measurement of 
expression levels in a large cohort of melanoma specimens, we have demonstrated some 
of the most promising prognostic biomarkers in malignant melanoma.
These preliminary analyses demonstrate great promise for predicting metastasis 
based on molecular information. Sentinel lymph node biopsy only identifies those 
melanomas that metastasize through the lymphatic system. Melanoma, however, can 
metastasize through other routes, including direct extension and hematogenous 
dissemination. In the era before sentinel lymph node biopsy, initial presentation of 
melanoma metastases occurred in the lymph nodes only 50% of the time, with 
satellite/in-transit metastases (15-20%) and distant metastases (30-35%) representing the 
remaining patients who develop metastatic disease.383,384 It is likely that the 
development of metastatic disease through these different pathways represents different 
biological classes of melanoma; a reasonable explanation for the low sensitivity and high
09“false negative” rate (up to 25%) of SLNB for melanoma. The goal of our test is to 
identify those patients who are likely to have (or develop) a metastasis, regardless of their 
Breslow depth and despite the presence of negative lymph nodes.
Further studies are needed to validate the current models we have constructed and 
are in the process of constructing. Although the risk test we have developed through
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genetic algorithms is intuitive, and easy to apply to future patients (in a prospective 
fashion), it may be too simple in its current form. Plans are in place to develop more 
complex models that will impart weightings to the score given to markers, as their 
contribution to outcome prediction is probably not equal (as the current model assumes). 
Additionally, patient follow-up on our validation cohort is a work in progress.
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